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Foreword 
Global drug control policies have been based on the 
general principles of eliminating the production, 
trade or use of any illegal psychoactive substance 
from the world. Yet policies which seek to reach that 
objective have involved harsh law-enforcement 
and even militarisation. These end up affecting the 
most vulnerable people who use drugs, subsistence 
farmers involved in illegal crop cultivation and 
small-scale traffickers because they are easier to 
apprehend than are wealthy and well-connected 
people. The collateral damages are human rights 
and lives – those of the most vulnerable and 
those of the voiceless. To quote the Deputy High 
Commissioner for Human Rights (May 2018), in a 
world that is meant to be more inclusive and where 
no one should be left behind, ‘people who use drugs 
are not left behind. They are left outside’.
A decade ago, the international community 
reiterated its aspiration to achieve a drug-free 
world. Yet over that decade, available data shows 
that the production, sale, and consumption of 
currently illegal drugs are soaring. So are the harms 
related to current policies, with dramatic increases 
in overdoses, prison overcrowding, HIV and 
hepatitis transmission, a more revenue-generating 
and increasingly violent illegal market, and in the 
condoning by some of extrajudicial killings against 
people who use drugs – killings that often take 
place in broad daylight.
Ten years after the world’s governments adopted at 
the UN the Political Declaration and Plan of Action 
on drugs, there is still little discussion on how to 
evaluate the impact of current policies, or on how 
to analyse the results of the policies implemented 
during this period. In 2014, there was a mid-term 
High-Level Review of the Political Declaration and 
Plan of Action. It resulted in a new negotiated 
document that reiterated the commitments, without 
providing any such ‘High-Level Review’. Two years 
later, the 2016 UNGASS on drugs provided another 
opportunity to review the current approach, to no 
avail. Although progress was made in bringing in 
more visibility to issues related to health, human 
rights and development, the resulting Outcome 
Document failed to recognise the harmful 
consequences of the war on drugs approach.
The international community is meeting again at a 
Ministerial Segment at the Commission on Narcot-
ic Drugs in March 2019 to decide upon a common 
strategy for the next ten years. But how can we 
plan the future without a serious and far-ranging 
assessment of the past’s errors and successes? How 
can we quantify the unintended consequences of 
drug control policies when they are not evaluat-
ed? Up until now, no comprehensive evaluation 
has been carried out either on progress towards 
achieving the 2009 targets or on the consequences 
of the past decade in global drug control on human 
rights, health, security, development, the environ-
ment, and on the lives of the millions of affected 
people worldwide.
Furthermore, there is little appetite among countries 
for such a review from the UN, proving once more 
that drug policy remains mostly an ideological 
issue rather than a societal topic that needs to be 
addressed based on evidence, dialogue, and building 
consensus. In that vacuum, I welcome this Civil 
Society Shadow Report in which the International 
Drug Policy Consortium which provides us with an 
excellent overview of the progress and the lack of 
it made in the last decade, as well as highlighting 
the challenges and opportunities ahead – using all 
existing government-based and UN-based data, 
along with scientific and grey literature. 
What we learn from the shadow report is compel-
ling. Since governments started collecting data 
on drugs in the 1990s – based on the seizures of 
illegal substances, on the arrests of people who 
use drugs and their admission to treatment ser-
vices, and on the eradication of illegal crops – the 
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drugs have reached record levels. Moreover, current 
drug policies are a serious obstacle to other social 
and economic objectives: progress on combating 
the HIV epidemic had been significant in the last 
20 years, but is now stalled among people who 
inject drugs; prison overcrowding has worsened, 
with a fifth of the world’s inmates being arrested 
for drug-related offences and mostly for drug use 
alone; and the ‘war on drugs’ has resulted in mil-
lions of people murdered, disappeared, or internally 
displaced. As the situation stands today, the major 
Sustainable Development Goals that concern gen-
der equality, the protection of the environment, 
socioeconomic development, and the reduction of 
violence and corruption will not be achieved for an 
important part of the population because of current 
drug policies.
But there is still hope for a better outcome and for 
the international community to do better during 
the 2019 high-level meeting. While the possibility 
of building a new negotiated political declaration 
and plan of action is unlikely with the lack of any 
monitoring and assessment apart from the current 
Shadow Report, the Vienna-based consensus that 
Rt Hon Helen Clark
has driven countries to agree on the paths to 
control drugs is breaking, both at the multilateral 
and at the regional levels.
It is our hope, at the Global Commission on Drug 
Policy, that the next decade in global drug policy 
will align with the 2030 Agenda for Sustainable 
Development to alleviate the pain and suffering of 
millions of people affected by current drug policies, 
with the objective of leaving no one behind. By 
providing the most comprehensive assessment 
of the past lost decade, I am certain that this Civil 
Society Shadow Report will greatly contribute to 
the global drug control debates and ensure that 
the coming decade will be better embedded in 
the international community’s priorities of human 
rights, development, peace and security. 
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Executive Summary
Objective of the Shadow Report
‘Taking stock: A decade of drug policy’ evaluates 
the impacts of drug policies implemented across 
the world over the past decade, using data from the 
United Nations (UN), complemented with peer-re-
viewed academic research and grey literature re-
ports from civil society. The important role of civil 
society in the design, implementation, monitoring 
and evaluation of global drug policies is recognised 
in the 2009 Political Declaration and Plan of Action 
on drugs, as well as in the Outcome Document of 
the 2016 United Nations General Assembly Special 
Session (UNGASS) on drugs. It is in this spirit that 
the International Drug Policy Consortium (IDPC) 
has produced this Shadow Report, to contribute 
constructively to high-level discussions on the next 
decade in global drug policy.
Background
In 2009, the international community agreed on 
a 10-year global drug strategy with the adoption 
of the ‘Political Declaration and Plan of Action on 
International Cooperation towards an Integrated 
and Balanced Strategy to Counter the World Drug 
Problem’. Article 36 of the Political Declaration es-
tablished 2019 ‘as a target date for states to elimi-
nate or reduce significantly and measurably’ the 
illicit cultivation, production, trafficking and use of 
internationally controlled substances, the diversion 
of precursors, and money-laundering.
As this target date is fast approaching, member 
states have agreed to hold a two-day Ministerial 
Segment at the 62nd Session of the Commission 
on Narcotic Drugs (CND) to take stock of progress 
made and delineate the global drug strategy for the 
next decade. Both the mid-term review of the 2009 
Political Declaration in 2014 and the 2016 UNGASS 
were missed opportunities for an honest and objec-
tive review of the successes and failures of global 
drug policies since 2009. Only a few months away 
from the 2019 high-level event, no comprehensive 
review of the impacts of drug policies worldwide 
has yet been undertaken. This Civil Society Shadow 
Report seeks to fill this gap, firstly by assessing the 
progress made, or lack thereof, against the objec-
tives set in the 2009 Political Declaration and Plan 
of Action. Secondly, the Report considers whether 
global drug policy has contributed to, or under-
mined, the broader priorities of the UN of protect-
ing human rights, advancing peace and security, 
and promoting development. 
Evaluating progress made against the targets 
included in Article 36 of the 2009 Political 
Declaration
Target 1: Eliminate or reduce significantly and 
measurably ‘the illicit cultivation of opium pop-
py, coca bush and cannabis plant’. Data from the 
United Nations Office on Drugs and Crime (UNODC) 
shows no reduction in the global scale of cultiva-
tion of opium, coca and cannabis between 2009 
and 2018. Over this period, cultivation has in fact 
increased by 130% for opium poppy and by 34% for 
coca bush. As for cannabis, although recent global 
estimates are unavailable, the UNODC concluded 
that cultivation was reported in 145 countries in the 
period 2010-2016, with no sign of reduction.
Target 2: Eliminate or reduce significantly and 
measurably ‘the illicit demand for narcotic drugs 
and psychotropic substances; and drug related 
health and social risks’. The overall number of 
people aged 15 to 64 who used drugs at least once 
in 2016 is estimated at 275 million, representing a 
31% increase since 2011. The main drug of choice 
remains cannabis, followed by opioids, and am-
phetamines for which consumption has increased 
by 136% since 2011. The UNODC estimates that 
the global HIV prevalence among people who in-
ject drugs has remained stable at 11.8%, as has the 
Key conclusions 
• Data from the Shadow Report show that 
the targets and commitments made in 
the 2009 Political Declaration and Plan 
of Action have not been achieved, and 
in many cases have resulted in counter-
productive policies.
• The Shadow Report highlights the urgent 
need to conduct more comprehensive 
and balanced research and evaluations on 
the impacts of drug policies worldwide, 
taking into account government data, 
but also academic research and civil  
society findings.
• The Shadow Report concludes that mem-
ber states should identify more meaning-
ful drug policy goals and targets in line 
with the 2030 Agenda for Sustainable 
Development, the UNGASS Outcome 
Document and international human  
rights commitments.
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drugs’. Although tighter national, regional and 
global policies and regulations have been adopted 
to counter money-laundering, the amount of 
money laundered globally each year amounts to 
US$ 800 million to 2 trillion, representing 2 to 5% 
of global GDP – with a quarter of overall revenues 
of transnational organised crime proceeding from 
drug sales. The global drug market is currently 
estimated to turnover between US$ 426 and 652 
billion. Of this, well over half of the gross profits 
generated are channelled into money-laundering, 
and less than 1% of the total amount of money 
being laundered is seized. 
Assessing progress made towards the 2009 Plan 
of Action against the broader priorities of the 
United Nations
This section of the Shadow Report assesses progress 
made towards selected actions of the 2009 Political 
Declaration and Plan of Action. Progress is evaluat-
ed against the broader UN priorities of protecting 
human rights, promoting peace and security, and 
advancing development.
Protecting human rights
Over the past decade, overly punitive drug policies 
focusing on eradicating the illegal drug market have 
been associated with wide-ranging human rights 
violations and threats to public health and order. 
These abuses have had dire implications on the lives 
of marginalised people and communities worldwide. 
The right to life: At least 3,940 people were 
executed for a drug offence over the past decade, 
global prevalence of hepatitis C at 51.9% and tuber-
culosis at 8%. Meanwhile, the number of drug-relat-
ed deaths surged by 145%, from 183,500 deaths in 
2011 to 450,000 in 2015. 
Target 3: Eliminate or reduce significantly and 
measurably ‘the illicit production, manufacture, 
marketing and distribution of, and trafficking 
in, psychotropic substances, including syn-
thetic drugs’. Available UN data shows ongoing 
production and use of methamphetamines across 
the world with an expanding market in North and 
West Africa, North America, East and South East Asia 
and Oceania. In parallel, between 2009 and 2017, 
over 800 new psychoactive substances (NPS) have 
emerged on the global drug market, while the UN-
ODC states that the illegal use of prescription drugs 
has reached record levels in various parts of the 
world, especially North America. 
Target 4: Eliminate or reduce significantly and 
measurably ‘the diversion of and illicit traffick-
ing in precursors’. Despite efforts made by member 
states to control and monitor precursor chemicals, 
over the past five years the International Narcotics 
Control Board (INCB) has reported an increase in 
the use and number of precursors in illegal drug 
production. Furthermore, although seizures of 
precursor chemicals like potassium permanganate 
(used in the manufacture of cocaine) increased from 
92,702 kg in 2012 to 585,072 kg in 2016, global co-
caine production has risen by 44% since 2009.
Target 5:  Eliminate or reduce significantly and 
measurably ‘money-laundering related to illicit 
Opium
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3,940
people have been executed for 
drug oﬀences over the past decade
33 jurisdic�ons retain the death penalty for drug-related crimes.
27,000~extrajudicial killings since Rodrigo 
Duterte became President of the 
Philippines, in 2016.
with 33 jurisdictions worldwide retaining the 
death penalty for drug crimes. Since 2009, various 
countries, including India, Iran, Malaysia, Palestine 
and Thailand, have taken steps to reduce or 
eliminate the use of capital punishment for drug 
offences, while others are considering reinstating 
the practice with bills in progress in Bangladesh, 
the Philippines and Sri Lanka. The recent escalation 
of punitive drug policies in South and South East 
Asia has resulted in the extrajudicial killings of over 
27,000 people under Rodrigo Duterte’s Presidency 
of the Philippines since June 2016. 
The right to health: Despite increases in the num-
ber of countries providing various harm reduction 
interventions, only 1% of people who inject drugs 
worldwide live in countries with adequate cov-
erage of both needle and syringe programmes 
(NSPs) and opioid substitution therapy (OST). 
Access to harm reduction is even more limited in 
prisons and other places of detention, resulting 
in the prevalence of HIV, hepatitis B and tuber-
culosis among people in prison being two to ten 
times higher than among the general population. 
The surge in overdose deaths – in particular in the 
United States where over 71,000 people died of an 
overdose in 2017 alone – is also a major issue of 
concern. While the federal response in the United 
States has overwhelmingly been law enforcement 
focused, Canada – which has also been affect-
ed by a surge in overdose deaths – has adopted 
a number of public health measures, including 
the opening of 25 new drug consumption rooms 
since 2016. The criminalisation and stigmatisation 
of people who use drugs has been identified by 
a number of UN agencies as a major barrier to 
accessing service provision. At national level, 26 
countries have adopted a decriminalisation model 
to facilitate access to health services and reduce 
stigma and prison overcrowding. 
Meanwhile, 75% of the world population, concen-
trated in the Global South, remain without access 
to essential medications for pain relief, while 92% 
of morphine is being used by just 17% of the world 
population. Overall reforms remain inadequate 
to address this issue. However, countries such as 
Costa Rica, India, Mexico, Uganda and Ukraine have 
recently taken various steps to improve access to 
morphine for palliative care and pain relief, and 48 
countries have now established medicinal cannabis 
systems for a number of ailments.
Criminal justice rights and right to be free from 
torture: The Shadow Report also sheds light on the 
human rights associated with incarceration and dis-
proportionate punishments. According to UN data, 
one in five prisoners worldwide is incarcerated for 
drug offences, the overwhelmi ng majority of whom 
for drug possession for personal use. In certain re-
gions, this proportion is even greater for women, 
as is the case in various Latin American countries, 
and in Thailand where over 80% of the 47,000 wom-
en in prison are incarcerated for a drug offence. In 
several countries, drug offenders also continue to 
be victims of excessive punishments, sometimes 
including acts of torture or other cruel, inhuman 
or degrading treatment. This includes forced urine 
Credit: Juan Fernandez O
choa, ID
PC
Only 1 in 100 people who inject drugs lives in a country 
with adequate coverage of both NSP and OST
75%of theworld
remain without access to 
proper pain relief treatment.
92%
of the global supply of 
morphine is used by 
17% of the world 
popula�on.
Credit: Juan Fernandez O
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PC
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countries are now considered as drug trafficking 
hubs, with the collusion between high-level officials 
and traffickers constituting a major threat to securi-
ty, governance and development. 
Posing an additional layer of complexity, the devel-
opment of crypto-drug markets has forced policy 
makers to adapt their law enforcement strategies. 
However, available data show that only 17% of 
crypto-drug markets were closed down as a result 
of drug law enforcement interventions; the rest 
having been shut down because of exit scams, vol-
untary closure or hacking. Further studies conclud-
ed that only a small minority of those purchasing 
drugs in crypto-drug markets stopped using these 
markets because of drug law enforcement action – 
putting into question the efficacy of current drug 
control efforts. Nevertheless, the rise in the use of 
online drug markets has led to interesting devel-
opments in the field of health and harm reduction. 
For instance, online forums within crypto-drug 
markets have facilitated peer-based reviews and 
feedback on drug purchases, sellers, purity and 
effects of products bought online, enabling peo-
ple who use drugs to reduce health harms, and 
facilitating discussions on the availability of drug 
support services.
Advancing development
Tracking progress towards development – and the 
Sustainable Development Goals (SDGs) – consti-
tutes the third key analytical research area of this 
Shadow Report. Evidence collected for the Re-
port shows that drug control efforts have mainly 
testing, compulsory registration requirements, in-
carceration in compulsory detention centres and 
corporal punishment, including on children. At 
the same time, tens of thousands of people have 
recently been arbitrarily arrested in Cambodia and 
Bangladesh for suspected involvement in illicit drug 
activities. Although discussions have been held at 
regional and international levels on these issues, on 
the ground little progress has been made to remedy 
these human rights abuses.
Promoting peace and security
Instead of reducing the overall scale of the illegal 
drug market, overly punitive drug policies have of-
ten exacerbated violence, instability and corruption. 
In the case of opium, while cultivation fell in South 
and South East Asia over the past decade, it has in-
creased significantly in Afghanistan which now pro-
duces 86% of the world’s opium. Academic research 
concluded that forced eradication campaigns had 
led to increased levels of crime, an ongoing Talib-
an insurgency and militias remaining active in the 
region, with severe consequences for subsistence 
farmers. Similarly, despite forced crop eradication 
campaigns in Colombia, coca cultivation increased 
by 115% between 2009 and 2016. Interdiction ef-
forts in the country have resulted in violent clashes 
between affected communities and the police and 
the military, forcing millions of people to be inter-
nally displaced. In Mexico, a militarised war on drug 
cartels launched in 2006 resulted in over 150,000 
deaths associated with the drug trade and more 
than 32,000 disappearances. In West Africa, several 
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consisted of eradication measures, with little atten-
tion given to the critical development issues faced 
by affected communities in rural and urban contexts. 
Although alternative development has gained much 
visibility in UN forums and discussions over the past 
decade, such programmes have generally been 
used to justify crop eradication campaigns, rather 
than focusing on creating the conditions that im-
prove people’s livelihoods and reduce their depend-
ence on illegal crop cultivation. The use of harmful 
pesticides to destroy drug crops has impacted upon 
the health of local communities and damaged the 
environment by displacing subsistence farmers into 
new, more remote areas, including national parks 
and indigenous territories. In Colombia, 32% of 
coca is cultivated in national parks and indigenous 
reserves. In recognition of concerns over human 
and environmental harms associated with harmful 
pesticides, Bolivia, Ecuador, Peru and Thailand have 
banned the use of these chemical agents.
While alternative development programmes have 
mostly been counter-productive, two country ex-
amples stand out as more positive models. Since 
the 1960s, Thailand has adopted a long-term de-
velopment strategy in areas where illegal opium 
cultivation was concentrated. This approach has led 
to reductions in poverty levels through increased 
access to education, employment, basic health and 
social services and infrastructure. On the other side 
of the world, since 2008 Bolivia has allowed farmers 
to grow a sufficient amount of coca for subsistence 
purposes, facilitating access to a national legal mar-
ket for coca products, as well as improving access to 
safe water, education and other sources of income. 
Both the Thai and Bolivian models rely on strong 
community participation. 
As in areas of illicit crop cultivation, poverty has now 
been recognised as a main driver of engagement in 
illicit drug trafficking and other supply-side activi-
ties. In Latin America, the overwhelming majority of 
women incarcerated for drug offences are first time, 
non-violent offenders, with limited formal educa-
tion or employment opportunities and the sole care 
provider of several children and other dependents, 
who engage in illegal drug activities because of sit-
uations of socio-economic vulnerability. Although 
these issues are better understood and visible in re-
gional and global forums, few member states have 
taken action on the ground. Costa Rica is a notable 
exception. Since 2013, the country has adopted a 
number of reforms to reduce the high rate of incar-
ceration of women in situation of vulnerability, by 
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Conclusion
The commitments and targets set in the 2009 Polit-
ical Declaration and Plan of Action have not been 
achieved, and in many cases have resulted in coun-
ter-productive policies. The Shadow Report also 
raises a number of issues on the past and future 
evaluation of global drug policies. Firstly, the Report 
highlights the urgent need to conduct more thor-
ough and regular research on the broader range of 
impacts of drug policies at local, national, regional 
and international level. 
Secondly, and related to the need for more research, 
the Report puts into question the sources of data 
currently being be used for such formal evaluations. 
These rely heavily on government reporting. A more 
comprehensive and balanced picture of the situa-
tion requires incorporating civil society and academ-
ic research. This is particularly important for sensitive 
issues related to drug policy and human rights. 
And thirdly, the lack of progress made towards the 
drug-free targets, along with the negative conse-
quences associated with efforts to achieve those tar-
gets, mean that member states should reflect upon 
what to measure. Focusing exclusively on measur-
ing the scale of the illegal drug market is clearly not 
enough to understand the impact of drug policy on 
the key UN Charter commitments to health, human 
rights, development, peace and security. The third 
section of this Shadow Report attempts to provide 
some recommendations which we hope will pro-
vide a useful starting point for further discussions as 
to which goals and metrics could be considered for 
the post-2019 global drug strategy.
drug offences, providing alternatives to incarcer-
ations and offering social and health support for 
those in need. 
What next: Designing new benchmarks for 
global drug policy
The 2016 UNGASS was instrumental in expanding 
the scope of global drug policy debates beyond the 
siloed three pillars of demand reduction, supply re-
duction and international cooperation to also focus 
on health (including harm reduction and access to 
controlled medicines), development, human rights 
and new challenges. Going forward, this seven-pil-
lar structure should prevail in global drug control 
debates. 
This Shadow Report demonstrates that the objec-
tive of achieving a drug-free world is unrealistic and 
unachievable. The pursuit of ‘drug-free world’ targets 
has resulted in policies and punitive enforcement 
practices which have undermined health, human 
rights, development and security. Beyond 2019, the 
overall goals of global drug policy – as well as the 
metrics and indicators used to evaluate progress – 
urgently need to be reconsidered. New goals, met-
rics and indicators should be aligned both with the 
UNGASS Outcome Document and the SDGs, and 
focus on the critical need to minimise drug-related 
health harms, improve access to healthcare, uphold 
basic human rights, ensure gender equality, reduce 
poverty in cultivation and trafficking areas, improve 
citizen safety and reduce corruption. A detailed list 
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Recommendations
In preparation for the 2019 Ministerial Segment, the 
IDPC network recommends that:
• The international community should consider 
adopting more meaningful goals and targets in 
line with the 2030 Agenda for Sustainable Devel-
opment, the UNGASS Outcome Document and 
international human rights commitments, and 
move away from targets seeking to eliminate the 
illegal drug market.
• Post-2019, member states should meaningfully 
reflect upon the impacts of drug control on the 
UN goals of promoting health, human rights, de-
velopment, peace and security – and adopt drug 
policies and strategies that actively contribute 
to advancing the 2030 Agenda for Sustainable 
Development, especially for those most margin-
alised and vulnerable.
• Global drug policy debates going forward 
should reflect the realities of drug policies on the 
ground, both positive and negative, and discuss 
constructively the resulting tensions with the UN 
drug control treaties and any human rights con-
cerns associated with drug control efforts.
• Beyond 2019, UN member states should end pu-
nitive drug control approaches and put people 
and communities first. This includes promoting 
and facilitating the participation of civil society 
and affected communities in all aspects of the 
design, implementation, evaluation and moni-
toring of drug policies. 
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In March 2009, the 52nd session of the Commission 
on Narcotic Drugs (CND) featured a High-Level Seg-
ment held in Vienna,1 with a view to define the inter-
national community’s 10-year global drug strategy. 
The event resulted in the adoption, by consensus, 
of the ‘2009 Political Declaration and Plan of Action 
on International Cooperation towards an Integrated 
and Balanced Strategy to Counter the World Drug 
Problem’.2 In order to understand the implications 
of the 2009 process and the ensuing framework for 
international drug  policy,3 it is critical to analyse the 
period running up to 2009. 
1.1 The UNGASS decade: ‘A drug-free 
world, we can do it’
The first ever UN General Assembly Special Session 
(UNGASS) on drugs was held in 1990, at which 
member states adopted a Political Declaration to 
strengthen the global approach.4 Eight years later, 
UN member states assembled again in New York 
at a second UNGASS on the ‘world drug problem’ 
under the strapline ‘A drug-free world, we can do 
it’.5 Echoing this overarching objective, the UN 
International Drug Control Programme had origi-
nally proposed the adoption, at the 1998 UNGASS, 
of the SCOPE plan – i.e. the ‘Strategy for Coca and 
Opium Poppy Elimination’ by 2008. Supported by 
the USA, the plan was met with strong criticism 
from NGO groups, and preventing its adoption 
became one of their main priorities. The fact that 
this plan was not adopted as the main outcome 
of the 1998 UNGASS was an important success for 
civil society.6 What remained of the SCOPE Plan 
was the inclusion, in the 1998 Political Declaration 
(S-20/2),7 of paragraph 19: ‘Welcome the global ap-
proach by the United Nations International Drug 
Control Programme to the elimination of illicit 
crops, and commit ourselves to working closely 
with the Programme to develop strategies with a 
view to eliminating or reducing significantly the illicit 
cultivation of the coca bush, the cannabis plant and 
the opium poppy by the year 2008’ (emphasis add-
ed).8 In a way, the SCOPE plan gave birth to the 
targets to eliminate the global illegal drug market 
with a first target period running until 2008, and 
which was then reiterated for the following dec-
ade. 1998 also marked an important shift in focus 
from a historical emphasis on supply reduction to 
focus both on demand and supply, with the adop-
tion of the ‘Declaration on the guiding principles of 
drug demand reduction’.9 
Ten years later, as the end of this ‘UNGASS decade’ 
was approaching, available data at the time showed 
no reduction in the overall scale of the illegal drug 
market. In its 2008 World Drug Report, and in par-
ticular its thematic chapter entitled ‘A century of in-
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Figure 1. UN drug control: The UNGASS decades, 1990-present
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on Drugs and Crime (UNODC) developed a ‘contain-
ment’ rhetoric,10 explaining that statistical evidence 
showed that drug use prevalence had remained 
stable since the adoption of the 1909 Shanghai 
Commission. Drug use prevalence, the UNODC stat-
ed, had ‘been contained to less than 5% of the adult 
population’.11 The containment argument, however, 
was criticised for its reliance on 1909 data a bench-
mark for comparison – opium, for instance, was 
relied upon for the medicinal treatment of multiple 
illnesses in 1909, and its use then cannot be com-
pared with non-medical opium or heroin use in the 
21st century.12 
In March 2008, Antonio Maria Costa also produced 
a seminal paper presented at the 51st session of the 
CND in the form of a conference room paper: ‘Mak-
ing drug control “fit for pu  rpose”: Building on the 
UNGASS decade’.13 Recognising that ‘Some of the 
more ambitious targets set at UNGASS in 1998 re-
main elusive’, the UNODC Executive Director open-
ly acknowledged the ‘unintended consequenc-
es’ associated with the dominant approach to 
drug control:
• ‘A huge criminal black market that now thrives’ 
• ‘Policy displacement’, with an imbalance of pub-
lic resource allocation towards drug law enforce-
ment at the expense of public health and social 
interventions
• ‘Geographical displacement’, also called ‘the 
balloon effect’, meaning that the rare successes 
in reducing cultivation or trafficking in one area 
merely lead to increases elsewhere
• ‘Substance displacement’, with tighter controls 
on certain drugs leading suppliers and people 
who use drugs to turn to other substances, 
sometimes with unintended consequences for 
health 
• ‘The way we perceive and deal with the users of 
illicit drugs’, in other words, the stigmatisation 
of drug use, which has resulted in the margin-
alisation and discrimination of people who use 
drugs and has negatively impacted their access 
to healthcare and social services.14 
Meanwhile, in recognition of the severe conse-
quences of punitive drug policies, reforms were 
materialising at national level, with an increasing 
number of governments supporting harm reduc-
tion measures and moving towards the decriminal-
isation of drug use and possession for personal use. 
It is in this context that member states initiated the 
negotiations process for the post-2008 global drug 
control strategy.
1.2  The 10-year review of the 1998 
Political Declaration
The High-Level Segment of the 52nd session of the 
CND in 2009 concluded a year-long review of the 
1998 UNGASS targets. To ‘allow additional time for 
conducting an objective, scientific, balanced and 
transparent global assessment’,15 member states 
had decided to divide the review process into 
three stages:
• A thematic debate at the 51st session of the CND in 
2008 to discuss the outcomes of the assessment 
conducted by the UNODC on global progress 
against the 1998 Political Declaration.16 ‘Making 
drug control “fit for purpose”’ was an integral part 
of this review. 
• A ‘period of reflection’ during which five inter-
governmental expert working groups17 elaborat-
ed a number of recommendations on demand 
reduction, supply reduction, money-laundering 
and judicial cooperation, eradication of illegal 
drug crops and alternative development, and 
precursors and amphetamine-type stimulants 
(ATS).18 The conclusions of the expert working 
groups provided the materials upon which the 
new strategy post-2008 would be drafted. 
• The negotiation of a new Political Declaration 
and Plan of Action, which was adopted by con-
sensus at the High-Level Meeting of March 2009. 
Civil society used this review period to organise a se-
ries of consultations and meetings. This culminated 
in the Global Civil Society Forum, held in July 2008 
and attended by over 300 civil society representa-
tives who worked together to agree on the ‘Beyond 
2008 Declaration’.19 The Declaration was formally 
presented at the 52nd session of the CND.20
1.3  The 2009 Political Declaration 
and Plan of Action: Setting a new 
target date
The 2009 ‘Political Declaration and Plan of Action 
on International Cooperation towards an Integrat-
ed and Balanced Strategy to Counter the World 
Drug Problem’ recognises that ‘the commitments 
made by Member States in 1998 to attain signifi-
cant and measurable results in the area of drug 
demand reduction have been attained only to a 
limited extent’ and that ‘despite some significant 
progress made in certain areas, efforts have not 
led to a significant overall decrease in the global 
illicit cultivation of crops used for the production 
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of narcotic drugs and psychotropic substances’.21 
However, in many respects, the 2009 Political 
Declaration is very similar to the declaration that 
emerged from the 1998 UNGASS and the objec-
tives established in 2009 are comparable to those 
formulated ten years before: 
‘the ultimate goal of both demand and supply re-
duction strategies and sustainable development 
strategies is to minimize and eventually elim-
inate the availability and use of illicit drugs and 
psychotropic substances… We are determined 
to tackle the world drug problem and to actively 
promote a society free of drug abuse in order to 
ensure that all people can live in health, dignity 
and peace, with security and prosperity’.22
The objectives flowing from this goal led member 
states once again to: ‘establish 2019 as a target date 
for States to eliminate or reduce significantly and 
measurably:
a. The illicit cultivation of opium poppy, coca 
bush and cannabis plant;
b. The illicit demand for narcotic drugs and 
psychotropic substances; and drug related 
health and social risks;
c. The illicit production, manufacture, market-
ing and distribution of, and trafficking in, 
psychotropic substances, including synthetic 
drugs;
d. The diversion of and illicit trafficking in pre-
cursors;
e. Money-laundering related to illicit drugs’.23
The High-Level Segment itself reflected several 
points of contention between member states on 
the direction of global drug control, in particular 
on the concept of harm reduction. A few member 
states fought a long and protracted battle to include 
the term in the document, but it was eventually 
removed, even as a footnote, during the negotia-
tions and ultimately replaced with the term ‘related 
support services’. However, reflecting the increas-
ing level of support for a health-based approach 
towards drug use, a group of 26 member states24 
led by Germany made a joint statement at the 2009 
Segment declaring that they would interpret the 
term ‘related support services’ to mean ‘harm re-
duction measures’.25 This was one of the early signs 
that cracks in the ‘Vienna consensus’26 were forming. 
Nonetheless, in the years that followed, the Political 
Declaration – with its ‘drug-free world’ goals at the 
centre – became a key document of reference for 
the international community in its efforts to control 
the illegal drug market.
1.4  The 2014 mid-term review of the 
2009 Political Declaration: A missed 
opportunity
The first occasion to review progress made against 
the goals established in 2009 was five years later 
in 2014, with the mid-term High-Level Review of 
the Political Declaration, held at the 57th session of 
the CND. The event, however, mainly consisted of 
country statements at a 2-day summit in Vienna 
and difficult negotiations over a consensus-based 
document, rather than an objective assessment of 
what had been achieved so far.27 While the discus-
sions acknowledged the continued challenges re-
lated to drug control, the resulting Joint Ministerial 
Statement mostly reiterated the themes of the 2009 
Political Declaration and Plan of Action. The Joint 
Ministerial Statement28 also made no reference to 
the lack of progress made towards the achievement 
of the target of halving new HIV infections among 
people who use drugs by 2015, which had been 
agreed by the UN General Assembly through a ma-
jority vote in the 2011 Political Declaration on HIV/
AIDS.29 
In 2014, some unprecedented reforms had taken 
place at national level, and perhaps in reflection 
of these changes, reaching consensus at the UN 
became increasingly difficult. At the time, Bolivia 
had withdrawn from the 1961 Single Convention 
on Narcotic Drugs (the first and only country to do 
so) and re-acceded with a reservation on coca leaf 
chewing.30 Various US states31 and Uruguay32 had 
adopted regulatory regimes for non-medical can-
nabis use, and around 20 countries had established 
a form of decriminalisation, whether de jure or de 
facto, of drug possession for personal use.33 In ad-
dition, calls for more humane, health-centred drug 
policies – including a harm reduction approach and 
the abolition of the death penalty for drug offences 
– were increasingly vocal.
These developments had a significant impact on 
the dynamics at the CND in Vienna. For the first time 
in the history of the international drug control re-
gime, a member state (Ecuador) called in its official 
statement for a reform of one of the three UN drug 
conventions34 – breaking a taboo that had long 
remained sacrosanct at the CND. These views were 
met by a more conservative front led by the Russian 
Federation.35 It is unsurprising, therefore, that it took 
over nine months for the Joint Ministerial Statement 
to be negotiated during intense debates, resulting 
in a relatively bland, watered-down document. 
The difficult negotiations contributed to a growing 
sense of frustration among many member states.36 
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1.5  The 2016 UNGASS: The winds of 
change
Even before the 2014 high-level review, a sense of 
exasperation was growing amongst those states 
seeking reform, particularly in Latin America, a re-
gion which was experiencing increasing levels of 
violence as a result of overly punitive drug policies. 
At the 2012 Summit of the Americas, most of the 
presidents of the region met privately to discuss 
drug policy and called on the Organization of Amer-
ican States (OAS) to analyse the results of present 
policies and explore alternatives. Shortly thereaf-
ter, the governments of Colombia, Guatemala and 
Mexico were successful in getting the issue of drug 
policy reform on the UN agenda. At the 2012 UN 
General Assembly meeting, those countries issued a 
formal statement underscoring the need to ‘review 
the approach’ of present drug policies and called 
on the UN to ‘exercise its leadership...and conduct 
a profound reflection to analyze all available op-
tions, including regulatory or market measures, in 
order to establish a new paradigm that prevents the 
flow of resources to groups involved in organized 
crime’. The statement concludes by asking the UN 
to host ‘an international conference to allow the 
necessary decisions to be made in order to achieve 
more effective strategies and tools with which the 
global community faces the challenges of drugs 
and their consequences’.37 The convening of a third 
UNGASS on drugs was agreed within the Omnibus 
Resolution adopted by the UN General Assembly in 
December 2012.38 





Held in New York on 19 to 21 April 2016, the third 
UNGASS on drugs was characterised by surface 
consensus and underlying conflict. As was the case 
in 2014, negotiating the UNGASS Outcome Doc-
ument39 was highly challenging, the divide being 
greater than ever on the key substantive issues of 
global drug control.40 Once again, human rights, 
the death penalty in particular, and harm reduc-
tion were at the forefront of the tensions between 
member states.41 While strong statements on these 
issues were made throughout the proceedings, 
neither was explicitly included as such within the 
final declaration, although key harm reduction 
interventions were referenced for the first time 
in such a high-level document on drug control.42 
These underlying tensions reflected a deeper divi-
sion between the narrative of achieving a ‘drug-free 
society’ and the view that this goal is unattainable 
and that drug policies should be trying to manage 
the ‘drug problem’ in a way that minimises poten-
tial harms as much as possible for individuals and 
affected communities. The resultant 26 page-long 
Outcome Document was a significant improvement 
over previous high-level declarations on drug pol-
icy, with unprecedented visibility given to certain 
human rights concerns (e.g. abuses in the context of 
law enforcement, proportionality of sentencing and 
gender equality), public health (including access to 
controlled medicines) and development, which was 
also reflected in a new 7-pillar thematic structure for 
member state discussions, breaking with the three 
traditional pillars of demand reduction, supply re-
duction and international cooperation.43  
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Box 1  The INCB’s shifting position on selected drug policy issues:  
A 10-year review
Historically, the International Narcotics Control 
Board (INCB) has been considered as the most 
conservative UN drug control body, with vocal 
statements against states having adopted harm 
reduction and decriminalisation policies, and lit-
tle condemnation of drug policies raising human 
rights concerns. However, over the past decade 
the Board’s positions have evolved on a number 
of drug policy issues. 
A key development has been the move from 
the INCB’s refusal to take a stance on the death 
penalty for drug offences to regular calls for UN 
member states to abandon the practice.44 More 
recently, the INCB condemned the extrajudicial 
killings of suspected drug offenders – albeit after 
intense pressure from civil society45 – as ‘a seri-
ous breach of the legal obligations to which the 
Philippines is held by the three UN drug control 
conventions and by the corpus of international 
legal instruments to which the country has ad-
hered’.46 Meanwhile, the Board has remained 
consistent in its calls for more proportionate 
sentencing, which was first touched on in 1996, 
and expanded in the thematic chapter of the 
INCB’s 2007 Annual Report.47 The INCB has advo-
cated for proportionate sentencing repeatedly  
since then.48
Another major change relates to the INCB’s po-
sition on decriminalisation. In 2015, the Board 
concluded that: ‘The treaties do not require the 
incarceration of drug users, but rather provide for 
alternatives to conviction or punishment for those 
affected by drug abuse…That some countries 
have chosen incarceration rather than treatment 
has been a denial by governments of the flexibili-
ty that the treaties provide’.49 Going a step further 
in supporting decriminalisation, the INCB spoke 
at a side event at the 58th session of the CND on 
the Portuguese decriminalisation model.50 
Similarly, there has been a noticeable difference 
of tone on medicinal cannabis. In 2013, the INCB 
President had pronounced: ‘If such “medical” 
schemes are not well managed and supervised, 
they could be seen as “backdoor legalisation” of 
cannabis for recreational use’.51 More recent pub-
lications by the Board have acknowledged the 
legality of medicinal cannabis use under the 1961 
convention, and focused on discussing the tech-
nical, administrative and legal factors involved.52  
With regards to harm reduction, the INCB has re-
mained timid on drug consumption rooms. The 
Board was highly critical of this intervention in 
past Annual Reports, stating in 2005 that ‘Drug 
injection rooms contravene the major principle of 
the treaties’.53 The 2016 Report was considered as 
softening the Board’s stance, at least in terms of 
the tone of its remarks, limiting its comments to 
technical and legal questions, implying that when 
certain conditions are fulfilled, such facilities do 
operate in line with the drug control treaties.54 
In its 2017 Report, however, the Board again 
expressed reservations concerning the fact that 
users of the facilities acquired their drugs prior to 
entering the drug consumption rooms, and utilis-
ing stigmatising language such as ‘drug abusers’ 
– representing subtle indications of a retraction of 
the 2016 position.55 
Identifying ways of addressing the existing ten-
sions between the rights of indigenous groups 
and member states’ obligations under the UN 
drug control treaties (see Box 13) is another 
matter on which the INCB has not yet adopted a 
clear position – although the INCB President rec-
ognised that ‘there are in fact contradictions’ but 
that ‘in the current state of drug control legislation’ 
allowing indigenous groups to use internationally 
controlled substances for traditional purposes ‘is 
not possible’.56
Yet another issue of concern remains the culture of 
lack of transparency in the INCB’s work. The Board 
meets in secret, and no minutes of its meetings 
are published. Further, there is no public access to 
the analysis through which it arrives at its policy 
positions,57 and reports from country visits are 
not made available online or shared with member 
states. However, adding some transparency to the 
Board’s functioning, the INCB’s engagement with 
civil society has also improved since 2009. The 
Board now undertakes a yearly dialogue with civil 
society at the CND, and regularly meets with NGOs 
during its most country visits. Further, the Board 
held a meeting with civil society delegates in May 
2018 – the first of its kind – in order to discuss the 
medical and non-medical uses of cannabis.58 
The INCB has come a long way since 2009, but 
there remains some way to go before the Board 
can become the champion of human rights and 
public health it appears as in its rhetoric.
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The fact that the Sustainable Development Goals 
(SDGs)59 were agreed just a few months before 
the UNGASS Outcome Document60 contributed to 
the incorporation of a more visible development 
perspective within the UNGASS proceedings and 
the Outcome Document, with a whole chapter 
dedicated to the issue independently from supply 
reduction imperatives, and a broader perspective 
focusing both on rural and urban settings.
Nevertheless, a genuine evaluation of global 
drug policies once again failed to materialise. The 
UN Secretary General had encouraged member 
states to use the UNGASS in order to ‘conduct a 
wide-ranging and open debate that considers all 
options’.61 However, the discussions remained en-
trenched in the usual narrow diplomatic parame-
ters, with no reconsideration of the harms caused 
by drug control policies, and with the goal of 
promoting ‘a society free of drug abuse’ reaffirmed 
and featuring prominently in the preamble of the 
Outcome Document.62 As in 2014, the establish-
ment of regulated markets in some member states 
for non-medical use remained the ‘elephant in the 
room’, with almost no discussions held on the in-
herent resulting tensions for the global drug con-
trol regime. As a result, despite some undeniable 
progress, there was no fundamental shift in the 
underlying punitive enforcement-led drug control 
paradigm, except for one singularly pivotal ele-
ment: for the first time in two decades, and apart 
from an inclusion in the preamble of the need to 
achieve a ‘society free of drug abuse’, no explicit 
mention was made of the detailed ‘drug-free world’ 
targets as they had been laid out in paragraph 19 
of the 1998 Political Declaration and paragraph 36 
of the 2009 Political Declaration.  
1.6  The next step: The 2019 
Ministerial Segment of the 62nd CND
The next step on the international drug policy 
roadmap will be in March 2019 – with a high-level 
Ministerial Segment scheduled before the 62nd ses-
sion of the CND. A core objective of this event is to 
‘take stock of’ progress made during the decade 
since the adoption of the 2009 Political Declara-
tion and Plan of Action, with a view to delineating 
the global drug strategy for the next decade.63 The 
event is particularly timely considering the signifi-
cant changes that have taken place since 2009. The 
illegal drug market has become more complex, with 
changing production regions and trafficking routes, 
the increasing use of online markets, and new drugs 
and drug use behaviours. The division between pro-
duction, trafficking and consumption countries has 
also become increasingly blurred. In the meantime, 
local and national drug policies have changed dra-
matically over the past decade, with some countries 
moving towards a harm reduction approach, de-
criminalisation and even regulated markets for cer-
tain substances, while others have escalated their 
punitive approach to counter supply and demand. 
In this rapidly changing environment, a review of 
progress made since 2009 and an evaluation of 
whether the 2009 strategy remains ‘fit for purpose’ 
constitute key priorities. Only a few months away 
from the Ministerial Segment, however, no such re-
view has been undertaken. 
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Both the 2014 High Level Review and the 2016 
UNGASS were missed opportunities for an honest 
and objective review of the successes and failures 
of global drug policies since the adoption of the 
2009 Political Declaration and Plan of Action. As 
the target period as set forth in paragraph 36 of 
the 2009 Political Declaration is set to expire in 
2019, and with the Ministerial Segment of the 62nd 
session of the CND drawing near, no independent 
evaluation has yet taken place. Biennial reports on 
the implementation of the Political Declaration 
were published by the UNODC Executive Director 
in 2012, 2014, 2016 and 2018,64 but like the UNODC 
World Drug Reports, these rely on member states’ 
responses to the Annual Report Questionnaire 
(ARQ), and therefore represent an incomplete 
and subjective picture of the overall drug control 
landscape. Furthermore, these reports focus al-
most exclusively on the scale of the illegal drug 
market, with little attention given to issues related 
to human rights, public health and development – 
although it should be noted that the more recent 
World Drug Reports have made efforts to provide 
more analysis of these aspects. 
In an attempt to help fill this gap, the objective of 
this ‘Shadow Report’ is three-fold. Firstly, it assess-
es the progress made, or lack thereof, against the 
objectives set out in the 2009 Political Declaration 
and Plan of Action. Secondly, we evaluate whether 
and how the implementation of the Political Decla-
ration and Plan of Action may have contributed to, 
or undermined, the broader priorities of the United 
Nations, namely protecting human rights, advanc-
ing peace and security and promoting develop-
ment. Thirdly, we offer recommendations for the 
2019 Ministerial Segment and the next decade in 
drug policy, focusing on the implementation of the 
UNGASS Outcome Document and the achievement 
of the SDGs. 
2  Objective of this shadow report
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peace and security and advancing development. 
Secondly, actions were selected according to the 
key priorities of the IDPC network – in particular 
those related to improving health, human rights, 
human security, social inclusion and development, 
in line with IDPC’s vision65 and policy principles.66 
Following this process, 33 actions were selected for 
this report and are listed, along with the relevant 
issue they relate to, in the Annex.
For each selected action, desk-based research was 
conducted to measure progress and remaining chal-
lenges. The research aimed to identify comparable 
data when available (taking into account methodo-
logical divergences in research conducted between 
2009 and 2018), but also to provide qualitative in-
formation on whether or not the objectives set out 
in 2009 were achieved. IDPC reviewed the UNODC 
Biennial Report for 2018, the UNODC World Drug 
Reports published between 2009 and 2018, docu-
mentation from UN agencies and civil society, and 
academic research – all of which are cited through-
out this document. The results of this research form 
the basis of the conclusions presented in Part 2. The 
findings of the Shadow Report are further supple-
mented by case studies aiming to show the human 
impacts – both positive and negative – of the past 
decade of international drug control. 
Part 3 of the Shadow Report looks to the future, 
analysing the gains achieved within the UNGASS 
Outcome Document, and offering recommenda-
tions on how to leverage the SDGs to develop new 
metrics and indicators against which to measure the 
progress in global drug policy for the next decade. 
The 2009 Political Declaration and its Plan of Ac-
tion recognise the ‘important role played by civil 
society’ in the ‘formulation and implementation’ of 
drug policy (Action 10). Action 12(b) also requests 
member states to ‘involve all stakeholders at the 
community level (including the target populations, 
their families, community members, employers and 
local organizations) in… monitoring and evaluation 
of demand reduction measures’. In light of these 
Actions, the International Drug Policy Consortium 
(IDPC) has worked with its network of civil society 
members and partners to evaluate progress against 
the 2009 goals and targets, with the aim of contrib-
uting to the debates in the lead up to, and during, 
the 2019 Ministerial Segment.
This report does not seek to provide a comprehen-
sive repository of all available data on drugs, but 
rather an analysis of the most relevant informa-
tion available regarding what is known about key 
achievements and failures of the global drug con-
trol regime between March 2009 and July 2018. 45 
experts from within civil society, academia, govern-
ments and UN agencies peer reviewed the report 
to ensure its validity and robustness (see Acknowl-
edgements section above). 
In preparation for this report, IDPC identified key 
actions within the 2009 Political Declaration and 
Plan of Action against which to measure progress. 
Two criteria were used to select which ones to focus 
on in this Shadow Report. Firstly, for each action, an 
assessment was made as to whether the target was 
tangible and quantifiable, and how progress could 
be measured towards its achievement against the 
UN priorities of protecting human rights, promoting 
3  Methodology
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Part 2: 
Evaluating progress made in addressing the ‘world 
drug problem’ since the adoption of the 2009 
Political Declaration and Plan of Action
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Article 36 of the 2009 Political Declaration is perhaps 
one of the most significant, as it established 2019 as 
the target date ‘to eliminate or reduce significantly 
and measurably 
a. the illicit cultivation of opium poppy, coca bush 
and cannabis plant; 
b. the illicit demand for narcotic drugs and psycho-
tropic substances; and drug related health and 
social risks; 
c. the illicit production, manufacture, marketing 
and distribution of, and trafficking in, psycho-
tropic substances, including synthetic drugs; 
d. the diversion of and illicit trafficking in precur-
sors; and 
e. money-laundering related to illicit drugs’.67 
This section discusses progress made against each 
of these objectives, drawing from official data pro-
vided by the UNODC (see Box 2), in particular the 
World Drug Reports from 2009 to 2018 and the lat-
est biennial report of the UNODC Executive Director 
on ‘Action taken by Member States to implement 
the Political Declaration and Plan of Action on 
International Cooperation towards an Integrated 
and Balanced Strategy to Counter the World Drug 
Problem’, published in March 201868 – taking due 
account of issues related to quality and gaps in the 
UNODC’s data (see Box 2).
1.1  The illicit cultivation of opium 
poppy, coca bush and cannabis plant
The latest data from the UNODC shows no reduc-
tion in the scale of cultivation of opium, coca and 
cannabis between 2009 and 2018 (see Table 1). 
Since 2009, cultivation has in fact increased for all 
these plants. According to data submitted by UN 
member states to the UNODC between 200969 and 
2018,70 the global illegal cultivation of opium pop-
py has increased by 130%. This is mainly due to a 
surge in cultivation in Afghanistan, where poppy 
cultivation increased from 123,000 hectares (with 
potential opium production at 6,900 tons) in 2009 
to 328,000 hectares in 2017 (with potential opi-
um production at 9,000 tons). Similarly, the global 
cultivation of the coca bush rose by 34% over the 
period 2009-2016. As for cannabis, while the World 
Drug Report estimated that between 200,000 
and 641,800 hectares of the plant were being 
Global cultivation 2009 Latest estimates Change since 2009
Opium poppy 181,373 ha71 418,000 ha (2017)72 + 130%
Metric tons of potential 
opium production 7,754 tons
73 10,500 tons (2017)74 + 35%
Coca bush 158,800 ha75 213,000 ha (2016)76 + 34%
Metric tons of potential 
cocaine production
976.5 tons (range: 842 to 
1,111)77 1,410 tons (2016)
78 + 44%
Cannabis 200,000-641,000 ha79 No recent estimate available from the UNODC Unknown
Table 1. Global cultivation of opium poppy, coca bush and cannabis plant 2009-2018
OPIUM
POPPY CULTIVATION
Substan�al investements into 
erradica�on eﬀorts have had no las�ng 
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1 Assessing progress made against 
Article 36 of the 2009 Political 
Declaration
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Continued on next page
Box 2 Global estimates on drug demand and supply: Methodology 
and gaps in data collection
Across the period 2009 to 2018, the UNODC has 
attempted to improve the data upon which it 
bases its annual World Drug Reports. However, 
these reports continue to be based essentially on 
data assembled from completed ARQs,80 which 
countries are mandated to provide to the UNODC 
secretariat each year. Although the ARQ was re-
vised in 2010, just a year following the adoption of 
the Political Declaration, the secretariat regularly 
acknowledges the gaps, irregularities and varying 
quality of data received from this mechanism.81
For example, in the 2018 World Drug Report 
(which refers to data from 2016) out of 199 re-
spondents, the UNODC received 110 replies to 
ARQ part 3 (‘Extent and patterns of drug use’) 
and 113 replies to ARQ part 4 (‘Extent and pat-
terns of cultivation, manufacture and trafficking’) 
(see Figure 2). The geographical distribution of 
responses is another issue of concern. While 87% 
of countries responded in Europe and 77% in 
Asia, only 57% responded in the Americas, 31% 
Figure 2. Response rate by member states to the ARQ on drug demand and supply for the World Drug 
Reports produced between 2010 (data from 2008-9) and 2018 (data from 2016)83
in Africa and, finally, only 2 out of 16 countries 
in Oceania. These issues severely impact upon 
the reliability, quality and comparability of the 
UNODC’s core data.82 In order to fill the gaps in 
data collection from the ARQ, the UNODC uses 
a number of additional data sources, including 
information provided by governments via offi-
cial communications with the UNODC, official 
national publications, as well as data from the 
Heads of National Law Enforcement Agencies, 
data published by international and regional or-
ganisations such as Interpol, the World Customs 
Organization, the European Monitoring Centre 
on Drugs and Drug Addiction, and the OAS In-
ter-American Drug Abuse Control Commission 
(CICAD).
The UNODC’s biennial reports on the 
implementation of the 2009 Political Declaration 
and Plan of Action, published in 2012, 2014, 2016 
and 2018, also rely upon the ARQ data submitted 
by governments. These analyse the progress – or 
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otherwise – made toward the objectives of the 
2009 Political Declaration and Plan of Action, and 
are therefore likewise affected by the gaps and 
lack in quality of data. The latest report published 
in 2018 deploys data gathered between 2010 
and 2016, taken from parts 1 ‘Legislative and 
institutional framework’ and 2 ‘Comprehensive 
approach to drug demand reduction and supply’ 
of the ARQ. For part 2, the UNODC notes that 
only about 40% of member states supplied data 
for use in the analysis of certain trends, such as 
activities related to supply reduction. Regions 
including Sub-Saharan Africa, Oceania and the 
Caribbean are heavily underrepresented in the 
sample, with only about 10% or less of member 
states in those regions responding consistently 
to parts 1 and 2 of the ARQ.84 A new round of 
consultations is currently underway to simplify 
and streamline the ARQ, with a view to adapt 
the ARQ to new realities but also to increase its 
response rate.85
Bearing in mind the multiple methodological 
complexities and gaps in available data, this 
section of the Shadow Report heavily relies 
on UNODC data, but also considers additional 
sources of information from other UN agencies, 
government reports and civil society findings. 
Furthermore, in 2013, the UNODC reported 
that data from 2011 represented improved ‘es-
timation methods applied and increased global 
coverage’ of drug use from previous years, as 
well as ‘an improved availability of more reliable 
data, which allows for setting a new baseline for 
global estimates on injecting drug use and HIV 
among people who inject drugs’.86 For drug use 
and drug-related harms, this report therefore re-
lies on baseline estimates from 2011, rather than 
on those for 2009.87 
cultivated in 2009, no global estimates were pro-
vided in 2018, although the UNODC concluded that 
cannabis cultivation was reported in 145 countries 
in the period 2010-2016, ‘representing 94 per cent 
of the world’s total population’.88 
It is important to note that, with the exception 
of Bolivia, which has implemented a sophisticat-
ed coca monitoring system carried out with the 
support of the European Union and local com-
munities, these cultivation figures should be con-
sidered as very rough estimates, as evidenced in 
the often vastly different reporting between the 
UN and the US government.89 They do, however, 
provide a useful measure for evaluating trends 
over time.
1.2 The illicit demand for narcotic 
drugs and psychotropic substances, 
and drug-related health and  
social risks
Here again, UNODC data for 201190 and 201691 show 
no  signi-ficant progress either on reducing demand, 
or on reducing drug-related health and social risks 
(see Table 2). The overall number of people aged 15-
64 who used drugs at least once in 2016 is estimated 
at 275 million, representing an increase by 31% on 
the 2011 numbers. It should be noted that over the 
same period, the overall world population increased 
by only 6%.92 The UNODC reported a reduction in 
the numbers of people who inject drugs from 14 
million in 2011 to 10.6 million in 2016 – although 
the 2018 World Drug Report also notes that ‘This 
estimate is based on the most recent and highest 
quality information currently available to UNODC. 
It does not imply that there has been a change in 
the global number of PWID compared with those 
published in previous editions of the World Drug 
Report’. The main drug of choice remains cannabis, 
with 192.2 million (increase by 17% since 2011), 
followed by opioids (increase by 16% since 2011) 
and amphetamines (with a major increase by 136% 
since 2011). 
Regarding drug-related health and social risks, 
the UNODC estimates that the global prevalence 
of HIV, hepatitis C and tuberculosis among people 
who inject drugs have remained high but stable, 
between 2011 and 2018 – although this does 
not reflect possible increases or decreases with-
in countries or regions, especially where data is 
scarce or of poor quality. According to the latest 
data, globally 11.8% of people who inject drugs 
are living with HIV (compared to 11% in 2011), 
and 51.9% are infected by hepatitis C (compared 
to 51% in 2011), while tuberculosis prevalence is 
at 8% (a slight decrease from the 2011 estimate 
at 8.4%). The number of drug-related deaths 
has surged by 145% since 2011, from 183,500 
deaths in 201193 to 450,000 recorded deaths in 
2015.94 Of those, 33 to 50% are caused by fatal 
overdose deaths.95
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Global estimates of people who use 
drugs 2011
96 Latest estimates (2016)97 Change since 2009
Total number of people who use drugs 210 million (range: 149-272 million)
275 million (range: 204-346 
million) + 31%
Total number of people who inject drugs 14 million 10.6 million* - 24%*
Total number of ‘problem drug users’ 27 million (range: 15-39 million)
30.5 million (range: 16.7-
44.4 million) + 13%
Number of people using cannabis 164 million (range: 125-203 million)
192.2 million (range: 165.8-
234.1 million) + 17%
Number of people using opioids 29.5 million (range: 24-35 million) 34.3 million + 16%
Number of people using ecstasy 19.5 million (range: 11-28 million) 26 million + 33%
Number of people using cocaine 17.5 million (range: 14-21 million) 18.2 million + 4%
Number of people using opiates 16.5 million (range: 12-21 million) 19.4 million + 18%
Number of people using amphetamines 
and prescription stimulants
14.5 million (range: 14-15 
million) 34.2 million + 136%
Table 2. Global estimates of people who use drugs, 2011 and 2016
1.3 The illicit production, 
manufacture, marketing and 
distribution of, and trafficking in, 
psychotropic substances, including 
synthetic drugs
Since 2009, the market for synthetic drugs – referred 
to in the UN conventions as ‘psychotropic substances’ 
– has become more complex and diversified than 
ever, and shows no signs of disappearing. The 2018 
World Drug Report found a persisting production 
and use of methamphetamine in North America 
and East and South East Asia, an expanding 
amphetamine market (both trafficking and use) from 
the well-established markets of the Near and Middle 
East/South West Asia to North African countries, and 
a surge in synthetic manufacture and consumption 
in South Asia.98 In 2015, the UNODC also reported an 
increase in methamphetamine production in West 
Africa, although this still constitutes a small share 
of overall global production of the substance.99 
The market for crystal methamphetamine was also 
reportedly on the rise in North America, East and 
South East Asia and Oceania, with a purer substance 
(crystals) than the traditional tablet form. Further, 
despite efforts to dismantle illegal manufacturing 
laboratories of MDMA (ecstasy) and to address 
trafficking of this substance, MDMA consumption is 
rising in Europe and Oceania.100 The increasing use 
of new technologies, in particular sales via the dark 
net, is posing additional challenges.101
In addition to the expanding market for traditional 
synthetic drugs, the past decade has seen the emer-
gence of hundreds of new psychoactive substances 
(NPS). In 2018, the UNODC reported that ‘the range 
of psychoactive substances available on the market 
has never been greater’, adding that ‘From 2009 to 
2017, 111 countries and territories reported a cumu-
lative total of 803 individual NPS’.102 
Another issue for this target relates to the non-med-
ical use of prescription drugs. Already in its 2011 
World Drug Report (corresponding to data from 
2009), the UNODC had characterised the ‘non-med-
ical use of prescription drugs’ as ‘a growing health 
803 NewPsychoac�veSubstances
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* This change can most likely be explained by methodological differences in data collection between 2011 and 2016 rather than by a reduction in the number of people who inject drugs, 
as noted in the 2018 World Drug Report.
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problem in a number of developed and developing 
countries’. In 2018, the situation was described as 
having ‘reached epidemic proportions in parts of 
the world’, in particular in North America where it 
has contributed to the opioid overdose crisis that 
has caused thousands of deaths over the past few 
years (see Box 4). Although ‘global estimates of the 
non-medical use of prescription drugs are not avail-
able’, the latest data led the UNODC to conclude that 
it ‘remains quite widespread’, with the use of benzo-
diazepines being the most common substance used 
in most countries.103 
1.4 The diversion of and illicit 
trafficking in precursors
Precursors are the ‘chemical substances that be-
come incorporated, at the molecular level, into a 
narcotic drug or psychotropic substance during the 
manufacturing process’.104 They are controlled under 
Article 12 of the 1988 Convention, which is policed 
by the INCB. The monitoring of precursor chemicals 
remains at the core of member states’ drug supply 
reduction activities.105 During the period 2010-2016, 
90% of ARQ respondents reported compiling lists 
of national companies authorised to manufacture, 
distribute and trade in precursors. Member states 
also adopted new measures to curb the diversion of, 
and illegal trafficking in, precursors, including the 
dissemination of lists of controlled substances to 
companies, the establishment of codes of conduct 
and guidelines for operators, and the adoption of 
legislation requiring companies to report the trans-
actions of controlled substances. Meanwhile, the 
proportion of member states engaging in monitor-
ing precursor chemicals decreased slightly between 
2010 and 2016 from 100% to 97%. The proportion 
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from 89,657 litres in 2012 to 135,184 litres in 2016.112 
Similarly, the seizures of potassium permanganate 
(used in the illegal manufacture of cocaine) increased 
from 92,702 kg in 2012 to 585,072 kg in 2016. Regard-
less of the increase in seizures, as mentioned above 
the production of cocaine has increased by 44% be-
tween 2009 and 2016 (see Table 1).
1.5 Money-laundering related to 
illicit drugs
While efforts have been made nationally to adopt 
new laws and regulations, and globally through re-
gional and international cooperation mechanisms 
to counter money-laundering associated to the 
illegal drug market (see Section 2.2.3 below), little 
impact has been recorded on the scale of mon-
ey-laundering between 2009 and 2018 – a UNODC 
study in 2011 estimated that less than 1% of the 
total amount being laundered is seized.113 
In 2009, criminal proceedings from the illegal drug 
market amounted to an estimated 3.6% of the glob-
al GDP, 2.7% of which was being laundered, repre-
senting US$ 1.6 trillion.114 The UNODC’s latest esti-
mates, released in 2017 and referring to data from 
2014, point to the fact that the amount of money 
laundered globally each year represents 2 to 5% of 
global GDP, that is, between US$ 800 million and 2 
trillion.115 The proceeds of drug sales ‘accounted for 
more than one quarter of overall revenues of trans-
national organized crime groups in 2014’. ‘In recent 
years’, the UNODC continues, ‘drug-related income 
seems to have represented the second largest 
for post-seizure investigations into precursor con-
trol decreased between 2010 and 2016, falling from 
94% to 77%.106 
At international level, the proportion of countries 
using the INCB’s Pre-Expert Notification Online 
(PEN Online) system – which enables easy online 
exchange of information between member states 
on shipments of chemicals and provides the ability 
to raise alerts to stop suspect shipments before they 
reach illegal drug manufacturers – increased from 
86% in 2010 to 98% in 2016.107 In the same period, 
around half of member states also reported taking 
steps to address the use of substances not under 
international control, as well as to target substitute 
chemicals for the manufacture of precursors used 
for the manufacture of heroin, cocaine or ATS.108
With regards to NPS, the challenge of controlling 
these substances begins with the identification of 
their precursor chemicals, and the methods used in 
their manufacture.109 The first NPS precursors to be 
internationally controlled were 4-anilino-N-pheneth-
ylpiperidine (ANPP) and N-Phenethyl-4-piperidi-
none (NPP), two precursors of fentanyl, which were 
scheduled into Table 1 of the 1988 Convention in 
October 2017.110 This brought the total of interna-
tionally controlled precursor substances to 26.
Despite these drug control efforts, however, the INCB 
reported that the use and number of precursors used 
in illegal production had increased in the past five 
years. Although there are major gaps in available data 
reported to the INCB on seizures of precursors,111 the 
Board reported a large increase in the seizure of acetic 
anhydride (used in the illegal manufacture of heroin) 
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source of income – after counterfeiting of a broad 
range of goods – of transnational organized crime 
groups at the global level’.116 Today, the global drug 
market is estimated to turnover between US$ 426 
and 652 billion.117 Of this, the UNODC estimates that 
‘well over half of the gross profits generated…are 
channelled into money-laundering’.118 
At regional level, similar trends have been observed. 
In Europe, the illegal drug market is valued at ap-
proximately 28.3 billion euros a year.119 A number of 
anti-money-laundering regulations were adopted 
by the EU over the past 10 years, with over US$ 20 
billion spent by banks each year to run a complex 
compliance regime. Despite these efforts, according 
to Europol, money launderers are running billions of 
illegal drug and other criminal profits through the 
European banking system with a 99% success rate 
– with only 1% of criminal assets seized each year 
in the EU.120 Similarly, West Africa has been greatly 
affected by the illegal drug market, corruption and 
money-laundering over the past 20 years. Despite 
efforts to tackle these issues, the number of court 
rulings on money-laundering is reportedly very low 
and, according to the Inter-Governmental Action 
Group Against Money-laundering in West-Africa, 
‘has not yielded the expected result’.121
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2  Assessing progress made towards the 
2009 Plan of Action against the broader 
priorities of the United Nations
Since the adoption of the UN Charter in 1945,122 the 
UN has aimed to maintain international peace and 
security, protect human rights, deliver humanitarian 
aid, promote sustainable development and uphold 
international law.123 It is against three of these over-
arching UN priorities – protecting human rights, 
maintaining peace and security and advancing 
development – that Section 2 evaluates progress 
made against selected actions to which member 
states unanimously committed themselves in the 
2009 Political Declaration and Plan of Action on 
drug control. Relevant actions are highlighted at the 
top of each sub-section in a text box. 
2.1  Protecting human rights
‘One of the shared elements to all declarations, action 
plans and resolutions that underline the principle of a 
comprehensive, integrated and balanced approach to 
addressing the world drug problem is the commitment 
to ensuring compliance with human rights norms’, 
INCB, June 2018124
The protection and promotion of human rights is 
a key purpose, as well as a guiding principle, of the 
UN and its founding Charter.125 In 1948, the Univer-
sal Declaration of Human Rights126 brought human 
rights into the realm of international law, with all UN 
bodies and entities – including the Vienna-based 
drug control bodies – being bound by the obligation 
to respect, protect and fulfil human rights and funda-
mental freedoms. Since then, a normative and insti-
tutional framework for the promotion and protection 
of human rights has been developed through the 
adoption of several binding human rights treaties. 
The 2009 Political Declaration itself reaffirms its 
‘unwavering commitment to ensure that all aspects 
of demand reduction, supply reduction and interna-
tional cooperation are addressed in full conformity 
with the purposes and principles of the Charter of 
the United Nations, international law and the Uni-
versal Declaration of Human Rights’ (paragraph 1). 
A similar paragraph was included in the preamble 
of the UNGASS Outcome Document,127 alongside an 
entire section dedicated to human rights. 
In recent years, increasing visibility has been given 
to the impacts of drug control on human rights, in 
particular with the adoption of the first ever Human 
Rights Council resolution on human rights and drug 
policy in 2015128 which resulted in a comprehensive 
analysis of the issue by the Office of the High Com-
missioner for Human Rights (OHCHR) a few months 
later.129 A second resolution was approved at the 
Human Rights Council in March 2018, mandating 
the OHCHR to draft a report aiming to contribute to 
the implementation of the UNGASS Outcome Docu-
ment from a human rights perspective.130
This section will assess the impacts of drug policies, 
strategies and programmes on the protection of 
human rights, in particular the right to health, the 
right to enjoy the benefits of scientific research, the 
right to life, the right to be free from torture and 
other cruel, inhuman and degrading treatment or 
punishment, the right to liberty and to be free from 
arbitrary detention, the right to a fair trial and due 
process, the rights of indigenous people, and the 
right to be free from discrimination.
2.1.1 The right to highest attainable standard of 
health
The right to the highest attainable standard of 
physical and mental health conducive to living a 
life in dignity (thereafter referred to as ‘the right to 
health’) is a human right which applies equally to all 
without discrimination. It is enshrined in a number 
of human rights treaties, including Article 12 of the 
International Covenant on Economic, Social and 
Cultural Rights131 (as well as General Comment No. 
20 on non-discrimination in economic, social and 
cultural rights132 and General Comment No. 22 on 
sexual and reproductive health133), Article 24 of the 
Convention on the Rights of the Child,134 Article 12 
of the Convention on the Elimination of All Forms 
of Discrimination against Women135 and Article 5 of 
the International Convention on the Elimination of 
All Forms of Racial Discrimination.136 
The right to health includes the rights to control 
one’s health and body, and to be free from non-con-
sensual medical treatment and experimentation 
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Assessing progress on
Human rights
27,000~extrajudicial killings in the 
Philippines, since June 2016
Death penalty Extrajudicial killings
Access to harm reduc�on Health in prisons Overdose response
3,940
people have been executed for drug 
oﬀences over the past decade
33 jurisdic�ons retain the death penalty for drug-related crimes
Only 1 in 100 people who inject drugs lives in a 
country with adequate coverage of both NSP 
and OST
2x - 10x
HIV, HCV & TB 
prevalence in prison








Decriminalisa�on Access to essen�al medicines
Incarcera�on Torture and cruel punishment
26
have adopted a model of
countries
decriminalisa�on
to facilitate access to health services, reduce 
s�gma and reduce prison overcrowding. 
75%of theworld
remain without access to 
proper pain relief treatment.
92%
of the global 
supply of 
morphine is 







83%~serve sentences for 
drug possession for 
personal use
In some parts of the world, 
over 80% of women 
incarcerated are serving 
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2009 Political Declaration and Plan of Action
Action 2(g): ‘Develop and implement, in coop-
eration with international and regional agen-
cies, a sound and long-term advocacy strategy, 
including harnessing the power of communi-
cation media, aimed at reducing discrimination 
that may be associated with substance abuse, 
promoting the concept of drug dependence as 
a multifactorial health and social problem and 
raising awareness, where appropriate, of inter-
ventions based on scientific evidence that are 
both effective and cost-effective’
which may amount to torture. In accordance with 
the obligation to uphold the right to health, member 
states must ensure that healthcare goods, services 
and information are available, accessible, afforda-
ble, acceptable and of good quality.137 States have 
an immediate obligation to take steps to progres-
sively realise the right to health to the maximum of 
their available resources, and should not take retro-
gressive measures which may result in reducing or 
preventing protections of the right to health.
Ensuring access to evidence-based drug 
prevention
Drug prevention programmes have historically 
consisted of mass media campaigns focusing on 
‘just say no’ messaging and scare tactics to deter 
people from using drugs. Both the UNODC138 and 
national policy makers have used this approach. In 
the USA, for example, the Montana Meth Project 
used slogans like ‘Not even once’, mistakenly im-
plying that methamphetamine use instantly leads 
to dependence, and portraying people who use 
methamphetamines as violent, engaging in risky 
and promiscuous behaviour, or induced into a 
‘zombie like’ status.139 In 2011, Romania launched 
a large-scale government-funded campaign to 
tackle the recent surge in NPS use, comparing peo-
ple who use drugs with cows eating grass.140 Sys-
tematic reviews of these mass media campaigns 
found that they have been ineffective at curbing 
the levels of drug use (which they had purported-
ly claimed to do), and may have exacerbated the 
social stigmatisation and demonisation of people 
who use drugs,141 exacerbating social exclusion, 
discrimination, violence and creating barriers to 
service and healthcare provision.
Similar campaigns have been developed to curb 
illegal cultivation – some of which have been found 
to be stigmatising towards indigenous groups. For 
instance, in 2008 the National Drug Commission of 
Colombia launched a prevention campaign called 
‘No cultives la mata que mata’142 – ‘Don’t grow the 
plant that kills’ – to dissuade people from cultivat-
ing, trafficking and using coca, cannabis and opium. 
The indigenous group Coca Nasa – a micro-firm cre-
ated to protect the rights of coca farmers – brought 
an official complaint against the campaign. This 
resulted in a Supreme Court decision in 2010 which 
found that the campaign infringed upon the rights 
of Coca Nasa and indigenous groups within Colom-
bia to grow and use coca for traditional purposes.143 
In 2018, the UNODC concluded that most preven-
tion interventions had reported ‘little or no effica-
cy’.144 Yet, based on ARQ responses, 57% of mem-
ber states continue to use media campaigns, 63% 
use information sharing and 15% use ‘vocational 
training and income generation’ programmes. 
On the other side of the spectrum, only 21% of 
UN member states use family and parenting skills 
training and just 17% use screening and brief in-
terventions, despite evidence of effectiveness for 
both interventions.145 
Worryingly, the UNODC also reported no improve-
ment since 2009 in the trend to evaluate prevention 
interventions, with most evaluations using process 
indicators, and ‘only a small number focusing on 
outcomes, and even fewer on impact’.146 The pro-
gress made towards ensuring that interventions are 
based on scientific evidence of effectiveness has 
therefore been limited since the adoption of the 
Political Declaration. In an effort to ‘guide policy-
makers worldwide to develop programmes, policies 
and systems that are a truly effective investment’, 
the UNODC launched a set of ‘International stand-
ards on drug use prevention’ in 2015.147 However, no 
follow-up study or evaluation on how the standards 
have been taken forward by member states has 
been conducted to date.
Credit: Private
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Ensuring access to harm reduction interventions 
Harm reduction refers to policies, programmes and 
practices that aim primarily to reduce the negative 
health, social and economic risks and harms asso-
ciated with drug use without necessarily reducing 
drug consumption. Harm reduction benefits people 
who use drugs, their families and the community.148 
Harm reduction is needed for all types of drugs 
(e.g. heroin, cocaine, cannabis, ATS, NPS, etc.) and 
all forms of use (e.g. smoking, injecting, snorting, 
etc.). Although not specifically mentioned by name, 
this evidence-based approach is implicitly recog-
nised within Article 36 of the Political Declaration 
and in two specific actions (Action 4(i) and 28(c)), 
and several key harm reduction interventions were 
included in the 2016 UNGASS Outcome Document 
(paragraphs 1.o and 1.m)149 for the first time. Harm 
reduction measures have also been recognised as 
essential for the realisation of the right to health 
by the UN General Assembly,150 the Human Rights 
Council,151 the Committee on Economic, Social and 
Cultural Rights,152 the Committee on the Rights of 
the Child,153 the Committee on the Elimination of 
All Forms of Discriminations against Women,154 the 
Special Rapporteurs on the right to health155 and on 
the prevention of torture,156 as well as the OHCHR.157
2009 Political Declaration and Plan of Action
Action 4(i): ‘Strengthen their efforts aimed at re-
ducing the adverse consequences of drug abuse 
for individuals and society as a whole, taking into 
consideration not only the prevention of related 
infectious diseases, such as HIV, hepatitis B and C 
and tuberculosis, but also all other health conse-
quences, such as overdose, workplace and traffic 
accidents and somatic and psychiatric disorders, 
and social consequences, such as family prob-
lems, the effects of drug markets in communities 
and crime’
Action 10(b): ‘Ensure, where appropriate, the 
sufficient availability of substances for medica-
tion-assisted therapy, including those within the 
scope of control under the international drug 
control conventions, as part of a comprehensive 
package of services for the treatment of drug 
dependence’
Action 28(c): ‘Develop prevention and treatment 
programmes tailored to the specific characteris-
tics of the phenomenon of amphetamine-type 
stimulants as key elements in any relevant strat-
egy to reduce demand and minimize health risks’
Box  3  CND resolutions 
related to harm reduction 
since 2009
 
Resolution 61/4. Promoting measures for the 
prevention of mother-to-child transmission 
of HIV, hepatitis B and C and syphilis among 
women who use drugs (2018)
Resolution 61/11. Promoting non-stigmatiz-
ing attitudes to ensure the availability of, ac-
cess to and delivery of health, care and social 
services for drug users (2018)
Resolution 60/8. Promoting measures to pre-
vent HIV and other blood-borne diseases as-
sociated with the use of drugs, and increasing 
financing for the global HIV/AIDS response 
and for drug use prevention and other drug 
demand reduction measures (2017)
Resolution 56/6. Intensifying the efforts to 
achieve the targets of the 2011 Political Dec-
laration on HIV and AIDS among people who 
use drugs, in particular the target to reduce 
HIV transmission among people who inject 
drugs by 50 per cent by 2015 (2013)
Resolution 55/7. Promoting measures to 
prevent drug overdose, in particular opioid 
overdose (2012)
Resolution 54/13. Achieving zero new infec-
tions of HIV among injecting and other drug 
users (2011)
Resolution 53/9. Achieving universal access 
to prevention, treatment, care and support 
for drug users and people living with or af-
fected by HIV (2010)
The effectiveness of harm reduction measures in 
protecting the health of people who use drugs is 
well documented. Since 2009, progress has been 
made to recognise and promote the nine inter-
ventions included in the Technical guide released 
by the WHO, UNODC and UNAIDS in 2012 on HIV 
prevention interventions among people who inject 
drugs, including needle and syringe programmes 
(NSPs) and opioid substitution therapy (OST).158 The 
number of countries with an explicit reference to 
harm reduction in national policy documentation 
increased from 71 in 2008 to 88 in 2016.159 Since 
2008, the number of countries providing NSPs, 
OST, drug consumption rooms and take-home 
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Harm reduction services
Number of countries with 
services in operation in 
2008-2010
Number of countries with 
services in operation in 
2017-2018 
Change since 2008
NSP 82 countries (2008)160 93 countries161 11 more countries
OST 70 countries (2008)162 86 countries163 16 more countries
Drug consumption rooms 8 countries (90 rooms) (2009)164 10 countries (118 rooms)
165 2 more countries
Take-home naloxone distribution 14 countries (2010)166 15 countries167 1 more country
Drug checking Unknown 18 countries168 Unknown
Heroin-assisted therapy Unknown 7 countries169 Unknown
Table 3.  Countries delivering key harm reduction interventions, 2008-present
naloxone (an opioid/opiate overdose antidote) has 
also increased (see Table 4). Globally, the number 
of drug consumption rooms has increased over the 
period 2008-2017, from 90 to 118 rooms, as Canada 
opened 25 new facilities over the past two years, 
spurred in part by the worrying increase in opioid 
overdose deaths in the country (see Box 4).170 Be-
tween 2014 and 2016, the UNODC also reported an 
increase in the coverage of antiretroviral therapy, 
condom distribution, targeted information and 
education, hepatitis B and C prevention, diagnosis 
and treatment, as well as tuberculosis prevention, 
diagnosis and treatment.171 
Despite such progress, significant challenges re-
main. At global level, only seven CND resolutions 
related to specific harm reduction were adopted 
since 2009 (i.e. 5% of all resolutions adopted, see 
Box 3), but the term ‘harm reduction’ has not yet 
been mentioned in any CND resolution or UNGASS 
declaration on drugs – although the term is en-
shrined in the Political Declarations on HIV and AIDS 
adopted in 2006,172 2011173 and 2016,174 and used 
widely across the UN agencies. Most recognised 
harm reduction interventions at the UN relate to 
drug injecting175 (see Box 4), with limited attention 
given to other methods of use, such as smoking 
and snorting, which require their own modes of 
harm reduction. This is despite the fact that the 
UNODC reported a 136% increase in ATS use since 
2009 – placing this category of drugs second only to 
cannabis176 (see Table 2). Although action 28(c) pro-
motes ‘prevention and treatment programmes’ to 
‘reduce demand and minimize health risks’ for ATS 
use, these programmes remain severely limited, and 
few efforts have been made to evaluate the level of 
coverage for harm reduction interventions among 
people who use ATS. To date, guidance from the UN 
on ATS use only consists of a WHO series of technical 
briefs published in 2011.177 The publication of a con-
ference room paper on stimulant harm reduction 
at the 61st session of the CND in March 2018 was a 
positive step in this regard.178 In this context, civil so-
ciety research and interventions have been instru-
mental in responding to non-injecting ATS use. ATS 
harm reduction interventions have included:
• Measures seeking to improve personal hy-
giene and nutrition, for example making water, 
fruits, toothpaste and toothbrushes available in 
low-thresholds drop-in centres, sharing of in-
formation on how to improve diets and getting 
adequate rest179
• Information on how to inject or smoke more 
safely, and the promotion of less harmful routes 
of drug use (e.g. smoking vs. injecting, although 
long-term smoking may also result in health 
harms) with the provision of smoking parapher-
nalia to reduce harms (e.g. in Canada, Italy, the 
Netherlands and Switzerland)
• Drug checking services, allowing people to as-
certain the content, purity and strength of their 
drug to reduce risks of overdoses and undesired 
or unexpected effects from ingesting toxic and/
or dangerous contaminants. Around 30 drug 
checking services (some officially recognised 
by governments, others operating informally) 
are available in 18 countries: Australia, Austria, 
Belgium, Canada, Colombia, France, Italy, Luxem-
bourg, Mexico, the Netherlands, New Zealand, 
Portugal, Slovenia, Spain, Switzerland, the UK, 
Uruguay and the USA180
• Housing first programmes and the provision 
of basic healthcare, food distribution and 
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employment services to reduce marginalisation 
and associated harms (e.g. in Brazil, Canada and 
Switzerland)
• Peer-led information sharing, reviews and feed-
back on drug purchases and use in online fo-
rums, and harm reduction advice on the dark net 
(e.g. community groups in Eastern Europe and 
Central Asia promoting HIV testing on the dark 
net).
Even for the more ‘traditional’ harm reduction servic-
es, access remains a key issue with no availability of 
OST, NSPs or naloxone in about 100 countries. Even 
in countries where these services are available, cov-
erage for the core interventions promoted in the UN 
Technical Guide remains ‘too low to be effective’,181 
with high coverage for NSPs in only nine countries, 
and OST only in 20 countries (see Figure 3). A 2017 
study also found that less than 1% of people who 
inject drugs live in countries with high coverage of 
both NSPs and OST.182 
Another major challenge remains the lack of fund-
ing allocated to harm reduction interventions. UN-
AIDS estimates that US$ 1.5 billion is required each 
year by 2020 to fund HIV prevention among people 
who inject drugs.183 However, only US$ 188 million 
was allocated to harm reduction in 2016 – the same 
amount (inflation adjusted) as in 2007, and just 13% 
of what is needed.184 It is also estimated that inter-
national donor funding – which accounts for two 
thirds of all harm reduction funding – fell by 24% 
between 2007 and 2016.185 Furthermore, while the 
funding gap for the broader HIV response in low- 
and middle-income countries is reported to be 20%, 
it should be noted that the gap is close to 90% for 
harm reduction.186 
The urgent need to address the funding gap for 
harm reduction was recognised at the CND in 2017, 
with the adoption of Resolution 60/8 ‘Promoting 
measures to prevent HIV and other blood-borne dis-
eases associated with the use of drugs, and increas-
ing financing for the global HIV/AIDS response and 
for drug use prevention and other drug demand re-
duction measures’.187 With indications of reduced in-
ternational donor funding for harm reduction, and 
limited domestic investment in harm reduction ap-
proaches within HIV budgets, civil society has called 
upon governments to critically evaluate their drug 
policy investments and consider redirecting a small 
proportion of funds from law enforcement to health 
and harm reduction responses.188 Indeed, Harm 
Reduction International estimated that redirecting 
just 10% of drug law enforcement funding towards 
harm reduction would cover harm reduction needs 
in the community and in prison189 – where coverage 
remains particularly poor (see below). 
Furthermore, there remain significant legislative, 
political and technical barriers hampering access 
to harm reduction. The WHO ‘Consolidated guide-
lines on HIV prevention, diagnosis, treatment and 
care for key populations’, first published in 2014 
and revised in 2016, identified four ‘critical enablers’ 
as part of an effective public health response to 
HIV, or in other words, ‘essential strategies for an 
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• Supportive legislation, policy and financial com-
mitment, including a call for countries to ‘review 
and revise policies and work towards the decrim-
inalisation of behaviours, such as drug use and 
possession for personal use’ (this will be further 
discussed below).
• Addressing stigma and discrimination, in-
cluding the adoption and implementation of 
anti-discrimination laws, the provision of drug 
user-friendly health and social services, and the 
training and sensitising of health workers.
• Community empowerment, including in the 
planning and delivery of services, especially peer 
education and training on safer injection, harm 
Credit: H
arm
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Figure 4. The global funding gap for harm reduction192
reduction and other issues related to the rights 
and health of people who use drugs.
• Addressing violence against people who use 
drugs, including the monitoring and reporting of 
cases of violence, and mechanisms established to 
provide justice to cases of violence, the provision 
of health and other support services to victims 
of violence, and training of law enforcement and 
health and social care providers on the rights of 
people who use drugs.190 
Nevertheless, the ongoing criminalisation of peo-
ple who use drugs, law enforcement operations 
near harm reduction services, the huge stigma and 
discrimination associated with drug use and the 
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lack of effective legal protection against these, as 
well as the widespread cases of violence against 
people who use drugs in various countries, act 
as a significant barrier to accessing health and 
social services.193 
As a result of these various factors, people who use 
drugs are made particularly vulnerable to health 
and social harms. In the 2011 Political Declaration 
on HIV and AIDS, UN member states had commit-
ted to reducing new HIV infections by 50% among 
people who inject drugs by 2015.194 As mentioned 
above, no progress has been made towards this 
target. On the contrary, both UNAIDS195 and the 
UNODC196 reported that the number of newly in-
fected people who inject drugs had increased by 
one third between 2011 and 2015, from 114,000 
to 152,000 new cases. UNAIDS also estimated that 
in 2017, the risk for people who inject drugs to ac-
quire HIV was 22 times higher than for the general 
population.197 Some regions have been particularly 
affected, especially Eastern Europe and Central Asia 
and the Middle East and North Africa, where people 
who inject drugs accounted for more than one third 
of new HIV infections in 2017.198 
Similarly, the global prevalence of viral hepatitis C and 
tuberculosis among people who inject drugs has re-
mained the same or increased slightly between 2009 
and 2016 – although these data do not take into ac-
count wide differences across countries and regions. 
The number of drug-related deaths has also increased 
dramatically during the same period from 183,500 
deaths in 2009 to an estimated 450,000 deaths in 
2015 – with opioid overdose deaths representing 












2009 Political Declaration and Plan of Action
Action 4(h): ‘Consider developing a compre-
hensive treatment system offering a wide range 
of integrated pharmacological (such as detoxifi-
cation and opioid agonist and antagonist main-
tenance) and psychosocial (such as counselling, 
cognitive behavioural therapy and social sup-
port) interventions based on scientific evidence 
and focused on the process of rehabilitation, 
recovery and social reintegration’
Action 10(b): ‘Ensure, where appropriate, the 
sufficient availability of substances for medica-
tion-assisted therapy, including those within 
the scope of control under the international 
drug control conventions, as part of a compre-
hensive package of services for the treatment 
of drug dependence’
Action 28(c): ‘Develop prevention and treat-
ment programmes tailored to the specific 
characteristics of the phenomenon of amphet-
amine-type stimulants as key elements in any 
relevant strategy to reduce demand and min-
imize health risks’
a third to half of drug-related deaths. Although the 
USA has been most impacted by the recent surge in 
overdose deaths (see Box 4), a similar trend can be 
observed in Canada (3,987 overdose deaths recorded 
in 2017)199 and Europe (9,138 overdose deaths in the 
EU, Norway and Turkey in 2016).200
Ensuring access to evidence-based drug 
dependence treatment
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‘By denying effective drug treatment, State drug pol-
icies intentionally subject a large group of people to 
severe physical pain, suffering and humiliation, effec-
tively punishing them for using drugs and trying to 
coerce them into abstinence, in complete disregard of 
the chronic nature of dependency and of the scientific 
evidence pointing to the ineffectiveness of punitive 
measures’, Juan E. Mendez, UN Special Rapporteur 
on torture and other cruel, inhuman or degrading 
treatment or punishment, 2013201
The UNODC reported little increase in the availabil-
ity of drug dependence treatment between 2010 
and 2016, and coverage remains low. Between 2009 
and 2017, only 40% of member states reported high 
coverage of counselling and treatment planning, 
while coverage remained low and unchanged for 
detoxification, OST, peer support groups, screening 
and brief interventions, contingency management, 
cognitive behaviour therapy, treatment for comor-
bidity, motivational interviewing, vocational train-
ing, social assistance, education activities, rehabili-
tation and aftercare.202 
Although OST is the treatment option with the most 
solid evidence base to manage opioid dependence, 
it is only operational in less than half of the world, 
and remains ‘the least provided’ drug dependence 
treatment service,203 despite an increase from 70 
to 86 countries providing OST between 2008204 
and 2017.205 In various countries, methadone and 
buprenorphine – the most common drugs used for 
OST which are also included in the WHO Model List 
of Essential Medicines206 – are banned in national 
legislation; this is the case in countries such as Egypt, 
Jordan, the Russian Federation, Saudi Arabia, Syria, 
Turkmenistan and Uganda. Countries like the Rus-
sian Federation have been criticised by a number 
of UN human rights treaty bodies for not providing 
methadone as a form of OST, and several cases on 
the issue are pending within the European Court of 
Human Rights.207 
When OST is indeed available, additional barriers 
include cost (with many services only provided in pri-
vate facilities), accessibility (especially in rural areas 
and for women and LGBTQ+ individuals), long waiting 
lists, restrictive prescription and delivery regulations, 
lack of awareness about OST and available services, 
and fear of breach of confidentiality.208 Morphine 
(slow release) and heroin-assisted treatment – an-
other treatment option for opioid dependence with 
strong evidence of effectiveness209 – remains limited 
to a small number of countries (Canada, Denmark, 
Germany, the Netherlands, Spain, Switzerland and 
the UK), often in the form of pilot or high-threshold 
programmes with a small number of beneficiaries.210
Additionally, substitution treatment for people de-
pendent on stimulants, including ATS and crack/
cocaine, is severely limited, and research is lagging 
behind despite evidence of extensive problematic 
use and hence clinical need. With regards to ATS 
dependence, substitution treatment was reported 
in Australia with dextroamphetamine.211 In the UK, 
substitution programmes using dexamphetamine 
have been in place since 1988, and although no 
controlled studies were conducted, ‘the doctors…
generally regard their amphetamine maintenance 
as clinically successful’, with ‘significant reductions 
in amphetamine use, benzodiazepine use, fre-
quency of injection, needle-sharing, and money 
spent on illicit drugs’.212 In Asia, mild plant-based 
stimulants are used as a form of substitution 
treatment, including kratom in Thailand and My-
anmar,213 and ephedra in China, although more 
evaluations are needed to assess the effectiveness 
of these programmes.214 Regarding substitution 
treatment for people dependent on cocaine, sev-
eral studies have analysed the benefits of using 
cannabis to help people to regain control over 
their crack use. In Brazil, available studies have 
shown that cannabis use helped to reduce crav-
ing for crack, improve people’s sleep and appetite 
and improve their overall quality of life.215 Similar 
initiatives have been developed in Jamaica216 and 
Canada.217 However, such initiatives remain limited 
to a few selected countries and localities, and so far 
scientific evaluations of these interventions have 
been scarce.
Finally, in many countries, particularly in the global 
south, the quality of drug dependence treatment 
provided is questionable and is not based on availa-
ble scientific evidence,218 with cases of ill-treatment 
and other human rights abuses documented by 
non-governmental organisations (NGOs) and UN 
agencies alike.219 This is despite the recommenda-
tion of Special Rapporteur on the right to health 
that ‘the same standards of ethical treatment ap-
ply to the treatment of drug dependence as other 
health-related conditions’, and that ‘health-care 
personnel have an obligation…not to stigmatize or 
violate a patient’s human rights’.220 The Special Rap-
porteur on torture has documented several instanc-
es of torture and other ill-treatment of people who 
use drugs in the name of treatment and rehabilita-
tion.221 In 2012, the UNODC published its ‘TREATNET 
Quality standards for drug dependence treatment 
and care services’, in an effort to contribute to ‘the 
development of evidence-based drug depend-
ence treatment services’.222 However, good quality 
treatment remains a major issue of concern. 
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Box 4 The unprecedented opioid overdose crisis in  
North America
North America has recently experienced an un-
precedented number of overdose deaths. In the 
USA, between 1999 and mid-2018, more than 
350,000 people have died from an opioid over-
dose.223 This is six times more than the number of 
deaths of American soldiers during the entirety of 
the Vietnam War.224 The highest number on record 
was in 2017, when total overdose deaths reached 
71,568.225 The White House estimated the financial 
cost of the ‘opioid epidemic’ to be US$ 504 billion 
in 2015.226 People of colour, in particular African 
American men, have been disproportionately im-
pacted by fatal overdoses.227 Numerous explana-
tions have been provided for this highly worrying 
trend. Some have identified the powerful pharma-
ceutical industry228 and over-prescription in the 
1990s and 2000s while others point to economic 
insecurity, deindustrialisation,229 the widespread 
criminalisation and demonisation of people who 
use drugs, and their social exclusion.230 
Like the USA, Canada is experiencing an epidem-
ic of opioid-related overdoses. In 2017, a record 
3,987 people in Canada died of apparent opioid 
overdoses, an increase of 34% since 2016.231 The 
majority of opioid-related deaths involved the 
potent synthetic opioid fentanyl or fentanyl ana-
logues.232 In addition to overdose deaths, opioid 
poisonings in 2016-2017 resulted in an average of 
16 hospitalisations a day.233 
Article 36(b) of the 2009 Political Declaration, and 
Actions 4(i) and 10(b) commit member states to 
‘strengthen their efforts aimed at reducing the 
adverse consequences of drug abuse… such as 
overdose’. The response to this crisis by the US 
and Canadian governments has been drastically 
different in that regard. 
In the USA, the Trump White House has acknowl-
edged the severity of the opioid crisis by declaring 
it as a national emergency,234 but in the context of 
rhetoric promoting border crackdowns and other 
punitive enforcement. When it comes to crucial 
life-saving healthcare programmes, such as ex-
panded drug dependence treatment, the Trump 
Administration and the Republican-controlled 
Congress have moved to curtail funding and crip-
ple the Affordable Care Act. A 2016 report by the 
Surgeon General found that only 10% of Americans 
suffering from drug dependence obtain specialty 
treatment, due to severe shortages in the supply 
of care and lack of affordable options.235 Currently, 
only 8% of US counties implement overdose edu-
cation and naloxone distribution programmes – a 
key harm reduction intervention to reduce the risk 
of opioid overdose deaths.236
In the meantime, Canada’s federal government 
chose a ‘public health approach to problematic 
substance use’ and adopted a new ‘Canadian 
drugs and substances strategy’, under leadership 
from the Minister of Health.237 The new strategy 
restores harm reduction as a key pillar of drug 
policy (which had been excised entirely in 2007 
by the previous government), alongside the other 
three pillars of treatment, prevention and law en-
forcement. This was accompanied by legislation 
to simplify the process of applying for an exemp-
tion under federal drug law to operate drug con-
sumption rooms without risk of prosecution to 
clients or staff for drug possession.238 As a result, 
the number of these facilities has grown from one 
legally-sanctioned room in 2016 to 26 currently 
operating in four provinces in August 2018, with 
more applications under review.239 
In addition, frustrated by the insufficiently rapid 
response at various levels of government, com-
munity advocates in several cities opened, with-
out legal sanction, lower-barrier pop-up ‘over-
dose prevention sites’ to enable easier access to 
sterile injection equipment and the opportunity 
for immediate interventions, such as naloxone 
administration, in the event of an overdose. In re-
sponse, Health Canada ultimately agreed to give 
provinces and territories the ability obtain a class 
exemption from federal drug laws for any provin-
cially-approved overdose prevention sites so as to 
approve temporary sites based on urgent need, 
without requiring the lengthy application process 
for a full service.240 The Federal Parliament also 
8%UnitedStatescounties
implement overdose 
education and naloxone 
distribution programmes
only
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Against Women: Article 12 of the Convention 
(Women and Health) requires that states ‘eliminate 
discrimination against women in their access to 
healthcare services throughout the life cycle’.248 
Nevertheless, most harm reduction and treatment 
services continue to be tailored primarily to men 
who use drugs,249 and many fail to provide suitable 
environments and support for women and girls, 
including for example childcare facilities, sexual 
and reproductive health services, services to tackle 
gender-based violence, adequate opening hours, 
geographical access, and staff trained to respond 
to gender-specific needs.250 Breaches of confidenti-
ality in healthcare settings – a fundamental human 
rights principle251 – in relation to their drug use and 
HIV status may deter women from accessing ser-
vices and increases the likelihood of them experi-
encing exclusion, harassment, abuse and violence. 
Finally, the fear of loss of child custody when mak-
ing contact with healthcare providers acts as an im-
portant deterrent for mothers to access services.252 
In countries or jurisdictions where drug use during 
pregnancy is criminalised, women may avoid sex-
ual and reproductive health services for fear of ar-
rest, putting themselves and their babies at risk of 
further harm.253
As a result, although women make up one third of 
people who use drugs globally, they only repre-
sent one fifth of those in treatment.254 In 2017, the 
INCB concluded that this was particularly the case 
‘in low- and middle-income countries’, mentioning 
Afghanistan, where ‘women make up only 4% of 
those in treatment’, and Pakistan, where ‘that fig-
ure is 13 per cent’.255 These data suggest that little 
progress has been made towards Action 14(a) at 
national level.  
The specific challenges faced by women have be-
come more visible in international debates since 
2009, although only three CND resolutions have 
been dedicated to the issue over the past nine years 




Women and girls are particularly at risk of drug-relat-
ed health harms because of criminalisation, stigma-
tisation and social exclusion, which are compound-
ed with endemic gender inequality, gender-based 
violence and misogyny. In various EU countries, 
average HIV prevalence can be up to 50% higher 
among women who use drugs than among their 
male counterparts.246 Risk factors include the fact 
that women are more likely than men to be ‘second 
on the needle’ (i.e. they inject after, and are often in-
jected by, a male partner), the high level of gender 
stereotyping and stigma associated with their use, 
which deters them from accessing harm reduction 
and treatment services, and the severe lack of gen-
der-sensitive drug services. For women sex workers 
who use drugs, they face additional criminalisation 
which serves to further enhance their risk of sexual-
ly-transmitted or blood-borne infections.247 
General Recommendation No. 24 of the UN 
Committee on the Elimination of Discrimination 
passed the Good Samaritan Drug Overdose Act 
to protect both overdose victims and witnesses 
from certain charges related to drug possession 
when seeking emergency help.241 Among other 
additional actions, the federal government has 
adopted regulatory amendments to make na-
loxone available without a prescription242 and to 
remove regulatory barriers to the prescription 
of methadone and diacetylmorphine (heroin).243 
At international level, Canada, alongside other 
member states, spearheaded the adoption by the 
CND of the first-ever resolution addressing stigma 
against people who use drugs, including in health 
and other social services.244 While these efforts are 
commendable, Canada – as many other countries 
across the globe – continues to rely on criminal 
sanctions against all those involved in illegal drug 
activities, including people who use drugs. The 
ongoing criminalisation of people who use drugs 
is an important factor hampering progress in the 
response to this ‘national public health crisis’.245 It 
also remains to be seen what impact the recent 
move towards a legal, regulated cannabis market 
might have on the opioid crisis.
2009 Political Declaration and Plan of Action
Action 14(a): ‘Ensure that a broad range of 
drug demand reduction services, including 
those in the areas of prevention, treatment, 
rehabilitation and related support services, 
provide approaches that serve the needs of 
vulnerable groups and are differentiated on 
the basis of scientific evidence so that they 
respond best to the needs of those groups, 
taking into account gender considerations and 
cultural background’
Action 14(c): ‘Provide specialized training for 
those who work with vulnerable groups, such 
as patients with psychiatric co-morbidities, mi-
nors and women, including pregnant women’
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women in all stages of the development, implemen-
tation, monitoring and evaluation of drug policies 
and programmes, and to develop and disseminate 
gender-sensitive and age-appropriate measures that 
take into account the specific needs and circumstanc-
es faced by women and girls with regard to the world 
drug problem, bearing in mind that targeted inter-
ventions that are based on the collection and analysis 
of data, including age- and gender-related data, can 
be particularly effective in meeting the specific needs 
of drug-affected populations and communities’.260
Nevertheless, although issues affecting women are 
now being discussed in Vienna-based UN agen-
cies, those affecting LGBTQ+ communities have 
so far been entirely ignored by the CND, although 
these issues are increasingly being discussed with-
in UNAIDS261 and are mentioned in the OHCHR re-
port on UNGASS implementation.262 At local level, 
various programmes have sought to address the 
health risks associated with practices like chemsex 
(i.e. drugs used to accompany, enhance and/or 
facilitate sexual activity, in particular among gay, 
bisexual and other men who have sex with men, as 
well as in queer and fetish communities).  These in-
clude peer support groups, helplines, distribution 
of harm reduction paraphernalia and counselling, 
but overall these initiatives remain severely lim-
ited.263 At national level, Ireland’s latest national 
drug strategy for 2017-2025 explicitly addresses 
chemsex.264
Ensuring access to prevention services for  
children and youth
(that is, only 2% of all resolutions adopted since 
2009, see Box 5). The inclusion, in 2016, of an entire 
chapter dedicated to the issue of human rights, 
women, children, youth and vulnerable members 
of society in the UNGASS Outcome Document is 
therefore welcome.256 In 2017, the INCB also dedi-
cated the thematic chapter of its Annual Report to 
women and drugs and a specific section on human 
rights,257 while Booklet 5 of the 2018 UNODC World 
Drug Report also focuses exclusively on this issue.258 
The UNODC also collaborated with the International 
Network of People Who Use Drugs, UN Women and 
the WHO to produce a policy brief analysing the 
specific needs of women who inject drugs.259 These 
are late but welcome steps towards providing more 
visibility to the specific issues faced by women and 
the need to ensure differentiated responses to guar-
antee their rights.
Furthermore, Human Rights Council Resolution 
37/42 calls upon States to ‘mainstream a gender 








Box  5  CND resolutions 
focusing on women
Resolution 61/4. Promoting measures for the 
prevention of mother-to-child transmission 
of HIV, hepatitis B and C and syphilis among 
women who use drugs (2018)
Resolution 59/5. Mainstreaming a gender 
perspective in drug-related policies and pro-
grammes (2016)
Resolution 55/5. Promoting strategies and 
measures addressing specific needs of wom-
en in the context of comprehensive and inte-
grated drug demand reduction programmes 
and strategies (2012)
2009 Political Declaration and Plan of Action
Action 14(b) ‘Ensure that prevention 
programmes target and involve youth and 
children with a view to increasing their reach 
and effectiveness’.
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The Convention on the Rights of the Child is the only 
UN human rights treaty making a specific reference 
to drugs, requiring signatory states to ‘take all ap-
propriate measures…to protect children from the 
illicit use of narcotic drugs and psychotropic sub-
stances’ (Article 33). The Convention also recognises 
‘the right of the child to the enjoyment of the high-
est attainable standard of health and to facilities for 
the treatment of illness and rehabilitation of health’ 
and the obligation for states parties ‘to ensure that 
no child is deprived of his or her right of access to 
such health care services’ (Article 24.1). 
In an effort to achieve this obligation, most coun-
tries have tried to prevent drug use among youth 
and children with ‘just say no’ messaging and scare 
tactics, instead of seeking to strengthen protective 
factors and reduce risk factors leading to drug use, 
in line with the UNODC International standards 
on drug use prevention.265 A prominent example 
of such an approach was promoted by Singapore 
at the 2016 CND in the form of postcards being 
shared in schools as a drug prevention strategy.266 
Although ‘just say no’ prevention interventions 
remain widespread, scientific evidence suggests 
that they have had limited to no impact on drug 
use prevalence, and have side-lined initiatives with 
greater efficacy.267 
Mandatory drug testing in schools and educational 
settings have also been used by a number of gov-
ernments to deter drug use among youth, despite 
the human rights concerns raised over this practice. 
Human Rights Watch notably concluded that ‘tak-
ing a child’s bodily fluids, whether blood or urine, 
without their consent may violate the right to bodily 
integrity and constitute arbitrary interference with 
their privacy and dignity’. ‘Depending on how such 
testing occurs’, Human Rights Watch continued, ‘it 
could also constitute degrading treatment, and may 
deter children from attending school or college…
depriving them of their right to an education’.268 
Mandatory drug testing efforts may also be coun-
terproductive, with people switching to less detect-
able (but sometimes more harmful) substances.
Furthermore, despite efforts to prevent drug use 
among youth and children, the latest data from the 
UNODC show that the extent of drug consump-
tion is higher among young people than among 
older people in most countries, and for most drug 
types.269 Reflecting this trend, many prevention pro-
grammes have not only sought to deter drug use, 
but have also focused on providing life-saving harm 
reduction advice and services and aimed to address 
the wider social issues faced by young people. In 
its General Comment No. 15, the UN Committee 
on Rights of the Child endorsed harm reduction as 
an important approach to minimising the negative 
health impacts of drug use among children and 
young people.270 The Committee also urged states 
to increase the production and dissemination of 
accurate and objective information with regards 
to drug use.271 Similarly, the Special Rapporteur on 
the right to health has stressed the importance of 
states providing prevention, harm reduction and 
treatment services specifically tailored to the needs 
of children and adolescents.272
In order to better ‘involve youth and children’ in 
prevention programmes in line with action 14(b), 
some peer-led drug education initiatives have been 
developed by civil society. For instance, Students 
for Sensible Drug Policies, a student-led organisa-
tion promoting harm reduction access for young 
people, recently launched a peer-led programme 
called ‘Just Say Know’.273 The programme provides 
certification and training for young people to be-
come peer educators and organise workshops and 
seminars on drug education and harm reduction in 
schools and universities. The programme was pilot-
ed in the USA and Nigeria and has received positive 
feedback from the peer educators, the students and 
the schools themselves.274 Although this initiative 
requires further scientific evaluation, it is an inter-
esting example of how to better involve young peo-
ple in prevention and education campaigns. 
To date, limited progress has been made in expand-
ing youth-friendly harm reduction services since 
2009, and young people continue to face a number 
of barriers in accessing harm reduction services, such 
as age restrictions, the need for parental consent in 
accessing NSPs and OST, or lack of training on how 
to respond to their needs.275 To improve young 
people’s access to youth-friendly harm reduction 
services, several NGOs have developed toolkits and 
guides for practitioners.276 Various UN agencies also 
collaborated with NGOs to produce a technical brief 
on HIV and young people who inject drugs in 2015.277 
These documents recommend expanded access 
to child and family welfare services, housing, food, 
social protection benefits, legal assistance, access 
to education, vocational training and employment, 
mental health support, as well as harm reduction 
services in festivals and nightlife settings, including 
drug checking services.278 The work of youth-led 
NGOs (e.g. Students for Sensible Drug Policies, Youth 
Organisation for Drug Action, Youth RISE and others) 
focusing on harm reduction and drug policy reform 
has also brought more visibility to the issue and tech-
nical expertise on how to address the complex range 
of problems faced by young people who use drugs. 
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but are poorly served’.284 UNAIDS also estimated 
that rates of drug injection among prisoners ranged 
from 2 to 38% in Europe, 34% in Canada and up to 
55% in Australia.285 Where there is little or no access 
to sterile injection equipment in such settings, it fol-
lows that most injection involves the sharing, often 
by multiple people, of non-sterile equipment, often 
makeshift ‘rigs’ fashioned from other items.
The UNODC found that the level of access to a com-
prehensive range of drug dependence treatment 
in prisons has only marginally improved between 
2010 and 2017, while coverage of some services had 
Ensuring access to drug services in prisons
According to the Nelson Mandela Rules, the right 
to the highest attainable standard of physical and 
mental health extends to people held in prison and 
other closed settings. As such, people in custody 
should receive a level of healthcare comparable to 
that available to people in the community and with-
out discrimination.279
There are an estimated 10 million people incarcer-
ated worldwide,280 and evidence shows that prisons 
are high risk environments for the spread of com-
municable diseases, with ‘the prevalence of HIV, 
HBV and tuberculosis among people in prison and 
other closed settings…2 to 10 times higher than 
among the general population’.281 In some regions, 
the Americas in particular, incarceration is driven by 
the mass incarceration of low-level drug offenders. 
It is therefore unsurprising that drug use in closed 
settings remains high. Worldwide, the UNODC esti-
mates that around one in three prisoners have used 
drugs at least once while in prisons,282 stating that 
‘prisoners are at higher risk for infectious diseases 
2009 Political Declaration and Plan of Action
Action 15(a): ‘Working within their legal 
frameworks and in compliance with applicable 
international law, consider allowing the 
full implementation of drug dependence 
treatment and care options for offenders, 
in particular, when appropriate, providing 
treatment as an alternative to incarceration’
Action 15(c): ‘Implement comprehensive 
treatment programmes in detention facilities; 
commit themselves to offering a range of 
treatment, care and related support services 
to drug-dependent inmates, including those 
aimed at prevention of the transmission of 
related infectious diseases, pharmacological 
and psychosocial treatment and rehabilitation; 
and further commit themselves to providing 
programmes aimed at preparation for release 
and prisoner support programmes for the 
transition between incarceration and release, 
re-entry and social reintegration’
Action 16(d): ‘Provide appropriate training so 
that criminal justice and/or prison staff carry 
out drug demand reduction measures that are 
based on scientific evidence and are ethical 
and so that their attitudes are respectful, non-
judgemental and non-stigmatizing’
Box  6  UN comprehensive 
package of 15 key 
interventions in prison
In 2013, the UNODC, the International Labour 
Organization, UNDP, the WHO and UNAIDS 
released a policy brief on the prevention, 
treatment and care of HIV in prisons and oth-
er closed settings which promotes a compre-
hensive package of 15 interventions:
1. Information, education and  
communication
2. Condom programmes
3. Prevention of sexual violence
4. Drug dependence treatment, including 
opioid substitution therapy
5. Needle and syringe programmes
6. Prevention of transmission through  
medical or dental services
7. Prevention of transmission through tat-
tooing, piercing and other forms of skin 
penetration
8. Post-exposure prophylaxis
9. HIV testing and counselling
10. HIV treatment, care and support
11. Prevention, diagnosis and treatment of 
tuberculosis
12. Prevention of mother-to-child  
transmission
13. Prevention and treatment of sexually  
transmitted infections
14. Vaccination, diagnosis and treatment of 
viral hepatitis
15. Protecting staff from occupational hazards.283
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already receiving OST prior to their incarceration. 
Treatment quality also remains an issue, with servic-
es available ‘not necessarily of the same standard as 
those provided in the community’.292 Additional is-
sues include long waiting times to access treatment, 
unnecessary restrictions for some prisoners, and the 
ongoing stigma and discrimination associated with 
OST in prison.293
With regards to other drug services in prison, in 
particular those included in the UN comprehensive 
package of 15 key interventions in prison (see Box 
6), the UNODC reported that only antiretroviral 
therapy and HIV testing and counselling were con-
sistently reported to be widely available in prison 
settings, and coverage for tuberculosis prevention, 
diagnosis and treatment among people who use 
drugs has increased since 2014.294 However, the 
availability of NSPs in prison, which was already 
limited to only 10 countries in 2010,295 was further 
reduced in 2016 to only eight countries, with Iran 
and Romania having closed down their services.296 
Discussions are underway in Canada to start imple-
menting NSPs in all federal prisons. Condoms are 
rarely made available in prisons despite the higher 
risks of contracting sexually transmitted diseases 
while in prison.297 Little progress was also made in 
expanding the provision of measures aimed at re-
ducing the risks of overdose, despite the fact that 
‘people who use heroin are exposed to a severe risk 
of death from overdose after release from prison, 
especially in the first two weeks’.298 In 2016, only a 
small number of countries provided varying de-
grees of overdose prevention training and distribut-
ed naloxone to prisoners on or prior to their release, 
Figure 5. Comparing the percentage of countries reporting a high degree of coverage of treatment services in 
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actually decreased during the 2010-2017 period, 
including for opioid antagonist therapy, treatment 
planning and contingency management (see Figure 
5).287 However, access to OST in prison has improved, 
being available in 52 countries in 2016288 compared 
to 33 in 2008.289 
Despite such progress, however, more than 140 
countries still have no access to OST in prison set-
tings, in contravention of the right to health of peo-
ple deprived of their liberty. In countries where it is 
available, OST is sometimes only available in one or 
two prisons, generally in male prisons – even though 
women incarcerated for drug offences ‘suffer worse 
consequences than men’, meaning that women 
generally have no access to these programmes 
while incarcerated.290 This is despite the recommen-
dation from the UN Committee on the Elimination 
of Discrimination against Women that ‘gender-sen-
sitive and evidence-based drug treatment services 
to reduce harmful effects for women who use drugs, 
including harm reduction programmes for women 
in detention’ should be available.291 In some cases, 
people can only access OST in prison if they were 
2x - 10x
HIV, HCV & TB 
prevalence in prison
higher than among 
the general popula�on
Credit: Juan Fernandez O
choa, ID
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including Estonia, Ireland, Norway, Spain, the UK,299 
various provinces in Canada and two US states.300
In terms of progress towards Action 16(d), train-
ings targeted at criminal justice and prison staff 
on demand reduction measures in prison settings 
have fallen in 2016-2017 to the ‘lowest recorded 
level’, with a decrease most noticeable among ‘law 
enforcement and prison staff’.301 The UNODC also 
reported that ‘harm reduction activities initiated 
by officers were primarily focused on the potential 
threat of prisoner-to-staff transmission’,302 rather 
than aiming to reduce the health risks of drug use 
among prison inmates. 
Providing alternatives to prison or punishment 
for people who use drugs 
‘A criminal record for a young person for a minor drug 
offence can be a far greater threat to their well-being 
than occasional drug use’, Kofi Annan, former UN 
Secretary General303 
Article 4(c) of the 1988 UN Convention against Illicit 
Traffic in Narcotic Drugs and Psychotropic Substanc-
es provides that ‘in appropriate cases of a minor 
nature, the Parties may provide, as alternatives to 
conviction or punishment, measures such as educa-
tion, rehabilitation or social reintegration, as well 
as, when the offender is a drug abuser, treatment 
and aftercare’ (emphasis added).304 The 2009 Plan 
of Action also promotes for the use of such alterna-
tives in action 15(a), while recognising ‘the concept 
of drug dependence as a multifactorial health and 
social problem’ in action 2(g). Despite these com-
mitments, data from the UN Commission on Crime 
Prevention and Criminal Justice (CCPCJ) shows that 
one in five prisoners worldwide is incarcerated for a 
drug offence,305 of whom 83% are in prison for drug 
use or possession for personal use.306 
The need to make better use of alternatives to prison 
and punishment for people who use drugs has been 
recognised in paragraph 4.j of the UNGASS Outcome 
Document,307 in CND resolution 58/5 ‘Supporting the 
collaboration of public health and justice authorities 
in pursuing alternative measures to conviction or 
2009 Political Declaration and Plan of Action
Action 15(a): ‘Working within their legal 
frameworks and in compliance with applicable 
international law, consider allowing the 
full implementation of drug dependence 
treatment and care options for offenders, 
in particular, when appropriate, providing 
treatment as an alternative to incarceration’
punishment for appropriate drug related offences of 
a minor nature’,308 and by a number of UN agencies 
and entities that have called for the decriminalisation 
of people who use drugs, including the UNODC,309 
the OHCHR,310 UNAIDS,311 WHO,312 the United Nations 
Development Programme,313 a number of UN Special 
Rapporteurs on human rights,314 the UN Commit-
tee on Economic Social and Cultural Rights,315 UN 
Women,316 as well as the UN High Commissioner for 
Refugees, UNICEF, the World Food Programme, the 
International Labour Organization, UNESCO, the UN 
Population Fund and the International Organization 
for Migration.317 Similarly, various regional bodies 
have given visibility to the issue. In 2015, CICAD com-
missioned a study on the availability and effectiveness 
of alternatives to incarceration to inform the debate 
in the Americas,318 and also concluded that ‘Decrim-
inalization of drug use needs to be considered as a 
core element in any public health strategy’.319 More 
recently, the Inter-American Commission on Human 
Rights recommended the decriminalisation of drug 
use and possession for personal use as a way of re-
ducing pre-trial detention and improving prison con-
ditions.320 The European Union also released a study 
on the various alternatives to incarceration across 
the region321 and adopted Council Conclusions in 
support of the practice.322 Finally, the need for ‘alter-
natives to incarceration for minor offenses’ featured 
in the African Union’s 2013-2017 Plan of Action on 
Drug Control.323 
At national level, only 26 countries have adopted a 
decriminalisation model, whether de jure (enshrined 
in the law), or de facto (in practice only), focusing on 
all substances for some or only cannabis for many 
others.324 These include: Armenia, various provinces 
in Australia, Belgium, Chile, Colombia, Costa Rica, 
Croatia, the Czech Republic, Ecuador, Estonia, Ger-
many, Israel, Italy, Jamaica, Latvia, Mexico, the Neth-
erlands, Paraguay, Peru, Poland, Portugal, Slovenia, 
Spain, Switzerland, various US states and Uruguay.325 
In Argentina and Georgia, the criminalisation of 
drug possession for personal use was ruled as un-
constitutional, but no legislative reform has yet tak-
en place in either country. Only six of the countries 
26
have adopted a model of
countries
decriminalisa�on
Credit: Juan Fernandez O
choa, ID
PC
50  Taking stock: A decade of drug policy
The Portuguese decriminalisation policy 
emerged in 2000 – under the leadership of for-
mer President and current UN Secretary Gen-
eral Antonio Guterres – thanks to a confluence 
of several political and social factors. At the 
time, the HIV epidemic among people who use 
drugs had surged massively, more than 75% of 
prisoners were incarcerated for drug-related 
crimes, and mass media was fuelling public 
fears that people using drugs would inevitably 
die. As a result, drug policy quickly became 
the top priority of the government. A com-
mission, composed of experts from different 
backgrounds and expertise, was established in 
1998 to draft a new ‘National strategy to fight 
against drugs’. At the time, the country’s strat-
egy already promoted inclusiveness and broad 
participation of people who use drugs, their 
families, health and education professionals, 
the courts, the community, etc. The national 
strategy was approved in April 1999, enshrin-
ing in the law the fundamental principles 
of humanism, pragmatism, innovation, the 
importance of scientific evidence, as well as 
community participation in drug policy design  
and implementation. 
The decriminalisation model was officially 
adopted with Law 30/2000 in July 2001, and 
was followed by significant investments in 
a broad and coordinated network of health 
and social services. Law 30/2000 introduced 
a system of referral to administrative panels 
called ‘Commissions for the Dissuasion of Drug 
Addiction’. A person detained by the police 
with up to 10 days’ worth of drugs is referred 
to the Commission which can orientate them 
towards voluntary harm reduction and treat-
ment services, social services, and also impose 
fines and community service – although sanc-
tions are rarely used in practice. 
Although still enshrined in a punitive approach, 
the model adopted in Portugal has nonethe-
less greatly improved health outcomes, with 
a drop in new HIV infections attributed to in-
jection, reduced numbers of overdose deaths, 
and a significantly lower rate of drug-induced 
mortality among adults than the European 
average (3.86 deaths per million recorded in 
Portugal compared to 21.8 deaths per million 
across the EU in 2016). The policy has also fa-
cilitated access to voluntary drug dependence 
treatment and harm reduction interventions, 
and has reduced the incarceration rate for 
drug offences, while enabling law enforce-
ment efforts to focus on high-level traffickers 
and organised crime.326
However, even the Portuguese decriminalisa-
tion model is facing various challenges, not 
least the issue of funding. Harm reduction ser-
vices in Portugal are mainly provided by NGOs, 
with a strong community basis, and are funded 
by up to 80% by the state, with NGOs covering 
the remaining 20%. Government budget cuts, 
combined with the difficulty for NGOs to raise 
money for an issue that is no longer a top pri-
ority for Portuguese society, have resulted in 
hard working conditions, low salaries and lack 
of training for harm reduction service provid-
ers. The Portuguese Harm Reduction Network 
submitted a set of recommendations to the 
Health Secretary of State in October 2017 to 
improve harm reduction sustainability, includ-
ing the need to change the funding rules for 
drug services. So far, however, no change has 
been made, and the Portuguese policy remains 
under pressure. Recent reforms have also split 
the management of drug services into two 
branches, the first managed by the Portuguese 
drug agency (Serviço de Intervenção nos Com-
portamentos Aditivos e nas Dependências) 
and in charge of defining the national strate-
gy, producing information, introducing inno-
vation and evaluating implementation; and 
the second concerned with local diagnosis of 
needs and implementation.327 Tension and lack 
of coordination between the two branches are 
also issues of concern. Finally, although drug 
use is decriminalised, people continue to rely 
on the criminal black market to purchase their 
drug of choice, with no control over the purity 
or quality of the substance used. Nevertheless, 
and despite these challenges, the Portuguese 
decriminalisation policy is regarded as an im-
portant model, having proven its effectiveness 
in protecting the health and improving the 
social inclusion of people who use drugs. 
Box 7 A health and social response to drug use:  
The case of Portugal
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Vietnam and Uzbekistan) and compulsory regis-
tration requirements for people who use drugs 
(used in Azerbaijan, Brunei Darussalam, Cambodia, 
China, India, Indonesia, Japan, Kazakhstan, Kyr-
gyzstan, Lao PDR, Malaysia, Myanmar, Pakistan, Ta-
jikistan, Turkmenistan and Uzbekistan).331 In some 
countries, including Vietnam, the Philippines and 
Indonesia, the families of people who use drugs 
and/or the general public are required, or strongly 
encouraged, to report people who use drugs to 
public authorities. In some cases, law enforcement 
agencies use these registries and the information 
they contain for interrogation purposes.332 In 2013, 
the UN Special Rapporteur on Torture concluded 
that ‘Use of drug registries – where people who 
use drugs are identified and listed by police and 
health-care workers, and their civil rights curtailed 
– are violations of patient confidentiality that lead 
to further ill-treatment by health providers’.333 
These practices also act as a strong deterrent for 
accessing life-saving health and social services.334
Other countries or jurisdictions which have not 
decriminalised drug use have nonetheless adopted 
diversion models for people who use drugs, which 
can be triggered at time of arrest, during trial and 
post-incarceration. The level of effectiveness for 
these alternatives to incarceration varies greatly.335 
For instance, the drug courts model implement-
ed in the USA and promoted in various regions of 
the world, especially in Latin America, has been 
subject to considerable criticism. A 2018 compre-
hensive study of drug courts implemented across 
the Americas has found that they were ‘a costly, 
cumbersome intervention that has limited, if any, 
listed above – Croatia, the Czech Republic, Ecuador, 
Israel, Jamaica and Mexico; the province of Western 
Australia and several US states made their move 
towards decriminalisation during the period 2009-
2018, with ongoing discussions in several countries 
such as Ghana, Ireland, Norway and Tunisia. Canada 
is expected to bring into force, in late 2018, legis-
lation decriminalising possession of cannabis for 
personal use, although the government continues 
to reject calls to decriminalise possession of other 
substances. The low prevalence of decriminalisa-
tion among member states as a viable alternative 
to punitive approaches persists, despite increasing 
evidence that removing criminal sanctions against 
people who use drugs can reduce prison over-
crowding, improve health outcomes, and address 
drug use-related stigma and discrimination.328 The 
decriminalisation models adopted in the countries 
mentioned above vary considerably, as do their lev-
el of effectiveness.329 The model with the most solid 
evidence base is Portugal330 (see Box 7).
Some countries do not impose criminal sanctions 
against drug use or possession for personal use per 
se but continue to use excessive and dispropor-
tionate administrative punishments that violate a 
number of human rights, including the rights to 
health, liberty and privacy. These include compul-
sory detention (see below), forced urine testing 
(including in Azerbaijan, Bangladesh, Cambodia, 
China, Georgia, Indonesia, Iran, Kazakhstan, Kyr-
gyzstan, Lao PDR, Malaysia, Myanmar, Pakistan, 
the Philippines, Singapore, South Korea, Sri Lan-
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barrier to an effective drug court system.342 Other 
approaches have yielded better results. For exam-
ple, the Law Enforcement Assisted Diversion (LEAD) 
programme launched in 2011 in Seattle, USA, has 
focused on diverting people who use drugs at the 
time of arrest to a case worker providing health and 
social guidance on a case-by-case basis. Evaluations 
of the programme have shown positive results, and 
similar initiatives are now being implemented in 
other US cities.343
Improving access to controlled substances for 
medical purposes
One of the stated key objectives of the UN drug 
control treaties is to ensure access to controlled 
substances for medical and scientific purposes – but 
only one action in the entire 2009 Political Declara-
tion and Plan of Action is dedicated to the issue: 
Action 10(c). The cornerstone essential medicine 
for palliative care and pain relief is oral morphine. In 
its General Comment No. 14, the UN Committee on 
Economic, Social and Cultural Rights also recognised 
the obligations for member states to ‘respect the 
right to health by, inter alia, refraining from denying 
or limiting equal access for all persons…to preven-
tive, curative and palliative health services’, and en-
sure the availability of ‘essential drugs’ included on 
the WHO Model List of Essential Medicines without 
delay as a ‘core minimum obligation’.344
2009 Political Declaration and Plan of Action
Action 10(c): ‘Continue to comply with the 
procedures established under the international 
drug control conventions and relevant 
resolutions of the Economic and Social Council 
relating to the submission to the International 
Narcotics Control Board of estimates of 
their requirements for narcotic drugs and 
assessments of requirements for psychotropic 
substances so as to facilitate the import of 
the required narcotic drugs and psychotropic 
substances and to enable the Board, in 
cooperation with Governments, to maintain 
a balance between the demand for and the 
supply of those drugs and substances in order 
to ensure the relief of pain and suffering and 
the availability of medication-assisted therapy 
as part of a comprehensive package of services 
for the treatment of drug dependence, while 
bearing in mind, in accordance with national 
legislation, the World Health Organization 
Model List of Essential Medicines’
Box  8  Addressing the health 
impacts of aerial spraying 
of crops cultivated for drug 
production
The 2009 Political Declaration and its Plan of 
Action focus exclusively on the health aspects 
of drug use, without considering the health 
implications of supply reduction efforts in ar-
eas affected by illegal crop cultivation. This is 
despite evidence that forced crop eradication 
through aerial spraying using harmful herbi-
cides have had severe impacts on the rights 
and health of local communities. In 2015, the 
WHO International Agency for Research on 
Cancer concluded that glyphosate – often 
used for aerial spraying – ‘probably causes 
cancer’,336 while the UN Special Rapporteur 
on the Right to Health declared that there 
was ‘trustworthy evidence that aerial fumi-
gation with glyphosate…damages the phys-
ical health’337 of affected communities. This 
includes respiratory problems, skin rashes, 
diarrhoea, eye problems and miscarriages.338 
Aerial spraying also has indirect health 
impacts. In Colombia, for instance, aerial 
spraying has damaged legal subsistence 
food crops such as bananas, beans, plantains 
and yuca, as well as chicken and fish farms, 
located near coca fields.339 In such contexts, 
subsistence farmers not only lose their main 
source of income (coca and other crops des-
tined for the illegal drug market), but also 
their main source of food (as is the case with 
any form of forced eradication). Furthermore, 
aerial spraying can damage rivers and wa-
ters, threatening to leave entire communities 
without access to clean water.340 
impact on reducing incarceration. Indeed, for many 
it may have the opposite effect: increasing criminal 
justice supervision and subjecting participants who 
fail to graduate to harsher penalties than they may 
have otherwise received’.341 In many cases, instead 
of focusing on people dependent on drugs having 
committed other offences, drug courts focus on 
people caught for simple drug use or possession for 
personal use (generally cannabis). The unavailability 
of evidence-based treatment programmes in vari-
ous countries in the region also acts as a significant 
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The need to ensure access to ‘essential medicines, 
including controlled medicines’ for surgical care 
and anaesthesia was also recognised by the World 
Health Assembly as an essential component of uni-
versal health coverage. The World Health Assembly 
also noted that a large proportion of the global 
population had limited access to opioid analgesics 
for pain relief, and that 5.5 billion people (i.e. 83% 
of the world’s population) lived in countries with 
low to non-existent access to analgesics, with only 
710 million people (11% of the world’s population) 
having moderate to adequate access.348 
In 2013, the Special Rapporteur on torture con-
cluded that ‘Ensuring the availability and accessi-
bility of medications included in the WHO Model 
List of Essential Medicines’ was ‘a legal obligation 
under the Single Convention on Narcotic Drugs, 
1961’, adding that ‘When the failure of States to 
take positive steps, or to refrain from interfering 
with health-care services, condemns patients to 
unnecessary suffering from pain, States not only 
fall foul of the right to health but may also violate 
an affirmative obligation under the prohibition of 
torture and ill-treatment’.349
The severe lack of access to controlled substances 
for medical purposes is driven, among other issues, 
by national rules and regulations around controlled 
medicines that go far beyond the requirements 
of the 1961 and 1971 drug control treaties. These 
In 2010, the INCB reported that ‘Although medical 
science has the capacity to provide relief for most 
forms of moderate to severe pain, over 80 per cent 
of the world population will have insufficient anal-
gesia, or no analgesia at all, if they suffer from such 
pain’.345 In 2015, the INCB published a special report 
on access to controlled medicines, which showed 
little improvement from the 2009 data. In its special 
report, the INCB concluded that ‘Around 5.5 billion 
people still have limited or no access to medicines 
containing narcotic drugs, such as codeine or mor-
phine, leaving 75 per cent of the world population 
without access to proper pain relief treatment. 
Around 92 per cent of morphine used worldwide 
is consumed in countries in which only 17 per cent 
of the world population lives: primarily the United 
States of America, Canada, Western Europe, Austral-
ia and New Zealand’.346 In 2017, a study also estimat-
ed that 298.5 metric tonnes of morphine-equivalent 
opioids were distributed in the world each year, but 
only 0.1 metric tonnes (0.03%) were made available 
in low-income countries. As a result, 25.5 million 
people who died in 2015 – representing 45% of 
all global deaths that year – experienced serious 
health-related suffering. 80% of these deaths were 
in developing regions of the world. The study also 
found that each year, 2.5 million children die ex-
periencing serious health-related suffering. 98% of 
these children lived in developing countries, and 
93% of these deaths were avoidable.347
75%of theworld
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proper pain relief treatment.
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hampering access, increased empowerment and 
training of frontline healthcare workers, the adop-
tion of a palliative care policy or strategy, and the al-
location of more funding towards providing access 
to palliative care and pain relief.356 
It is in the field of medicinal cannabis that most 
progress has been made since the adoption of 
the 2009 Political Declaration – despite the UN 
drug control system delineating cannabis as a 
drug whose liability ‘to abuse and to produce ill 
effects…is not offset by substantial therapeutic 
advantages’.357 48 countries now provide some 
form of medicinal cannabis for a number of ail-
ments (see Figure 6).358 24 of these countries have 
adopted or reviewed drug legislations to allow 
or expand access to medicinal cannabis between 
2009 and 2018, including Argentina, Australia, 
Brazil, Chile, Colombia, Croatia, the Czech Re-
public, France, Germany, Greece, Italy, Jamaica, 
Lesotho, Luxembourg, Malta, Macedonia, Mexico, 
Peru, the Philippines, Poland, Portugal, Romania, 
various states in the USA and Zimbabwe. In the 
UK, a recent scandal involving a 12-year old boy 
whose anti-epileptic medicine (cannabidiol oil) 
was confiscated by customs agents at a London 
airport showcased the urgent need to review 
drug legislations and ensure broader access to 
include overly strict requirements such as special 
prescription forms, limitations on the number of 
days a prescription can cover, limitations on which 
healthcare workers can prescribe controlled sub-
stances, the criminalisation of healthcare providers 
for prescribing medications and the resulting fear of 
arrest, requirements for additional licenses for hospi-
tals, pharmacists and healthcare workers, additional 
record keeping or reporting requirements, and lim-
itations on the daily doses that can be prescribed. 
Lack of understanding and training about palliative 
care and pain relief – in particular ‘opiophobia’ – are 
also important barriers to improving the availabil-
ity of controlled medicines.350 The funding gap is 
also a major issue for ensuring adequate access to 
controlled medicines – although it is estimated that 
‘the cost of meeting the global shortfall of about 
48.5 metric tonnes of morphine-equivalent opioids 
is about $145 million per year’, the equivalent of 
0.0002% of global GDP.351
Despite the urgency of ensuring better access to 
controlled medicines, only four CND resolutions 
were adopted on this issue since 2009 (see Box 
9) – representing just 3% of all CND resolutions 
adopted between 2009 and 2018. The UNGASS 
Outcome Document has made considerable pro-
gress in this area, with an entire chapter aimed 
at improving access to controlled substances for 
medical and scientific purposes.352 In 2014, the 
World Health Assembly also adopted Resolution 
67.19 ‘Strengthening of palliative care as a com-
ponent of comprehensive care throughout the life 
course’, noting CND resolutions 53/4 and 54/6, and 
recognising that ‘access to palliative care and to 
essential medicines…including opioid analgesics 
such as morphine, in line with the three United 
Nations international drug control conventions, 
contributes to the realization of the right to the 
enjoyment of the highest attainable standard of 
health and well-being’.353 In 2018, in order to pro-
vide ‘concrete information about actions Member 
States can take to address the negative health out-
comes, such as the enormous burden of untreated 
pain around the world, associated with inadequate 
access to controlled medicines’, the UNODC re-
leased its ‘Technical guidance: Increasing access 
and availability of controlled medicines’.354 
Some progress has been made in various countries 
to improve access to and availability of controlled 
medicines, including in Costa Rica, India, Mexico, 
Uganda (see Box 10) and Ukraine – with Kenya, Ma-
lawi, Nigeria, Rwanda and Swaziland expected to 
follow similar steps undertaken by Uganda.355 These 
have included the removal of regulatory barriers 
Box  9  CND resolutions 
adopted on access to 
controlled medicines  
since 2009
Resolution 57/10. Preventing the diversion 
of ketamine from legal sources while ensur-
ing its availability for medical use (2014)
Resolution 54/6. Promoting adequate avail-
ability of internationally controlled narcotic 
drugs and psychotropic substances for med-
ical and scientific purposes while preventing 
their diversion and abuse (2011)
Resolution 54/3. Ensuring the availability 
of reference and test samples of controlled 
substances at drug testing laboratories for 
scientific purposes (2011)
Resolution 53/4. Promoting adequate avail-
ability of internationally controlled licit drugs 
for medical and scientific purposes while pre-
venting their diversion and abuse (2010) 
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2.1.2 The right to enjoy the benefits of scientific 
research
Article 15 of the International Covenant on Eco-
nomic, Social and Cultural Rights364 recognises ‘the 
right of everyone…to enjoy the benefits of scien-
tific progress and its applications’, and ‘the freedom 
indispensable for scientific research and creative 
activity’.365 The UN drug conventions also promote 
access to controlled substances for research pur-
poses, with a view to assessing their potential me-
dicinal use. This is recognised and encouraged in 
Action 22(l) of the 2009 Political Declaration and 
Plan of Action.
medicinal cannabis for children with epilepsy.360 
As a result of intense civil society pressure, the UK 
Home Office announced that it would make cer-
tain products available on prescription imminent-
ly based on advice from medical authorities – and 
would reschedule cannabis to Schedule 2 of the 
Misuse of Drugs Regulations 2001.361
In response to the rapid expansion of medicinal 
cannabis worldwide, the INCB released guidelines 
for member states to follow to ensure compliance 
with the UN drug control treaties.362 In addition, 
for the first time in 83 years, a scientific assess-
ment by the WHO Expert Committee on Drug 
Dependence (ECDD) on cannabis and its deriva-
tives is underway. In its provisional conclusions, 
the ECDD recommended that pure CBD ‘should 
not be scheduled within the International Drug 
Control Conventions’. The ECDD also decided 
to proceed to a critical review of cannabis plant 
and resin, extracts and tinctures of cannabis, Del-
ta-9-THC and isomers of THC, with conclusions 
planned to be released on time for the 2019 
Ministerial Segment.363
Medicinal cannabis regulated
Argen�na, Australia, Brazil, Canada, Chile, Colombia, Croa�a, Czech Republic, 
Finland, France, Germany, Greece, Israel, Italy, Jamaica, Macedonia, Mexico, 
the Netherlands, New Zealand, Peru, the Philippines, Poland, Puerto Rico, 
Romania, Spain, Switzerland, United Kingdom, United States, Uruguay
Pilot projects on medical cannabis
Denmark, Ireland
Nabiximols (Sa�vex) authorised
Austria, Belgium, Brazil, Denmark, Finland, Hungary, Iceland, Ireland, Italy, 
Kuwait, Liechtenstein, Luxemburg, Malta, New Zealand, Norway, Portugal, 
Slovakia, Spain, Sweden, United Arab Emirates, United Kingdom







 briefing paper on m
edicinal cannabis
2009 Political Declaration and Plan of Action
Action 22(l): ‘Remain up to date on scientific 
studies, data and research on the medicinal 
and other legitimate uses of plants containing 
narcotic and psychotropic substances, taking 
into account the provisions of the three 
international drug control conventions’
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grant-giving bodies’, further hampering research.374 
Finally, the fear and threat of prosecution of doctors 
and scientists involved in such research may also act 
as yet another barrier.375
This is despite growing evidence of the potential 
benefits of these substances to treat a number of 
illnesses. Available scientific evidence, for instance, 
supports the potential therapeutic use of cannabis 
in neurological diseases376 such as multiple sclero-
sis377 and epilepsy,378 chronic pain379 and appetite 
stimulation.380 Similarly, several studies have high-
lighted the possible benefits of MDMA for patients 
with treatment-resistant post-traumatic stress dis-
order, of LSD for cluster headaches, and of psilocy-
bin for obsessive-compulsive disorder and cluster 
headaches, among others.381 
It should nonetheless be recalled that ‘science’ may 
be conceptualised differently from one country to 
another. This issue was particularly visible in 2015 
However, there remains significant barriers in medi-
cal research on controlled drugs, with little improve-
ment since 2009. The classification of substances like 
LSD, MDMA, cathinone and psilocybin in Schedule I 
of the 1971 Convention and of cannabis in Sched-
ules I and IV of the 1961 Convention has resulted in 
tight controls at national level, severely restricting 
their access for scientific research due to the bu-
reaucracy associated with conducting research or 
clinical trials.372 In the UK, for example, obtaining a 
Schedule 1 licence under the Misuse of Drugs Act to 
conduct scientific research takes over a year, costs 
around GBP 5,000 (US$ 6,500), and requires high 
levels of security for the research facility.373 Obtain-
ing the substance itself may also present difficulties 
as they are usually unavailable from standard chem-
ical manufacturers. Furthermore, the fact that these 
substances are placed in Schedule I – and are there-
fore considered as dangerous with little therapeutic 
value – was found to be ‘a powerful deterrent to 
Box 10  Improving access to controlled medicines in Uganda
Uganda has become a leader in East Africa for 
improving access to palliative care. Although 
coverage remains severely limited with 90% of 
Ugandans in need not being able to access pal-
liative care,366 over the past 20 years the gov-
ernment has undertaken a number of steps to 
improve the situation. 
These steps have included incorporating 
palliative care in the Ugandan ‘Health sector 
development plan for 2015/16 to 2019/20’,367 
and the approval of the first ‘National palliative 
care policy’ in 2015,368 hence providing a com-
prehensive framework to scale up palliative 
care services nationwide. Palliative care was 
also integrated in the curriculum of healthcare 
professionals, in an effort to facilitate its appli-
cation in mainstream healthcare, but also to 
broaden the range of opioid prescribers – al-
lowing nurses and clinical officers to prescribe 
oral morphine for pain management.369 The 
registration of oral morphine as a palliative 
care treatment by the National Drug Authority 
and its inclusion into Uganda’s national list of 
essential medicines was also instrumental to 
ensure better access to the medicine for pain 
relief and palliative care. Other factors of suc-
cess have included a long-standing relation-
ship between the Ministry of Health, Hospice 
Africa Uganda, the Palliative Care Association 
of Uganda and the private sector,370 as well as 
the allocation of government funding to pur-
chase morphine. Finally, efforts were made to 
destigmatise and conduct more research on 
palliative care.
Despite these positive steps, various obstacles 
remain. For instance, the Narcotic Drugs and 
Psychotropic Substances (Control) Act, prom-
ulgated in 2015, inadvertently made prescrip-
tion and dispensation of morphine by nurses 
illegal, hampering efforts to expand palliative 
care since nurses are at the frontlines of pallia-
tive care provision. The 2015 legislation, draft-
ed by the Ministry of Internal Affairs without 
consultation with the Ministry of Health, also 
approved an approach overly focused on inter-
diction of drug use and trafficking, greatly im-
pacting upon access to controlled substances 
for palliative care and pain relief and hindering 
the realisation of the right to health.371 Civil 
society calls to reform the 2015 Act led to the 
creation of an ad hoc committee in September 
2017. Comprised of representatives from the 
Ministry of Health, the Ministry of Internal Af-
fairs and civil society, the committee advises 
the government on issues related to palliative 
care and harm reduction, and on how to im-
prove the 2015 legislation. In the meantime, 
the Chief of Counter-Narcotics has committed 
not to prosecute nurses prescribing and dis-
pensing morphine. 
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governments should adopt “all positive measures” 
to “increase life expectancy”’.389 This includes several 
elements, particularly a range of economic, social 
and cultural rights which are essential to meet the 
basic needs and lead a dignified life. 
The death penalty for drug offences
Although the death penalty is not specifically men-
tioned in the 2009 Political Declaration, international 
human rights mechanisms and the INCB are unani-
mous in their conclusion that drug offences do not 
meet the threshold of ‘most serious crimes’, which are 
the only crimes under international law to which the 
death penalty may conceivably be applied.390 How-
ever, 33 jurisdictions worldwide still prescribe capital 
punishment for drug-related crimes. Although only 
a minority execute for these offences (see Table 4),391 
since 2009 at least 3,940 people were executed for 
drug offences.392 This figure is likely to amount for 
only a fraction of those executed because of the un-
der-reporting and secrecy surrounding the practice 
in various countries – most notably China, where 
thousands of people are believed to have been exe-
cuted for drug offences in the past decade.393
In addition to the serious human rights implications 
of such an approach, available evidence shows that 
the death penalty has no measurable impact on 
deterring involvement in drug-related offences, the 
prevalence of drug use and drug-related health and 
social harms. In fact, Asia – where most countries 
imposing the death penalty for drugs are locat-
ed – is one of the regions where drug use overall 
is increasing.394
A growing number of human rights mechanisms, 
drug control bodies and governments have called 
for an end to the death penalty for drug offences, 
including the UNODC395 and the INCB.396 The wide 
opposition to capital punishment for drugs was ev-
ident during the 2016 UNGASS, where 66 member 
states spoke against the practice.397 Regrettably, as 
in 2009, no consensus could be achieved between 
member states on the issue, leading to its omission 
from the UNGASS Outcome Document.398
during the negotiation of CND Resolution 58/7382 
on strengthening cooperation with the scientific 
community on drug demand and supply reduction 
policies. Proposed by the Russian Federation, the 
resolution was the subject of concerns among civil 
society groups since the country’s discourse around 
harm reduction, and OST in particular, has failed to 
recognise available scientific evidence of effective-
ness for these interventions. Instead, the Russian 
Federation has long promoted its science of ‘nar-
cology’, which draws its roots from Soviet Russian 
psychiatry.383 In such contexts, the UNODC, WHO 
and other UN entities have a key leadership role to 
play in collating and assessing scientific evidence 
on drug control. 
2.1.3 The right to life
‘Although drugs and crime kill, governments should 
not kill because of them’, UNODC Executive Director 
Foreword of the 2009 Political Declaration384
The right to life, enshrined within Article 3 of the 
Universal Declaration of Human Rights,385 Article 
6 of the International Covenant on Civil and Polit-
ical Rights,386 and Article 6 of the Convention on 
the Rights of the Child,387 is the precondition for 
the full realisation of human dignity and the effec-
tive exercise of all human rights.388 The UN Human 
Rights Committee has stressed that the ‘right to 
life…should not be interpreted narrowly and that 
2009 Political Declaration and Plan of Action
Action 22(c): ‘Ensure that supply reduction 
measures are carried out in full conformity 
with the purposes and the principles of the 
Charter of the United Nations and international 
law, the three international drug control 
conventions and, in particular, with full respect 
for the sovereignty and territorial integrity of 
States, the principle of non-intervention in the 
internal affairs of States and all human rights 
and fundamental freedoms’
Action 41(c): ‘Ensure that measures to control 
precursors and amphetamine-type stimulants 
are carried out in full conformity with the 
purposes and the principles of the Charter of 
the United Nations and international law, the 
international drug control conventions and, in 
particular, with full respect for the sovereignty 
and territorial integrity of States, the principle of 
non-intervention in the internal affairs of States 
and all human rights and fundamental freedoms’
3,940
people have been executed for 
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for Human Rights  condemned these killings and 
expressed concern that marginalised communities 
were being particularly targeted.417 Similarly, the ap-
proach of ‘shoot to kill’ while enforcing drug laws, in 
violation of the right to life, has been condemned by 
the UNODC which concluded that ‘Such responses 
contravene the provisions of the international drug 
control conventions, do not serve the cause of justice, 
and will not help to ensure that “all people can live in 
health, dignity and peace, with security and prosper-
ity”’.418 The INCB,419 various UN human rights bodies420 
and governments421 also condemned the practice of 
extrajudicial killings as a drug control strategy. 
2.1.4 The right to be free from torture and other 
cruel, inhuman and degrading treatment or 
punishment
The right to be free from torture and other cruel, in-
human and degrading treatment or punishment is 
enshrined in Article 7 of the International Covenant 
on Civil and Political Rights422 and the Convention 
against Torture and Other Cruel, Inhuman or Degrad-
ing Treatment or Punishment.423 This prohibition is 
absolute and non-derogable, even in time of public 
emergency, and can never be justified whether on 
the basis of ‘exceptional circumstances’, ‘superior 
orders’, ‘necessity’ or other reason. In 2009, member 
states committed to ensure that both demand reduc-
tion and supply reduction measures would respect 
human rights. However, a large number of human 
rights violations associated with drug control efforts 
have been documented by the UN and civil society 
between 2009 and 2018. Perhaps in response to these 
abuses, in 2016 member states committed to ‘uphold 
the prohibition of…torture and other cruel, inhuman 
At national level, positive trends have been doc-
umented since 2009. The number of reported 
executions (excluding those carried out in secret) 
dropped from over 600 in 2010 to 280 in 2017.399 
Countries are progressively moving away from the 
death penalty as a mandatory punishment for drug 
crimes, either by removing it from their legal system 
or allowing more discretion for judges when impos-
ing the sentence (e.g. India400 and Malaysia401) or by 
limiting its scope (e.g. Singapore402). Other initia-
tives aimed at curbing the use of the death penalty 
were adopted by Thailand403 and Palestine.404 One of 
the most significant developments was the amend-
ment approved in November 2017 by Iran which 
raised the minimum quantity of drugs required to 
incur capital punishment.405 This reform had impres-
sive effects, with the number of executions for drug 
crimes dropping from 242 in 2017 (an average of 
one execution every 1.5 days), to just three in the 
first seven months of 2018.406
At the same time, however, some governments 
have revamped their war on drugs approach. In the 
Philippines, a bill reinstating the death penalty for a 
wide range of drug-related offences was approved 
in the House of Parliament and is now sitting in the 
Senate,407 despite the fact that the reintroduction of 
capital punishment would also contravene the Phil-
ippines’ obligations under the Second Optional Pro-
tocol to the International Covenant on Civil and Po-
litical Rights,408 an international treaty ratified by the 
country in 2007 which categorically prohibits exe-
cutions and commits countries to abolish the death 
penalty. Similar bills aimed at widening the use of 
the death penalty for drugs are being considered in 
Bangladesh409 and Sri Lanka.410 Furthermore, since 
2009, countries which had previously abandoned 
or strongly limited this practice resumed executions 
– in particular Indonesia and Singapore411 – while 
other countries, such as Saudi Arabia, continue to 
execute large numbers of drug offenders each year.
Extrajudicial killings of suspected drug 
offenders
The recent trend of targeting and killing suspected 
drug offenders has raised many concerns over vio-
lations to the right to life. Such practices have been 
reported in the Philippines (see Box 11),412 Indone-
sia413 and Bangladesh.414 In Indonesia, the police were 
involved in the killing of an estimated 79 suspected 
drug dealers in 2017 – a sharp rise from the 14 killings 
recorded in 2016 and 10 killings in 2015.415 In Bangla-
desh, between May and July 2018, at least 200 people 
were killed at the hands of the police and more than 
25,000 were arrested for suspicion of involvement in 
the illegal drug trade.416 The UN High Commissioner 
2009 Political Declaration and Plan of Action
Action 6(a): ‘Ensure that demand reduction 
measures respect human rights and the inherent 
dignity of all individuals and facilitate access for 
all drug users to prevention services and health-
care and social services, with a view to social 
reintegration’
Action 22(c): ‘Ensure that supply reduction 
measures are carried out in full conformity with 
the purposes and the principles of the Charter 
of the United Nations and international law, the 
three international drug control conventions and, 
in particular, with full respect for the sovereignty 
and territorial integrity of States, the principle of 
non-intervention in the internal affairs of States 
and all human rights and fundamental freedoms’
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Box 11  Extrajudicial killings in the Philippines
While campaigning for the Philippines’ pres-
idential election in 2016, Rodrigo Duterte 
committed to launch a war against drugs that 
featured killing people suspected of using or 
supplying drugs, which he justified to the pub-
lic by the extensive level of drug-related activ-
ities in the country. On the day of his inaugu-
ration as president on 31 July 2016, he made a 
plea to the people: ‘If you know of any addicts, 
go ahead and kill them yourself as getting their 
parents to do it would be too painful’.424 He also 
encouraged the police to kill drug offenders 
and promised them immunity.425
According to the Philippines government, 
4,075 ‘drug personalities’ were killed by secu-
rity forces during drug law enforcement op-
erations in the period 1 July 2016 to 20 March 
2018.426 The Philippine National Police report-
ed that an additional 22,983 people were killed 
from 1 July 2016 to 21 May 2018 – this repre-
sents at least 33 people killed each day during 
this period, in cases classified as ‘deaths under 
inquiry’.427 In total, this amounts to over 27,000 
people killed since 1 July 2016.428 Recognising 
that the reported numbers of people killed are 
disputed by some NGOs, a project supporting 
multidisciplinary and evidence-based research 
on the drug control campaign in the Philip-
pines known as the ‘Drug Archive’ has collated 
and analysed data on verified cases of killings 
from 10 May 2016 to 28 September 2017, which 
represent only a fraction of the killings.429
During the first 15 months of the Duterte presi-
dency, there were only 19 days where no deaths 
were reported in the media, including four days 
in February 2017 after the Philippines National 
Police drug law enforcement operations were 
suspended following the kidnapping and mur-
der of a South Korean businessman; and five days 
in August 2017 after public outrage against the 
killing of 17-year old Kian delos Santos, where 
CCTV footage showed him being dragged away 
by police then shot to death in an alley.430
Reports from civil society organisations also un-
veiled a network of links between state author-
ities and unidentified armed persons, and un-
der-the-table payments to police to kill suspects. 
In addition, ‘drug watch lists’, used to identify 
people suspected of using or selling drugs, have 
acted as unsubstantiated blacklists, in violation 
of the right of due process.431 
Despite the thousands of people unlawfully 
killed in police operations or cases of ‘deaths 
under inquiry’, as of September 2017 the Philip-
pines Department of Justice reported that pros-
ecutors had only filed 19 murder and homicide 
cases nationwide in connection with the gov-
ernment’s war on drugs, with no convictions.432 
The UN High Commissioner for Human Rights 
has condemned the impunity for extrajudicial 
killings related to the Philippines’ war on drugs, 
as well as the ongoing threats by Duterte against 
people suspected of drug-related activities and 
people working to uphold and protect human 
rights (including national and international hu-
man rights defenders such as Senator Leila de 
Lima,433 the Philippines Commission on Human 
Rights and the UN Special Rapporteur on extra-
judicial, summary or arbitrary executions).434 
According to civil society organisations, this 
wave of deliberate and widespread extrajudi-
cial executions, which appear to be systematic, 
planned and organised by the authorities, may 
constitute crimes against humanity. In February 
2018, the International Criminal Court opened 
a preliminary examination into whether crimes 
against humanity had been committed in the 
Philippines’ war on drugs,435 prompting Presi-
dent Duterte to announce, a few weeks later, 
that the Philippines would withdraw from the  
Rome Statute.436 
Memorial during the 2017 Support. Don’t Punish 
Global Day of Action 
Credit: Support. D
on’t Punish 
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human rights issues and threaten the health of 
detainees, including through increased vulnerabil-
ity to HIV and tuberculosis (TB) infection’.442 The UN 
Working Group on Arbitrary Detention found that 
compulsory detention regimes for the purposes of 
drug ‘rehabilitation’ through confinement or forced 
labour are inherently arbitrary.443 
However, various countries retain this practice to-
day: Brunei Darussalam, Cambodia, China, Egypt, 
Indonesia, Iran, Lao PDR, Malaysia, Myanmar, Russia, 
Saudi Arabia, Singapore, Sri Lanka, Thailand and Vi-
etnam (see Figure 7).444 Several Latin American and 
Caribbean countries also use some form of compul-
sory detention, although these practices are gener-
ally not sanctioned by national laws and are often 
run by private actors, including by religious groups 
and other non-governmental organisations with 
little or no supervision by state authorities. This is 
the case in Brazil, the Dominican Republic, Ecuador, 
Guatemala, Mexico, Peru and Puerto Rico.445 Numer-
ous studies from NGOs, UN agencies and academics 
have reported widespread cases of human rights 
violations associated with compulsory detention, 
including lack of due process, inhuman, cruel and 
degrading treatment (including beatings, whipping 
and flogging) sometimes amounting to torture, 
arduous physical exercises, forced labour, denial of 
medical treatment, imposition of unscientific and 
abusive methods of ‘treatment’, and humiliation of 
various kinds.446
In 2015, the UNODC issued a discussion paper 
providing recommendations to support member 
states to transition from compulsory detention to 
or degrading treatment or punishment’ within the 
UNGASS Outcome Document.437
Corporal punishment for drug offences
Under the laws and religious practices of several 
countries, criminal courts and/or administrative 
bodies may impose corporal punishment for a num-
ber of drug offences, either as the main sanction 
or in addition to a prison sentence. The offences 
range from simple drug use, to possession of cer-
tain amounts of drugs and drug trafficking. Corporal 
punishments can include caning, whipping, lashing, 
flogging, stoning and bodily mutilation. Such prac-
tices have been reported in Brunei Darussalam, In-
donesia, Iran, Malaysia, the Maldives, Nigeria, Saudi 
Arabia, Singapore, the United Arab Emirates and 
Yemen.438 Brunei Darussalam, Malaysia, Saudi Arabia 
and Singapore were also reported to use corporal 
punishment on children.439 The intensity of applica-
tion of corporal punishment varies from country to 
country, with Singapore and Malaysia being some 
of the most active states in the number of cases 
for which corporal punishment is applied.440 This 
practice has been condemned by UN human rights 
bodies and entities as amounting to cruel, inhuman 
and degrading punishment and contravenes the 
absolute prohibition of torture.441
Compulsory detention as ‘treatment’
In 2012, 12 UN entities – including the UNODC, 
WHO, UNAIDS, UNICEF, UN Women, OHCHR and 
others – called for the closure of compulsory drug 
detention centres, concluding that they ‘raise 
27,000~extrajudicial killings since Rodrigo 
Duterte became President of the 
Philippines, in 2016.
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drug offenders were tortured, including through 
beatings, to provide information about their drug 
suppliers.450 Another study found that people who 
use drugs in Russia were regular victims of physical 
violence, ill-treatment and rape at the hands of law 
enforcement officers to obtain information and ‘fa-
cilitate “confession”’.451 The UN Special Rapporteur on 
Torture also documented cases of people depend-
ent on drugs being denied OST ‘as a way of eliciting 
criminal confessions through inducing painful with-
drawal symptoms’, which is recognised as a form of 
torture.452 The UN Committee against Torture has 
recently raised concerns over this practice.453 Addi-
tional studies found that women are particularly at 
risk of physical and mental abuse at the hands of the 
police.454 In Zimbabwe455 and Mexico456 for example, 
women who use drugs are regularly asked for sexual 
favour by the police in exchange for their release.  
voluntary community-based treatment.447 The UN 
Special Rapporteur on the right to health has high-
lighted the mounting evidence that healthcare and 
support in community settings yield better health 
outcomes, particularly for marginalised groups.448 
However, little progress has been made to close 
down the centres since 2009.
Violence and ill-treatment by law enforcement 
agencies
In various countries around the world, UN entities 
and civil society organisations have documented 
widespread cases of violence, excessive use of force 
and ill-treatment of people who use drugs and drug 
offenders at the hands of the police or the military. 
Furthermore, in several contexts the police have 
adopted militarised drug law enforcement strate-
gies, including through training, equipment and 
techniques to dismantle the illegal drug market. 
This has been the case, for instance, in countries like 
Argentina, Brazil and Mexico, where the armed forc-
es are granted increasing powers to tackle the drug 
trade, resulting in an exacerbation of violence. 
In the midst of Mexico’s drug war, between 2011 
and mid-2014, 3,260 complaints of torture, enforced 
disappearances and other human rights violations 
have been attributed to the armed forces – with only 
a handful being investigated.449 In 2010, the Special 
Rapporteur on Torture reported that in Indonesia 
Credit: Juan Fernandez O
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Figure 7. Map of countries officially (including by law) engaged in compulsory detention of people who use drugs
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Table 4. Global overview of sanctions against drug offenders that contravene human rights457 
Note that the list of countries for each category may not be exhaustive
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and extortion of money or drugs for police gains.462 
In response, a person who uses drugs in Russia 
brought his complaint of arbitrary detention all the 
way to the UN Working Group on Arbitrary Deten-
tion (in the case of Matveev v. Russian Federation) 
which concluded that Russia had violated his rights 
under the International Covenant on Civil and Polit-
ical Rights.463 In Cambodia, the drug war launched in 
January 2017 has resulted in 17,700 people arrest-
ed for suspected drug activities – an 80% increase 
from the previous year.464 In Bangladesh, more than 
13,000 people wer e arrested between May and 
June 2018.465
The UN Working Group on Arbitrary Detention 
also concluded that ‘the right to liberty of persons 
in Article 9 of the International Covenant on Civil 
and Political Rights requires that states should have 
recourse to deprivation of liberty only insofar as it 
is necessary to meet a pressing societal need, and 
in a manner proportionate to that need’. Regarding 
pretrial detention, the Working Group ‘noted with 
concern the practice of over-incarceration…as well 
as the factors that lead to over-incarceration, includ-
ing detainees’ ethnic or social origin, poverty and 
social marginalization’.466 According to international 
human rights law and standards, pre-trial detention 
must be an exceptional measure and based on an 
individualised determination that it is reasonable 
and necessary only when there is a substantial risk 
of flight, harm to others or interference with the 
evidence or investigation that cannot be allayed 
by other means. The UN Human Rights Commit-
tee has further established that pre-trial detention 
should not be mandatory for any particular crime 
nor should it be ordered for a period based on the 
potential sentence.467
The same year, the UN CCPCJ estimated that one 
in five prisoners worldwide was incarcerated for 
a drug offence.468 In various regions, women have 
been particularly affected, with over half of women 
in prison being incarcerated for drug offences. Al-
though they continue to represent a small propor-
tion of the general population, female prisoners are 
the fastest growing prison population, and this is 
driven by overly punitive drug laws (see Box 12).469 
The UN CCPCJ also concluded that the overwhelm-
ing majority of those in prison for drug offences 
were accused of drug use or drug possession for 
personal use. The rest are generally accused of 
low-level dealing and micro-trafficking, with a mi-
nor proportion imprisoned for high-level, violent 
drug offences. In Colombia, for example, only about 
2% of all prisoners convicted of drug offences are 
medium to high-ranking figures.470 
2009 Political Declaration and Plan of Action
Action 6(a): ‘Ensure that demand reduction 
measures respect human rights and the 
inherent dignity of all individuals and facilitate 
access for all drug users to prevention services 
and health-care and social services, with a view 
to social reintegration’
Action 15(a): ‘Working within their legal 
frameworks and in compliance with applicable 
international law, consider allowing the full 
implementation of drug dependence treatment 
and care options for offenders, in particular, 
when appropriate, providing treatment as an 
alternative to incarceration’
Action 22(c): ‘Ensure that supply reduction 
measures are carried out in full conformity with 
the purposes and the principles of the Charter 
of the United Nations and international law, the 
three international drug control conventions and, 
in particular, with full respect for the sovereignty 
and territorial integrity of States, the principle of 
non-intervention in the internal affairs of States 
and all human rights and fundamental freedoms’
2.1.5 The right to liberty and to be free from 
arbitrary detention
 
According to Article 9 of the International Cov-
enant on Civil and Political Rights,458 the right 
to liberty entails that no one shall be subjected 
to arbitrary arrest or detention, and that no one 
shall be deprived of their liberty except on such 
grounds and in accordance with such procedure as 
are established by law.459 Under the right to liberty, 
people who are arrested must be informed of the 
reasons of their arrest and notified of their rights 
at time of arrest, and must be brought prompt-
ly before the judge. Everyone deprived of their 
liberty has the right to challenge the lawfulness 
of their detention before a court, and a person 
unlawfully detained has the right to reparation, 
including compensation.
The UN Working Group on Arbitrary Detention 
found various instances in which people who use 
drugs were ‘particularly at risk of arbitrary deten-
tion’,460 and declared that compulsory detention for 
the purpose of drug ‘treatment’ was ‘inherently arbi-
trary’.461 Civil society studies have supported these 
findings. A report on Russia, for instance, found that 
people who use drugs were regularly victims of arbi-
trary arrest, planting of evidence to expedite arrest 
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and Mexico, for example, pre-trial detention is 
mandatory for all drug offences, whether of minor 
or high-level nature, and people can await trial for 
months up to several years.473 This runs counter to 
the recommendations by the UN Working Group on 
Arbitrary Detention to ‘ensure that persons are not 
held in pretrial detention for periods longer than 
those prescribed by law or proportionate, and that 
they are promptly brought before a judge’ (empha-
sis added).474 The principles of proportionality of 
sentencing and of alternatives to incarceration are 
welcome additions within the UNGASS Outcome 
These minor, non-violent drug offences are often 
punished with longer prison sentences than for 
violent offences such as rape or murder. In Bolivia, 
for example, the maximum penalty for drug traffick-
ing is 25 years, compared to 20 years for homicide 
and 15 years for rape.471 In various countries, drug 
laws and criminal codes impose mandatory mini-
mum sentences for drug offences, preventing any 
flexibility on the part of the judge to impose less se-
vere punishment for first-time, non-violent offences. 
The disproportionate nature of criminal sanctions 
for drug offences not only violates the right to lib-
erty; it can also undermine the rule of law where 
criminal systems have to absorb a high number of 
minor offences instead of focusing scarce resourc-
es on crimes that have a higher impact on society. 
Over-incarceration for drug offences can also exac-
erbate poverty and marginalisation, as many people 
involved in low-level dealing or micro-trafficking are 
in a situation of vulnerability (see Box 12).
The sheer number of people incarcerated for drug 
offences, as well as the proportion of people held in 
pre-trial detention for drug crimes, have contributed 
to severe prison overcrowding and dire conditions 
in detention in many parts of the world – with little 
progress made to tackle this phenomenon since 
2009. In 2015, the OHCHR raised concerns over ‘re-
ports of persons detained for drug-related offences 
not being registered or promptly brought before a 
judge’, adding that ‘In some States…an arrested per-
son suspected of a drug-related offence can be kept 
in custody without being charged for a substantially 
longer time than a person detained for other offenc-
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Box 12  The mass incarceration of women for drug offences in 
Latin America
The 2009 Political Declaration and Plan of Ac-
tion each have only one reference to women, 
and neither acknowledges the growing incar-
ceration of women for drug-related offences. 
According to the World Female Imprisonment 
List, more than 714,000 women and girls are 
currently being held in penal institutions 
worldwide.476 The number of women and 
girls in prison has increased by 53% between 
mid-2000 and mid-2016, a period in which the 
global male prison population increased by 
only 20%.477 In the most extreme example of 
Brazil, the country’s female prison population 
increased by 342% between 2000 and 2016478 
and women incarcerated for drug offences ac-
count for about 60% of the total female prison 
population.479 The highest levels of incarcera-
tion of women, however, can be found in East 
and South East Asia, where the mass incarcer-
ation of individuals charged with low-level, 
non-violent drug offences has led to severe 
prison overcrowding. As of 2015, over 47,000 
women were behind bars in Thailand, 80% of 
whom were convicted of drug offences.480 
In Latin America, most women are arrested 
for first time, non-violent, low-level but high-
risk drug-related activities, such as small-scale 
drug dealing or transporting drugs, or for sim-
ple drug use – and generally engage in illegal 
drug activities because of poverty, lack of op-
portunities and/or coercion. They often have 
little or no education and live in conditions of 
poverty. A large number are single mothers, 
and the sole care provider of their children 
because of entrenched gender norms.481 They 
may also need harm reduction or treatment 
services for drug dependence, mental health 
issues or physical problems, which are often 
hard to access in prison. Most have suffered 
some form of sexual violence before and/or 
during their incarceration.482 Their incarcera-
tion can have severe and long-lasting conse-
quences not only for themselves, but also for 
their families and communities.483
The ‘UN Rules for the Treatment of Women 
Prisoners and Non-Custodial Measures for 
Women Offenders’ (the Bangkok Rules), adopt-
ed in December 2010 by the UN General As-
sembly, were instrumental in recognising the 
specific characteristics and needs of women 
deprived of their liberty.484 Those rules, as 
well as reports from the UN Special Rappor-
teur on violence against women485 and the 
Committee on the Elimination of all forms of 
Discrimination against Women,486 have called 
upon governments to develop gender-sensi-
tive alternatives to incarceration. In Vienna, it 
was not until March 2016 that the CND adopt-
ed a landmark resolution (Resolution 59/5) 
on ‘Mainstreaming a gender perspective in 
drug-related policies and programmes’, which 
recognised the many risks faced by women in 
the illegal drug trade and called on member 
states to adopt gender-sensitive drug policies 
and programmes.487 The UNGASS Outcome 
Document was a significant step forward on 
gender issues, by highlighting the importance 
of promoting gender-sensitive drug policies, 
and recognising both the particular vulner-
abilities and specific needs of women in pri-
mary care and treatment programmes, as well 
as within the criminal justice system. With re-
gards to incarceration, operational paragraph 
4.n encourages ‘the taking into account of the 
specific needs and possible multiple vulnera-
bilities of women drug offenders when impris-
oned’, in line with the Bangkok Rules.488
Nationally, since 2009 only a handful of coun-
tries have adopted gender sensitive policies to 
address the high rates of incarceration of wom-
en for drug offences. Today, there is an urgent 
need to ensure proportionate penalties for 
drug offences, allowing for the consideration 
of mitigating factors such as socio-economic 
marginalisation, being the sole care provider 
of dependents, and drug dependence, and 
make better use of gender-sensitive alterna-
tives to incarceration for minor offenders. 
66  Taking stock: A decade of drug policy
suspected of engaging in illegal drug activities in 
South and South East Asia. The UN High Commis-
sioner for Human Rights characterised this practice 
as ‘dangerous…and indicative of a total disregard 
for the rule of law’.492 The compulsory detention of 
people who use drugs also raises concerns over the 
lack of due process associated with this practice.493
In less extreme cases, the right to a fair trial and due 
process is hampered in a number of ways for people 
accused of drug offences. The OHCHR, for instance, 
reported country cases where a person is automat-
ically presumed guilty of drug trafficking in specific 
conditions, thereby reversing the burden of proof in 
criminal proceedings.494 In several countries, trials 
rely on statements made under coercion during po-
lice investigation.495 In other cases, investigations, 
arrests and house searches are conducted without 
judicial authorisation and with reports of incommu-
nicado detention without charges.496 
2.1.7 The rights of indigenous peoples
 
The UN Declaration on the Rights of Indigenous 
Peoples (UNDRIP), adopted in 2007, reinforces the 
basic cultural rights embedded in Article 27 the Uni-
versal Declaration of Human Rights497 and Article 15 
of the 1966 International Covenant on Economic, 
Social and Cultural Rights.498 In particular, it estab-
lishes that indigenous peoples have the right not to 
be subjected to forced assimilation or destruction 
of their culture (Article 8); to practice and revitalise 
their cultural traditions and customs (Article 11); to 
be secure in the enjoyment of their own means of 
subsistence and development and to engage freely 
in all their traditional and other economic activities 
(Article 20); and to maintain, control, protect and 
develop their cultural heritage (Article 31).499 Ac-
cording to Julian Burger, former coordinator of the 
OHCHR Indigenous Peoples and Minorities Unit, this 
‘gives indigenous peoples the possibility of continu-
ing to produce crops and plants that they have tra-
ditionally grown for their own religious, medicinal, 
or customary purposes, and which constitute a part 
of their cultural practice and identity’.500 
2.1.6 The right to a fair trial and due process
 
The right to due process and a fair trial – protected 
in Article 10 of the Universal Declaration of Human 
Rights489 and Articles 14 and 16 of the International 
Covenant on Civil and Political Rights490 – includes 
the right to a fair and public hearing by a competent, 
independent and impartial tribunal established by 
law; to be presumed innocent until proven guilty; to 
be tried without delay; to access interpreters, con-
sular assistance and legal aid; and to receive prompt 
and detailed information and legal assistance in a 
language and format that is accessible.
The recognition, in the UNGASS Outcome Doc-
ument, of the need to ‘Promote and implement 
effective criminal justice responses to drug-related 
crimes to bring perpetrators to justice that ensure 
legal guarantees and due process safeguards…and 
ensure timely access to legal aid and the right to 
a fair trial’491 has been a significant step forward in 
ensuring more human rights protections in demand 
and supply reduction strategies. This operational 
recommendation is particularly relevant in light of 
the recent surge in extrajudicial killings of people 
2009 Political Declaration and Plan of Action
Action 6(a): ‘Ensure that demand reduction 
measures respect human rights and the inherent 
dignity of all individuals and facilitate access for 
all drug users to prevention services and health-
care and social services, with a view to social 
reintegration’
Action 22(c): ‘Ensure that supply reduction 
measures are carried out in full conformity with 
the purposes and the principles of the Charter 
of the United Nations and international law, the 
three international drug control conventions and, 
in particular, with full respect for the sovereignty 
and territorial integrity of States, the principle of 
non-intervention in the internal affairs of States 
and all human rights and fundamental freedoms’
Action 41(c): ‘Ensure that measures to control 
precursors and amphetamine-type stimulants 
are carried out in full conformity with the 
purposes and the principles of the Charter of 
the United Nations and international law, the 
international drug control conventions and, in 
particular, with full respect for the sovereignty 
and territorial integrity of States, the principle of 
non-intervention in the internal affairs of States 
and all human rights and fundamental freedoms’
2009 Political Declaration and Plan of Action
Action 22(e): ‘Promote supply reduction 
measures that take due account of traditional 
licit uses, where there is historical evidence of 
such use, as well as environmental protection, in 
conformity with the United Nations Convention 
against Illicit Traffic in Narcotic Drugs and 
Psychotropic Substances of 1988’
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2.1.8 The right to be free from discrimination
The right to be free from discrimination is 
recognised in the Universal Declaration of Human 
Rights,505 the International Covenant on Civil and 
Political Rights,506 the International Covenant on 
Economic, Social and Cultural Rights,507 as well as 
the International Convention on the Elimination of 
All Forms of Racial Discrimination,508 the Conven-
tion on the Elimination of All forms of Discrimina-
tion Against Women509 and the Convention on the 
Rights of Persons with Disabilities.510
Perhaps as a result of the inherent contradictions 
between indigenous rights and the international 
drug control regime (see Box 13), only a handful of 
member states have adopted laws and regulations 
to protect the rights of indigenous groups to grow 
and use controlled substances. The most emblem-
atic example is Bolivia’s constitutional protection of 
the traditional use of the coca leaf. Other examples 
include the protection of coca use among indige-
nous communities in Colombia, Peru and Argenti-
na;501 the 2015 legislation in Jamaica allowing the 
religious use of cannabis among the Rastafari;502 
ayahuasca use for traditional and religious purposes 
in Brazil, Peru, Colombia and Canada (in the latter, 
limited to the Ceu do Montreal religious group); the 
ancestral use of peyote among Native Americans in 
the USA; and the traditional use of khat in Ethiopia, 
Somalia and Yemen.503 
The 1989 Indigenous and Tribal Peoples Convention 
(No. 169) also enshrines indigenous peoples’ right 
to free prior and informed consent in all matters 
that affect them.504 In practice, drug control strate-
gies in indigenous peoples’ lands have largely been 
designed and implemented without consultations 
with local communities, and have mostly consisted 
in forced crop eradication campaigns, as will be fur-
ther discussed below.
Aymara women collectively harvesting coca in Bolivia’s Nor Yungas province
Credit: Caroline S. Conzelm
an
2009 Political Declaration and Plan of Action
Action 2(g): ‘Develop and implement, in 
cooperation with international and regional 
agencies, a sound and long-term advocacy 
strategy, including harnessing the power of 
communication media, aimed at reducing 
discrimination that may be associated with 
substance abuse, promoting the concept of 
drug dependence as a multifactorial health and 
social problem and raising awareness, where 
appropriate, of interventions based on scientific 
evidence that are both effective and cost-
effective’
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even though their prevalence of drug use is lower 
than for white people.517 
In recognition of these issues, the UN released a 
joint statement on ‘ending discrimination in health-
care settings’ in 2017, calling on member states to 
review and strengthen their drug laws to prohibit 
discrimination in the provision of healthcare, repeal 
punitive laws that have negative health outcomes, 
including the criminalisation of drug use and pos-
session of drugs for personal use, and strengthen 
The high level of stigma and discrimination people 
who use drugs are facing severely hampers their ac-
cess to life-saving services and increases their risks 
of contracting infections. Data suggests that wom-
en who use drugs are particularly vulnerable to stig-
ma and discrimination as they are seen as breaking 
with the traditional image of the woman as a care 
giver.516 An additional layer of discrimination exists 
for people of colour. In the UK, for instance, it is esti-
mated that black people are nine times more likely 
to be stopped and searched than white people, 
Box 13  Addressing the tensions between the rights of indigenous 
groups and UN drug control obligations
There is an undeniable conflict between the 
obligations imposed by the UN drug con-
trol system and indigenous rights – which is 
reflected in action 22(e). When the UN drug 
control regime was established, the rights of 
indigenous peoples had not yet acquired the 
international legal recognition that they have 
today. Indigenous peoples had no say at all 
in the negotiation of the drug treaties, while 
today consultation and consent are accepted 
principles for all matters of law and policy that 
impact indigenous peoples. 
The Single Convention allowed ‘transitional 
reservations’ for the traditional uses of opium, 
coca leaf and cannabis (Article 49), but by De-
cember 1989 the chewing of coca leaf, the 
use of cannabis in religious ceremonies, and 
all other non-medical indigenous practices in-
volving these plants were to be abolished. The 
1971 Convention on Psychotropic Substances 
addresses another range of substances and 
departs slightly from the zero-tolerance regime 
imposed for ‘narcotic drugs’ by leaving legal 
space for the use of ‘psychotropic substances’ 
in religious ceremonies, specifically for the pe-
yote cactus, hallucinogenic mushrooms and 
ayahuasca (Article 32.4). More importantly, 
plants containing psychotropic substances 
were not brought under international control; 
only the extracted alkaloids are included in the  
1971 Schedules.   
Subsequent diplomatic efforts led to the inclu-
sion of Article 14.2 in the 1988 Convention stat-
ing that measures to eradicate the cultivation of 
coca, opium poppy and cannabis ‘shall respect 
fundamental human rights and shall take due 
account of traditional licit uses, where there 
is historic evidence of such use’. However, the 
same article specifies that any measures under 
the 1988 Convention ‘shall not be less stringent 
than the provisions applicable to the eradica-
tion of illicit cultivation of plants containing 
narcotic and psychotropic substances’ under 
the 1961 and 1971 treaties (an obligation fur-
ther reinforced by Article 25). Therefore, while 
the insertion of the first and only mention of 
human rights across the three drug conventions 
was politically significant, its legal standing  
remains contentious.
Although the 2009 Political Declaration was 
adopted only two years after the adoption of 
the UNDRIP, it made no mention of it and kept 
with the contradictions enshrined in the 1988 
Convention. At the same time the Political Dec-
laration was being adopted, the UN Permanent 
Forum on Indigenous Issues ruled that certain 
provisions of the 1961 Convention were ‘incon-
sistent with the rights of indigenous peoples to 
maintain their traditional health and cultural 
practices’ and recommended that those treaty 
articles ‘be amended and/or repealed’. In 2016, 
whilst referring briefly to UNDRIP, the UNGASS 
Outcome Document once again failed to ad-
dress the contradictions between indigenous 
rights and international drug control obliga-
tions. In his UNGASS statement, the UN High 
Commissioner for Human Rights, Zeid Ra’ad Al 
Hussein, stated that the language regarding in-
digenous rights in the 2016 document was ‘am-
biguous’, concluding that ‘it would have been 
better if it were clearly indicated that indige-
nous peoples should be allowed to use drugs 
in their traditional, cultural or religious practices 
when there is historical basis for this’. 
511
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ty articles ‘be amended and/or repealed’.513 In
2016, whilst referring briefly to UNDRIP, the UN-
GASS Outcome Document once ag in failed to 
address the contradictions between 
514 In his UNGA S statement, the  
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policies, regulations and standards related to the 
prevention of discrimination on all grounds in 
healthcare settings.518 It is worth noting here that 
the UNODC is not among the 12 signatory UN agen-
cies and entities. In 2018, the CND adopted its first 
ever resolution on the need to address the stigma 
associated with drug use: Resolution 61/11 ‘Promot-
ing non-stigmatizing attitudes to ensure the avail-
ability of, access to and delivery of health, care and 
social services for drug users’.519 
Although limited to a small number of countries, 
several interventions have recently been developed 
with a focus on reducing stigma and improving ac-
cess to healthcare. The ‘Stop the Stigma’ campaign, 
launched by Citywide Drug Crisis in Ireland, uses 
information sharing to break down stigma and 
promote respect and dignity for people who use 
drugs, support community programmes, under-
stand the complexity of dependence and end the 
criminalisation of people who use drugs.520 Simi-
larly, the Vancouver Canucks hockey team and the 
provincial Ministry of Mental Health and Addictions 
launched the ‘Stop overdose’ campaign in 2018 in 
the Province of British Colombia, Canada. As part of 
this programme, US$ 322 million are being invested 
over three years to reduce stigma, show the human 
face of people who use drugs and provide a health 
and social response to drug use.521
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Strategies aiming to dismantle major trafficking hubs 
and routes, cultivation areas or eradicate a certain 
substance have generally resulted in market chang-
es, rather than an overall reduction in illegal drug 
activities globally. The phenomena of ‘geographical’ 
and ‘substance’ displacement resulting from drug 
control operations had already been identified in the 
2008 World Drug Report, and data collected by the 
UNODC between 2009 and 2018 have confirmed this 
trend. For instance, crackdowns on opium have led 
to reductions in cultivation in South East Asia, but 
opium cultivation has surged in Afghanistan which 
is now producing 86% of the world’s opium (see Box 
14).522 Opium cultivation also went up in Mexico, 
which is the main supplier for the growing US heroin 
market.523 Meanwhile, people who use drugs in East 
and South East Asia have been drawn towards phar-
maceutical opioids and ATS which are often more 
available than heroin.524
Similarly, in the Andean region, while Bolivia has 
seen a consistent reduction in coca cultivation since 
2009, production has largely increased in Colombia 
since 2014 – and overall, the global area cultivated 
has increased by 30% between 2009 and 2016 (see 
Figure 9). Drug control operations to shut down re-
tail markets for substances like cocaine, ecstasy, her-
oin and cannabis in Europe and North America have 
also led to hundreds of synthetic NPS flooding onto 
the market – with increasing levels of overall drug 
use525 and, in some cases, elevated levels of drug-re-
lated harm compared to more traditional drugs.
Instead of redressing this situation, policing and 
militarised drug control campaigns have generally 
2.2  Promoting peace and security
Following the devastation of the Second World War, 
one of the core goals of the UN in 1945 was to main-
tain international peace and security. The UN and 
its member states aimed to achieve this objective 
by working to prevent conflict, helping parties in 
conflict to make peace, peacekeeping, and creating 
the conditions to allow peace to hold and flourish. 
This section will assess how drug control in the past 
decade has contributed to promoting and consoli-
dating peace and security worldwide.
2.2.1 The ‘balloon effect’ and escalating levels of 
violence
2009 Political Declaration and Plan of Action
Action 22(c): ‘Ensure that supply reduction 
measures are carried out in full conformity with 
the purposes and the principles of the Charter 
of the United Nations and international law, the 
three international drug control conventions 
and, in particular, with full respect for the 
sovereignty and territorial integrity of States, 
the principle of non-intervention in the internal 
affairs of States and all human rights and 
fundamental freedoms’
Action 24(g): ‘Implement strategies to disrupt 
and dismantle major organizations involved in 
trafficking in narcotic drugs and psychotropic 
substances and to address emerging trends’
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Box 14  Unprecedented levels of opium cultivation  
in Afghanistan
When the Political Declaration and its Plan of 
Action were devised in 2009, Afghan poppy cul-
tivation stood at 123,000 hectares and potential 
opium production at 6,900 tons.526 According to 
the latest annual report produced by the UNODC 
and the Afghan Ministry of Counter Narcotics, 
the opium industry reached unprecedented lev-
els in 2017, with an area of 328,000 hectares un-
der cultivation and potential opium production 
up to 9,000 tons (see Figure 8).527 Cultivation of 
poppy increased by 63% since 2016 and passed 
the previous highest level (in 2014) by 46%, or 
104,000 hectares. Potential production of opium 
increased by 87% between 2016 and 2017. This 
is despite sustained and intensive intervention 
on the part of the international community – in-
cluding regular CND resolutions on the issue528 
– and the Afghan government to curb opium 
cultivation over the past decade. 
The failure to curb illegal opium cultivation in 
Afghanistan can be explained by a number of 
reasons. First and perhaps most importantly, 
the rise in illegal cultivation reflects the progres-
sive erosion of the Afghan government control, 
influence and presence in recent years, and 
the continued and the progressive deteriora-
tion in security and political uncertainty in the 
aftermath of the 2014 presidential election.529 
Secondly, the global demand for drugs derived 
from opium has continued to drive production 
in the country, especially with the decline in 
opium poppy cultivation in the Golden Trian-
gle region (Thailand, Myanmar and Laos PDR). 
Thirdly, drug control efforts in the country have 
mainly consisted of alternative development 
programmes focused on crop eradication and 
the replacement of opium poppy with other licit 
crops (e.g. wheat) – but with limited success as 
the country’s climate makes it well suited for 
poppy cultivation relative to other crops. In the 
absence of more lucrative alternatives, and with 
the reduction in international aid for broader so-
cio-economic development in rural areas, opium 
production remains at the heart of the Afghan 
economy with thousands of families relying on 
it to survive.530 In its 2018 World Drug Report, 
the UNODC concluded that the large-scale 
production of opiates was likely to ‘fuel further 
instability and insurgency and increase funding 
to terrorist groups in Afghanistan’, and to further 
‘constrain the development of the licit economy 
and potentially fuel corruption’.531 However, the 
UNODC pointed out elsewhere that the opium 
economy also stimulated the wider, licit rural 
economy as ‘Afghan farmers purchase food, have 
medical expenses, and purchase daily needs 
products. These expenses – paid from opium 
money – benefited local bakers, butchers and 
other small-scale businesses in rural Afghani-
stan’.532 Tackling the illegal cultivation of opium 
in the country therefore necessitates a thorough 
understanding of these complex development 
and peacekeeping dynamics. 







rug Report 2018, Booklet 3
72  Taking stock: A decade of drug policy
were reported between 2009 and April 2018.538 In 
Brazil, violent encounters between drug traffickers 
and security forces in Rio’s favelas have led to 5,400 
killings between 2009 and 2016.539 In Colombia, 
forced crop eradication campaigns have led to vio-
lent clashes with the police and the military and mil-
lions of people internally displaced (see Box 15).540 
The focus on p olicing and militarised drug control op-
erations has also shifted often scarce resources away 
from health and development programmes towards 
the police and the military. Recognising the severe 
consequences of this approach, prominent academic 
institutions, NGOs, UN agencies and various nation-
al-level policy makers have engaged in strategic dis-
cussions on how to modernise drug law enforcement. 
Illegal drug markets are not inherently violent, and 
although drug control may not be able to curb the 
scale of the illegal drug trade, it might help shape the 
market in a way that minimises the harms caused to 
affected communities and society as a whole.541
2.2.2 The rise of crypto-drug markets
undermined peace and security. The emergence of 
new trafficking routes in developing or fragile states 
where governance is weak has contributed to dest-
abilising affected countries, undermining the rule 
of law and facilitating high-level corruption. This 
has been observed in several West African coun-
tries, with Mali, Niger, Nigeria and Guinea-Bissau 
now recognised as major trafficking hubs, where 
the collusion between high-level officials and drug 
traffickers constitutes a major threat to security, 
governance and development.534 In South East Asia, 
punitive drug control policies aiming at curbing 
the expanding market for ATS have translated into 
an escalation in violence and human rights abuses, 
including extrajudicial killings. On the other side 
of the world, Mexico launched a militarised war 
on drugs in 2006, which has caused over 150,000 
drug trade-related deaths535 and more than 32,000 
disappearances.536 Between 2011 and 2015, 282,300 
people were internally displaced as a consequence 





Figure 9. Cultivation of coca bush in Bolivia, Colombia and Peru, 2009 to 2016 (in hectares)542
2009 Political Declaration and Plan of Action
Action 36(a): ‘Address through concerted 
action the illegal sale of preparations containing 
amphetamine-type stimulants via the Internet 
and the misuse of postal and courier services for 
smuggling such preparations’
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Box 15  Colombia’s peace process: Great hopes,  
significant challenges
Colombia’s internal armed conflict dates back to 
the 1960s, but it was not until the 1980s that coca 
cultivation started to expand in areas controlled 
by the FARC (Fuerzas Armadas Revolucionarias 
de Colombia) and paramilitary groups started 
engaging in the booming cocaine market. In the 
past four decades, Colombia has implemented 
forced eradication strategies to combat illegal 
drug supply, including aerial spraying, manual 
eradication, criminalisation of growers, destruc-
tion of processing ‘laboratories’ and interdiction. 
This strategy has had serious financial, environ-
mental, social and human rights implications,543 
among them the internal displacement of mil-
lions of people as a result of the conflict with 
the FARC and violent clashes with the military in 
coca cultivation areas.544 
In 2012, the Colombian government and the 
FARC began peace talks, with an agenda item 
on ‘Solution to the illicit drug problem’. Chapter 
4 of the 2016 Peace Agreement, dedicated to 
drug issues, paved the way to a new approach 
towards illegal drug production, with due regard 
to rural development (chapter 1). Under the Na-
tional Comprehensive Substitution Programme, 
farmers involved in illegal crop cultivation are 
encouraged to sign agreements with the state 
to voluntarily eradicate coca crops. In exchange, 
they receive a state subsidy, and the govern-
ment committed to improving land ownership, 
access to public goods, markets and infrastruc-
ture and access to credit.545 124,000 families 
across Colombia have expressed willingness 
to benefit from the Programme – representing 
approximately 100,000 hectares of coca. Indi-
vidual agreements were signed with 77,000 
families. The UNODC supports this initiative by 
monitoring compliance with the required ‘vol-
untary’ self-eradication.546 As of July 2018, the 
UNODC confirmed the self-eradication of 18,000 
hectares, with another 10,000 hectares still  
under verification.
The pilot for this ‘voluntary substitution’ pro-
gramme started in Briceño, Antioquia where, in 
an effort to generate trust, the government and 
the FARC committed to work with the farming 
community of 11 villages in the municipality 
to foster economic change and reduce their 
dependence on coca. Although the peace 
agreement itself included references to co-
ca-growing communities’ right to participate in 
decision-making processes in order to facilitate 
the voluntary and peaceful destruction of coca 
plants, those communities were in fact given 
no space at all to negotiate the terms of the 
contracts and were forced to sign up under the 
threat of forced eradication.547 
The joint substitution effort, however, is faced 
with several challenges, not least the serious 
setback created by the referendum vote against 
the original Peace Agreement in October 2016, 
the fact that the government and the FARC only 
released implementation protocols in Febru-
ary 2017, and the overall lack of coordination 
between state institutions. In addition, bureau-
cratic processes created delays in payments to 
participating families, while agricultural techni-
cal assistance, access to land and lack of basic 
infrastructure are lagging behind.548 In parallel, 
the bill providing differential criminal treatment 
for coca farmers has not yet been passed, mak-
ing them vulnerable to arrest and incarceration. 
Moreover, although financial subsidies are of-
fered to families in exchange for voluntary erad-
ication, the programme lacks a comprehensive, 
long-term development strategy that is able to 
deliver alternative crop cultivation and income 
generation. 
Cases of violence also continue to be reported 
in affected areas – with the UN estimating that 
106 community leaders were killed in 2017 
alone.549 Finally, Colombia is facing growing in-
ternational pressure due to the recent surge in 
coca cultivation, making the country the world 
leader in coca cultivation. The recent election of 
President Duque, who openly pronounced him-
self in favour of forced crop eradication, presents 
yet another key challenge for the years ahead.550 
It is equally worrying that, in its 2017 ‘Colombia 
coca cultivation survey’, the UNODC seems to 
encourage this approach, recommending that 
‘Forced eradication should be implemented 
on coca lots where growers did not sign agree-
ments to achieve continuous, coca-free territo-
ries’.551 These many issues highlight the urgency 
of guaranteeing more security, human rights 
protection and sustainable development in the 
implementation of the Peace Process.
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Report 2014,556 the UNODC has consistently – and 
with an increasing sense of alarm – described the 
issue as ‘growing’,557 and recognised the need for 
more research, money, and innovative thinking.558 
In practical terms, although the usage of these 
markets remains dominated by the Global North,559 
their international reach has extended in recent 
years with the appearance of Chinese vendors of 
NPS, precursors, fentanyl and fentanyl analogues. 
As such, crypto-drug markets are growing in several 
areas – in relation to traditional markets, in political 
significance, and in global reach. In 2017, UNODC’s 
Executive Director also conceded that drugs bought 
and sold online frequently utilise postal services for 
distribution,560 highlighting the lack of progress 
made by the international community towards the 
2009 goal of curbing postal trafficking.   
Many state-level law enforcement and criminal 
justice systems remain ill-equipped to deal with 
the issue of crypto-drug markets.561 Although 
there has been some international law enforce-
ment cooperation on the issue – most notably be-
tween US federal agencies, Europol, and state-level 
Box  16  Crypto-drug market operations
Crypto-drug markets have been in operation 
since 2010, but have gained importance with 
the Silk Road website in February 2011. Dark 
net markets usually remain active for just a few 
months up to a few years, and so the landscape 
changes rapidly, making it all the more difficult 
for drug law enforcement to target these online 
markets. Most closures, however, do not result 
from law enforcement action (only 17% of cryp-
to-drug market closures), but are generally the 
result of ‘exit scams’ (where operators suddenly 
close down the site and steal the money), vol-
untary exits and hacking by third parties552 (see  
Figure 10).
Since 2009, the use of the internet to facilitate 
transnational illegal drug transactions has become 
a phenomenon of growing significance. In the past 
decade responses to crypto-drug markets have 
been undertaken either unilaterally or through 
pre-existing strategic and security cooperation al-
liances, often on an ad-hoc basis, and in a vacuum 
left by the absence of clear international policy. Ac-
cording to the UNODC, 42% of member states have 
a system in place to monitor the sale of illegal drugs 
over the internet – with no increase since 2009.554 
Policy making in the area has been constrained by 
an inadequate technological understanding of the 
phenomenon, and without the required common 
legal frameworks necessary to adequately address 
the trans-jurisdictional nature of the issue. 
A 2016 study555 noted that crypto-drug markets 
continue to account for a relatively small percentage 
of drug sales globally, with all internet-facilitated 
transactions totalling around 1% of the total mar-
ket, but that percentage represented an increase of 
50% in the period 2013-2015. Since the first men-
tion of dark net markets in the UNODC’s World Drug 
Figure 10. Causes of closure of crypto-drug markets553
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enforcement – cooperation has occurred despite 
muddled international policy direction. States 
taking action have done so in response to press-
ing and immediate domestic law enforcement or 
public health challenges, rather than as part of any 
coherent policy landscape.562 Other states – such 
as the UK and Germany – have also taken action in 
response to requests for security cooperation from 
long-standing allies. More recently, individual mem-
ber states have worked within pre-existing alliances 
to coordinate several high-profile market interven-
tions. In general, US agencies continue to lead on 
the issue, as they have since the closure of the origi-
nal Silk Road website in October 2013. Of European 
states, the Netherlands has been notably proactive 
in the area, playing a key role alongside Europol in 
Operation Bayonet in 2017.563  
In the absence of cohesive national and internation-
al policy in the area, law enforcement agencies have 
continued the approach of shutting down markets, 
apprehending administrators, and seizing server 
assets in strategies reminiscent of the traditional 
offline drug law enforcement operations. So-called 
‘takedown’ operations seek to exploit either of two 
key structural weaknesses: the markets’ centralised 
authority (by apprehending the human administra-
tors of the sites), and/or the physically-centralised 
servers themselves. In each case, the takedowns 
result in the market sites going offline, but the sub-
sequent effect on vendors and buyers is less clear. 
Recent research suggests that takedown strategies 
may play a significant role in provoking technolog-
ical innovation,564 and the UNODC acknowledges 
that more research is required to better understand 
the effects of ‘hard’565 interventions.566 
Indeed, it is not yet clear whether closure under-
mines trust in – or the will to use – crypto-drug 
markets among people who use drugs. In 2018, 
only 15% of respondents to the Global Drug Survey 
said they felt closures discouraged their use of on-
line markets, and only 9% had stopped altogether, 
with more than 50% reporting that takedown had 
no effect on their usage patterns.567 Further, there 
is evidence of market migration, fragmentation, and 
online ‘turf wars’ similar to patterns observed in tra-
ditional markets, as surviving markets vie for market 
share following takedowns. This has led Europol to 
conclude that ‘law enforcement interventions in the 
form of darknet market take-downs disrupt darknet 
markets, although the overall ecosystem appears to 
be fairly resilient with new markets quickly becom-
ing established’, and vendors and customers migrat-
ing to the latest trading platform to continue their 
operations.568 Acknowledging this phenomenon, 
Operation Bayonet represented a somewhat evolved 
approach, with Europol and the US Department of 
Justice working together to quietly seize and op-
erate AlphaBay as an intelligence ‘honeypot’,569 in 
advance of taking down Hansa Market. Despite the 
new approach, there is evidence that crypto-drug 
markets are already evolving toward decentralised 
and distributed models.570 
Nevertheless, there is also evidence demonstrating 
the potential of such online platforms to reduce 
health harms for people who use drugs. Available 
research has shown that anonymised user forums 
and online chat rooms facilitate peer-based reviews 
and feedback about the quality of drug purchases, 
reliability of sellers, the purity and effects of certain 
products, representing a novel form of peer-based 
harm reduction, as well as ‘an entry point for drug 
support services’.571
Today, crypto-drug markets continue to operate as 
an efficient and growing means to transact canna-
bis, cocaine, and prescription opioids.572 They also 
facilitate the ‘marketing and distribution of, and 
trafficking in, psychotropic substances, including 
synthetic drugs’573 as well as precursors. Further-
more, crypto-currencies provide a means to launder 
money associated with the drug trade (see Section 
2.2.4 below). In short, the continued proliferation of 
crypto-drug markets speaks directly to many of the 
goals of the 2009 Political Declaration, and shows 
lack of progress for each. 
2.2.3 Tackling money-laundering
International provisions against money-launder-
ing were first included in the 1988 United Nations 
Convention against Illicit Traffic in Narcotic Drugs 
and Psychotropic Substances as a strategy against 
drug trafficking by criminal organisations. The im-
plementation of concrete measures was entrusted 
2009 Political Declaration and Plan of Action
Action 51(a): ‘Establishing new or strengthening 
existing domestic legislative frameworks to 
criminalize the laundering of money derived 
from drug trafficking, precursor diversion and 
other serious crimes of a transnational nature in 
order to provide for the prevention, detection, 
investigation and prosecution of money 
laundering’
Action 51(d): ‘Promoting effective cooperation 
in strategies for countering money-laundering 
and in money-laundering cases’
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by the G7 to the Paris-based Financial Action Task 
Force (FATF) in 1989, which became the global an-
ti-money-laundering standard-setter.575 A number 
of regional task forces modelled on the FATF were 
established in the 1990s and the 2000s – such as 
the Asia/Pacific Group on Money-laundering,576 the 
Financial Action Task Force for Latin America,577 the 
Inter-Governmental Action Group Against Money 
Laundering in West Africa,578 among others. 
Since 2009, several instruments have been adopted 
to consolidate the work of the FATF. These include 
the adoption, in 2012, of the ‘International standards 
on combating money-laundering and the financing 
of terrorism & proliferation – the FATF recommen-
dations’, which aim to strengthen international 
safeguards and protect the integrity of financial 
systems by providing governments with stronger 
tools to take action against financial crime.579 A year 
later, member states adopted the ‘Methodology for 
Assessing Compliance with the FAFT Recommenda-
tions and the Effectiveness of [Anti-Money-launder-
ing/Countering the Financing of Terrorism] Systems’, 
to help determine whether a country is sufficiently 
compliant with the 2012 standards, and whether 
their systems work effectively – with rounds of eval-
uation taking place regularly.580 
The UNODC has its own programmes to tackle 
money-laundering, in particular the ‘Global pro-
gramme against money-laundering, proceeds 
of crime and the financing of terrorism’ which 
encourages member states to develop policies 
to counter money-laundering and the financing 
of terrorism, monitors and analyses related prob-
lems, raises awareness and coordinates initiatives 
carried out by the UN and other international 
organisations.581 Through this programme, the 
UNODC has cooperated with a range of interna-
tional and regional organisations, including with 
the World Bank, the International Monetary Fund, 
the Organisation for Security and Cooperation in 
Europe, Interpol and others.582 In April 2009, just 
a month after the adoption of the 2009 Political 
Declaration, the UNODC published its ‘Model pro-
visions on money-laundering, terrorist financing, 
preventive measures and proceeds of crime’,583 
which are meant to be a ‘starting point for State 
authorities as they evaluate the measures that 
should be incorporated into domestic law in or-
der to prevent, detect, and effectively sanction 
money-laundering, the financing of terrorism 
and the proceeds of crime’.584 The World Bank 
also provides technical assistance to member 
states in developing effective laws, regulations 
and institutional framework, assessing the im-
pact of money-laundering, training the financial 
sector supervisors, investigators, prosecutors, 
judges, designing effective asset disclosure 
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systems for public officials, conducting national 
risk assessments.
Evaluation of anti-money-laundering efforts by 
the UNODC have mainly focused on ‘process’ or 
‘activity’ indicators. The data available through ARQ 
responses show that despite these global efforts, 
little progress has been recorded at national level 
in the past decade. In 2018, the UNODC reported 
a slight increase, from 37% in 2010 to 40% in 2016, 
in the percentage of states having legislation pro-
viding for the conclusion of bilateral or multilateral 
asset-sharing agreements. However, it recorded a 
slight fall between 2010 and 2016 in the percentage 
of states having measures in place to manage seized 
assets, for banks and other financial institutions to 
identify customers and verify their information to 
trace proceeds of crime, and to detect and monitor 
the cross-border transport of cash. There was also a 
slight decrease in the proportion of states in which 
it is mandatory to report suspicious transactions.585 
Despite the recorded slight fall, all these percentag-
es remain relatively high, at around 70% of report-
ing states – although it should be noted that only 
about 10% or less of member states in Sub-Saharan 
Africa, Oceania and the Caribbean provided consist-
ent data on this issue (see Box 1).
When one looks into the impacts that these process-
es have yielded on the scale of money-laundering, 
the results have been minimal. Despite an expan-
sion in global tools and collaboration at regional 
and international level to tackle money-laundering, 
the illegal drug trade remains the second largest 
source of income of transnational organised crime 
groups,586 who continue to launder money with im-
punity. Indeed, as discussed above, UNODC research 
concluded that less than 1% of the total amounts 
laundered were seized.587 In 2016, Europol’s Asset 
Recovery Unit frankly admitted that in Europe from 
2010 to 2014, only 2.2% of the estimated proceeds 
of crime were provisionally seized or frozen, and ul-
timately just 1.1% of the criminal profits were finally 
confiscated at EU level.588 A 1.1% interception rate 
means that ‘98.9 percent of estimated criminal prof-
its are not confiscated and remain at the disposal of 
criminals’,589 that is, in addition to the accumulated 
criminal wealth from previous years. The 2013 HSBC 
money-laundering scandal590 and the Panama Pa-
pers in 2016591 are merely two examples of the scale 
of the issue. 
Figure 11 highlights the interdiction rates and 
criminal proceeds retained by criminal enterprises 
in high-income countries. Tackling money-launder-
ing in lower-income countries, with fewer resourc-
es, may prove to be even more challenging. New 
technologies present additional challenges to the 
current anti-money-laundering framework, with 
growing volumes of transactions and large data sets 
requiring computational analysis to reveal patterns, 
trends and associations. The growing demand for 
online services and related internet payment sys-
tems also pose challenges with borderless virtual 
environments requiring an adaptation of current 
strategies.592 In its 2018 World Drug Report, the 
UNODC concluded that drug-related money-laun-
dering affected the economy in a number of ways, 
including by inflating property prices, distorting ex-
port figures, as well as by exacerbating unfair com-
petition, the gap in wealth distribution and corrup-
tion, while negatively affecting foreign investment 
in developing countries.593
This is not to say that the anti-money-laundering 
regime has entirely failed. Since 2000, most coun-
tries have adopted more legislation to tackle mon-
ey-laundering and extended the scope of their 
surveillance activities. There have also been more 
convictions for money-laundering, and countries 
are better equipped to cooperate against serious 
crimes and to seize proceeds. However, a thorough 
cost-benefit analysis remains to be undertaken on 
anti-money-laundering efforts, both globally and 
nationally.594 Furthermore, the anti-money-laun-
dering regime may also generate harms – efforts to 
control money-laundering may lead banks to cut 
down overseas remittances to ‘the most vulnerable 
populations in the poorest countries’.595 The failure 
to control illegal money flows also extends to the 
failure to counter tax evasion, tax avoidance and 
trade mispricing, which is eroding the tax base for 
development. Finally, it is worth nothing that the 
anti-money-laundering regime – which requires 
tighter government controls over the banking sec-
tor – was developed at a time when the world was 
in a process of complete deregulation of financial 
markets. It is unlikely that any significant improve-
ment in tackling money-laundering will material-
ise until there is political will to better control the 
financial sector.596 
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2.3 Advancing development
The third key priority of the UN, as established in 
its founding Charter, was to ‘achieve international 
co-operation in solving international problems 
of an economic, social, cultural, or humanitarian 
character’,597 and improving people’s well-being 
worldwide through a comprehensive development 
approach that ‘promotes prosperity and economic 
opportunity, greater social well-being, and protec-
tion of the environment’.598 This approach was first 
reflected in the Millennium Development Goals 
(2000-2015),599 and has since then been consolidat-
ed in the 2030 Sustainable Development Agenda.600
2.3.1 Analysing factors leading to 
 illegal cultivation
 
There are many factors leading to the cultivation 
of crops; primary among them is insecrity, armed 
conflict, poverty, marginalisation and lack of op-
portunities in the licit market. Another is cultivation 
for personal recreational use, and yet another is 
traditional usage. While cultivation for recreational 
and traditional use have so far not been adequately 
discussed at global level, progress has been made 
in identifying the developmental factors linked to 
illegal crop cultivation. For instance, the UNGASS 
Outcome Document requests member states to 
address the factors related to illegal crop cultivation 
‘by implementing comprehensive strategies aimed 
at alleviating poverty…and by promoting sustaina-
ble development aimed at enhancing the welfare of 
the affected and vulnerable population through licit 
alternatives’.601 The UNODC, which had traditionally 
mostly focused on assessing the impact of alterna-
tive development programmes through reductions 
in hectares of crops cultivated, is also taking steps 
to broaden its traditional ‘Crop Monitoring’ surveys 
to include socio-economic issues. An example of 
this new approach is the 2016 Afghanistan opium 
survey, in which the UNODC documented the links 
between illegal crop cultivation and various SDGs602 
(see Figure 12).
In its contribution to the 2016 UNGASS, the United 
Nations Development Programme was also instru-
mental in documenting and analysing the links 
between poverty and engagement in the illegal 
drug trade, in particular,603 and is now engaged in a 
very important exercise being carried out with the 
University of Essex to elaborate International Human 
2009 Political Declaration and Plan of Action
Action 43(b): ‘Conduct research to assess the 
factors leading to the illicit cultivation of drug 
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Rights Guidelines on Drug Control, including sections 
devoted to cultivation, rural development and 
indigenous uses of psychoactive plants. Similarly, 
several NGOs have conducted valuable research to 
better understand the factors leading to illegal crop 
cultivation and engagement in other aspects of the 
illegal drug trade.605
At national level, in 2018 the UNODC reported 
that only ‘some member states’ had conducted 
studies evaluating the impact of their alternative 
development programmes, while ‘others’ (not 
quantified) used human development indicators 
to review impact.606 Although limited, this 
is a recognition of the need to address the 
developmental factors pushing many vulnerable 
people to engage in illegal drug activities. 
Furthermore, since 2009, several new initiatives 
have led to the production of detailed research607 
and tools608 and have facilitated constructive 
dialogue among the UN, member states, civil 
society and academia, to better understand the 
development factors contributing to engagement 
in illegal cultivation and trafficking. This includes 
the ‘Global Partnership on Drug Policies and 
Development’ (GPDPD) programme led by the 
German development agency GIZ,609 and the 
Cooperation Programme between Latin America, 
the Caribbean and the European Union on Drug 
Policies (COPOLAD) project.610 At the same time, the 
need to evaluate alternative development projects 
by utilising human development indicators has 
been an issue of debate in UN expert meetings on 
alternative development for nearly two decades, yet 








 Survey Report 2016
Figure 12. Percentage of villages with and without opium poppy cultivation progressing towards 
selected SDGs in Afghanistan, 2016604
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Box 17  Adopting a development approach to illegal cultivation: 
The case of Thailand
In the 1960s, Thailand was one of the main 
producers of opium. However, instead of prior-
itising forced crop eradication, the government 
decided to undertake major long-term develop-
ment efforts to address the underlying causes of 
involvement in opium cultivation. The strategy 
focused on providing agricultural alternatives, 
improving access to healthcare and education 
and developing basic infrastructure such as 
roads, electricity and clean water supplies. The 
alternative livelihoods programme was incorpo-
rated in the broader local and national develop-
ment strategy and consisted in a bottom-up ap-
proach, driven by community engagement and 
strong partnerships with community leaders. 
The programme was also adequately sequenced, 
ensuring that opium poppy fields would not be 
eradicated until basic services and alternative 
livelihoods were in place.611 
A 2018 study by the Mae Fah Luang Foundation 
found that this approach had contributed to re-
ducing poverty levels among subsistence farm-
ers who were able to turn to alternative sources 
of income before opium poppy was eradicated, 
increasing household incomes and facilitating 
the development of small-scale businesses. The 
regions in which the programme was imple-
mented now benefit from more diverse econom-
ic activities, including the cultivation of crops 
like tea, Inca, peanut and bamboo, and increased 
tourism thanks to improved infrastructure. Ac-
cess to healthcare (including drug dependence 
treatment), education, electricity and clean 
water was also improved, and environment pro-
tection became an essential component of the 
approach through sustainable land distribution, 
reforesting initiatives and environmental ed-
ucation incorporated in school curriculums.612 
However, it is also important to point out that 
poppy cultivation migrated to other countries, 
mainly to neighbouring Myanmar, and that the 
Thai drug market shifted from opium/heroin 
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2.3.2 Promoting sustainable development in 
cultivation and trafficking areas 
In 2009, UN member states had recognised the 
need to address the socio-economic vulnerabilities 
pushing people to engage in illegal drug cultivation 
and trafficking via sustainable development strate-
gies, with mention made to the Millennium Devel-
opment Goals. Since 2009, most countries affected 
by illegal crop cultivation have adopted some form 
of alternative development programme, generally 
alongside eradication campaigns. These include 
Afghanistan, Bolivia, Colombia, Ecuador, Indonesia, 
Lao PDR, Morocco, Myanmar, Peru, the Philippines 
and Thailand.613 However, few have embedded 
these programmes in a comprehensive, long-term 
sustainable development strategy. 
In this regard, ‘proper and coordinated sequencing 
of development interventions’ is perhaps one of 
the most problematic issues related to alternative 
development. Proper sequencing means that no 
eradication should take place until there are suffi-
ciently developed alternatives in place to ensure 
subsistence farmers’ survival.614 In theory, most al-
ternative development programmes implemented 
since 2009 have included the concept of adequate 
sequencing. However, in practice only Bolivia and 
Thailand seem to have respected this core compo-
nent of an effective sustainable development ap-
proach. Others have merely implemented alterna-
tive development programmes as a complementary 
aspect of, or to justify, crop eradication, rather than 
as the primary means of creating the conditions that 
would improve people’s livelihoods and reduce their 
dependence on illegal crop cultivation.615 The cases 
of Colombia (see Box 12) and Peru are particularly 
illustrative of these concerns. In Thailand, efforts 
were made to implement a long-term development 
strategy for about 15 years before opium poppy 
started being eradicated, in close consultation with 
the local communities (see Box 17). In Bolivia, the 
government’s approach has focused on ensuring 
that farmers could grow a sufficient amount of coca 
for subsistence purposes, facilitating access to a 
national legal market for coca products, improving 
access to safe water, education and promoting addi-
tional sources of income.616
With regards to drug trafficking, it was only recently 
that the UN started recognising the complex vul-
nerabilities of those engaging in drug trafficking, 
with most debates revolving around women. The 
conversation made a significant step forward at the 
UNGASS, and with the adoption of Resolution 59/5 
‘Mainstreaming a gender perspective in drug-relat-
ed policies and programmes’ which ‘Urges Member 
States to implement broad-based programmes 
aimed at preventing women and girls from be-
ing used as couriers for trafficking in drugs’.617 The 
UNGASS Outcome Document also includes various 
2009 Political Declaration and Plan of Action
Action 45(c): ‘Establish, where possible, 
sustainable alternative development 
programmes, in particular in drug-producing 
regions, including those with high levels 
of poverty, as they are more vulnerable to 
exploitation by traffickers and more likely to be 
affected by the illicit cultivation of drug crops and 
the illicit production of and trafficking in narcotic 
drugs and psychotropic substances’
Action 45(d): ‘Consider, where appropriate, 
including in their national development 
strategies, integrated and sustainable alternative 
development programmes, recognizing that 
poverty and vulnerability are some of the factors 
behind illicit drug crop cultivation and that 
poverty eradication is a principal objective of 
the Millennium Development Goals; and request 
development organizations and international 
financial institutions to ensure that alternative 
development strategies, including, when 
appropriate, preventive alternative development 
programmes, are incorporated into poverty 
reduction strategy papers and country assistance 
strategies for States affected by the illicit 
cultivation of crops used for the production of 
narcotic drugs and psychotropic substances’
Action 47(f): ‘Ensure the proper and coordinated 
sequencing of development interventions 
when designing alternative development 
programmes; and, in this connection, the issues 
of the establishment of agreements and viable 
partnerships with small producers, favourable 
climatic conditions, strong political support and 
adequate market access should be taken into 
account’
Proper sequencing
tends to be ignored and 
alterna�ve development is o�en 
subordinated to crop eradica�on
Adequate sequencing requires 
that no eradica�on occurs 
before there are suﬃciently 
developed alterna�ve sources 
of income.
The importance of
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Box 18  Addressing the vulnerabilities faced by women: The case 
of Costa Rica
In 2017, Costa Rica had the fifth highest incarcer-
ation rate in Latin America, at 374 per 100,000 
inhabitants. Two in ten prisoners are currently in 
prison for drug offences – reaching a ratio of six in 
ten among female prisoners. The most common 
offences for which people are incarcerated include 
smuggling drugs in prisons, micro-trafficking, 
drug transportation and small-scale selling (drug 
possession for personal use is not criminalised in 
Costa Rica). Women incarcerated for drug offences 
are usually first time non-violent offenders, single 
mothers of several children, with limited formal 
education or employment possibilities. Their mass 
incarceration has had a devastating impact on 
women and their families and has led to serious 
prison overcrowding and poor prison conditions. 
In an effort to decongest the criminal justice sys-
tem and guarantee basic rights for prisoners, the 
Costa Rican government has carried out a series of 
legislative and political reforms.
Starting in 2013, Law 9161 (known as ‘77bis’) was 
approved and reduced the prison sentence for 
women accused of smuggling drugs in prison (a 
reduction from 8-20 years to 3-8 years), guarantee-
ing more proportionality and a gender perspective 
in Costa Rica’s drug legislation. The law opened 
up the possibility of alternatives to incarceration 
for women in situations of vulnerability accused 
of this specific drug offence.618 The approval of 
the law directly benefited a quarter of women 
incarcerated for drug offences with the immedi-
ate release of more than 120 women.619 The mass 
release of women from prison led to the creation 
of an inter-institutional network for the social re-
integration of women in conflict with the law. This 
network includes eight public institutions working 
in the areas of health, gender, family, employment, 
the judiciary, prisons and drug control. The active 
coordination of the Ministry of Women for the 
provision of a wide range of services and direct 
support to formerly incarcerated women has been 
instrumental to the network’s success.620
The most recent reform was the approval of Law 
9361 in early 2017, which reduces the time for 
which a criminal record is kept, according to the 
offence committed and the penalty imposed. 
This was in recognition of the difficulty faced by 
formerly incarcerated individuals to find employ-
ment after their release, increasing their vulnera-
bility to poverty and re-engagement in criminal 
activities. The law also allows the immediate elim-
ination of the criminal record for people found 
in situation of vulnerability. Before the reform, 
criminal records were kept in the judicial registrar 
for 10 years, without distinction between serious 
or minor crimes.621 Interestingly, this reform initi-
ative was initially going to target those who had 
committed drug offences and was then expanded 
to cover more offences. It has nonetheless had a 
major impact for drug offenders. The Costa Rican 
experience is therefore an excellent example of 
how to address the situation of poverty, margin-
alisation and exclusion faced by people engaged 
in criminal activities for subsistence purposes. 
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2.3.3 Support and cooperation for alternative 
development
The UNODC is currently supporting alternative 
development programmes in various countries, 
including Afghanistan, Bolivia, Colombia, Lao PDR, 
Myanmar and Peru.625 However, donors’ financial 
support for alternative development initiatives has 
key operational recommendations urging member 
states to take into account the specific vulnera-
bilities faced by women engaging in the illegal 
drug trade.622 
Nationally, only a few UN member states have trans-
lated these recommendations into practice. In 2012, 
the UK revised its sentencing guidelines to take 
into account the role of women in the overall drug 
trafficking chain during trial, with the recognition 
of various situations of vulnerability as mitigating 
factors – although the failure to review drug legisla-
tions has meant that these new guidelines only had 
a limited impact.623 In 2014, Ecuador adopted a new 
criminal code to ensure more proportionate sen-
tencing for drug offenders, in particular micro-traf-
fickers, in recognition that those at the lowest level 
in the drug trafficking chain were generally involved 
in drug activities because of socio-economic issues. 
However, the legislation was revised in 2015 which 
severely limited the positive impacts of the new 
policy on reducing prison overcrowding.624 Costa 
Rica is by far the country which has made most pro-
gress on this issue (see Box 18).
Box 19  Resolutions on alternative development adopted 
between 2009 and 2018
CND resolution 61/6. Promoting the implemen-
tation of the United Nations Guiding Principles 
on Alternative Development and related commit-
ments on alternative development and regional, 
interregional and international cooperation on de-
velopment-oriented, balanced drug control policy 
addressing socioeconomic issues (2018)
CND resolution 58/4. Promoting the implemen-
tation of the United Nations Guiding Principles on 
Alternative Development (2015)
CND resolution 57/1. Promoting the implemen-
tation of the United Nations Guiding Principles 
on Alternative Development and proposal to or-
ganize an international seminar/workshop on the 
implementation of the Guiding Principles (2014)
CND resolution 56/15. Follow-up to the Plan of 
Action on International Cooperation towards an 
Integrated and Balanced Strategy to Counter the 
World Drug Problem with respect to the develop-
ment of strategies on voluntary marketing tools 
for products stemming from alternative develop-
ment, including preventive alternative develop-
ment (2013)
CND resolution 55/8. Follow-up to the Plan of 
Action on International Cooperation towards an 
Integrated and Balanced Strategy to Counter the 
World Drug Problem with respect to the develop-
ment of strategies on special marketing regimes 
for alternative development, including preventive 
alternative development (2012)
CND resolution 55/4. Follow-up on the proposal 
to organize an international workshop and con-
ference on alternative development (2012)
CND resolution 54/4. Follow-up on the proposal 
to organize an international workshop and con-
ference on alternative development (2011)
CND resolution 53/6. Follow-up to the promo-
tion of best practices and lessons learned for the 
sustainability and integrality of alternative devel-
opment programmes and the proposal to organ-
ize an international workshop and conference on 
alternative development (2010)
CND resolution 52/6. Promoting best practices 
and lessons learned for the sustainability and in-
tegrality of alternative development programmes 
(2009)
2009 Political Declaration and Plan of Action
Action 43(d): ‘Ensure that States with the 
necessary expertise, the United Nations Office 
on Drugs and Crime and other relevant United 
Nations organizations assist affected States in 
designing and improving systems to monitor 
and assess the qualitative and quantitative 
impact of alternative development and drug 
crop eradication programmes with respect to the 
sustainability of illicit crop reduction and socio-
economic development; such assessment should 
include the use of human development indicators 
that reflect the Millennium Development Goals’
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been steadily reduced since 2009. The 2015 World 
Drug Report included a dedicated section on alter-
native development, concluding that: ‘Despite the 
amount of attention given to alternative develop-
ment at the international level, there is a disconnect 
between international rhetoric and funding’.626 De-
spite the level of visibility given to alternative devel-
opment in the CND (see Box 19) and the UN General 
Assembly,627 the report continues, ‘the funding for 
it has decreased considerably in the last few years’. 
In fact, ‘overall gross disbursements of alternative 
development funds from OECD countries have de-
clined by 71 per cent since the adoption of the Polit-
ical Declaration and Plan of Action on International 
Cooperation towards an Integrated and Balanced 
Strategy to Counter the World Drug Problem’.628
As noted above, GPDPD and COPOLAD have taken 
the lead in facilitating country visits in areas bene-
fiting from alternative development programmes, 
providing technical support, providing guidance for 
assessing the impacts of different alternative devel-
opment strategies on broader human development 
indicators and aligning alternative development 
efforts with the SDGs.
2.3.4 Ensuring collaboration with local 
communities in illegal crop cultivation areas
2009 Political Declaration and Plan of Action
Action 45(f): ‘Ensure that the design and 
implementation of alternative development 
programmes, including, when appropriate, a 
preventive approach, involve all stakeholders, 
take into account the specific characteristics 
of the target area and incorporate grass-
roots communities in project formulation, 
implementation and monitoring’
Action 47(b): ‘Develop alternative development 
programmes and eradication measures 
while fully respecting relevant international 
instruments, including human rights instruments, 
and, when designing alternative development 
interventions, taking into consideration the 
cultural and social traditions of participating 
communities’
Action 47(d): ‘Ensure that the implementation 
of alternative development and preventive 
alternative development, as appropriate, 
enhances synergy and trust among the 
national Government, local administrations and 
communities in building local ownership’
The need to involve affected communities in the 
design, implementation and monitoring of alter-
native development programmes is recognised 
in three actions. Community involvement in these 
programmes is critical to ensure that they are real-
istic and adapted to the local terrain, market access 
and know-how of affected communities. This key 
principle was recognised in the UN General As-
sembly Resolution 68/196 ‘United Nations guiding 
principles on alternative development’ and in the 
UNGASS Outcome Document.629 In its 2018 report 
on UNGASS implementation, the OHCHR also rec-
ognised that ‘In terms of the design of alternative 
development programmes, the participation of 
those affected, including women, minorities and 
indigenous peoples, should be essential’.630
On the ground, however, and with some notable 
exceptions, meaningful community participation 
in alternative development programmes is sorely 
lacking. For example, while the Colombian Peace 
Agreement recognises that poverty and conflict are 
at the root of coca cultivation in that country and 
calls for significant community involvement in rural 
development efforts,631 in reality community par-
ticipation was very limited. Despite being called to 
participate in many meetings, they were not given a 
significant role in negotiating the terms of crop sub-
stitution contracts, were forced to sign up for ‘vol-
untary’ coca eradication under the threat of forced 
eradication and had little opportunity for meaning-
ful input into development plans, which lag way 
behind in implementation (see Box 15). Thailand 
and Bolivia seem to have yielded better results. In 
Bolivia, a social control system enables farmers to 
cultivate a certain amount of crops, while the com-
munity is responsible for ensuring that households 
do not produce more than the quantity authorised 
(see Box 18).632 In Thailand, the government’s long-
term development strategy in opium cultivation 
areas has promoted a bottom-up approach aiming 
to identify the needs and problems of affected com-
munities, building partnerships with local commu-
nities and community leaders, and incorporating 
local know-how in all aspects of the programme 
(see Box 20).633
Community Assembly on crop substitution in 
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Box 20  Bolivia’s community coca control
Andean indigenous communities have used the 
coca leaf in cultural rituals, social and economic 
interactions, and medicinal uses for centuries.634 
From 1980s until the early 2000s, Bolivia’s drug 
control strategy fuelled forced coca eradication 
leading to human rights violations and exacer-
bating the poverty of affected farmers. From 2006 
onwards, Bolivia has shifted its strategy to expand 
and protect the rights of indigenous coca growers. 
In 2004, the Bolivian government allowed regis-
tered farmers in the Chapare to cultivate 1,600 m2 
of coca for the legal market, shifting away from 
defining coca growers as active participants in the 
illegal drug trade to identify them as subsistence 
farmers working to feed their families. Article 384 
of the 2009 Constitution defends coca in its natural 
state, asserting its cultural significance and grant-
ing it legal protection.635 In an effort to address the 
tensions between the licit national coca market and 
the international drug control regime, Bolivia with-
drew from the 1961 Single Convention on Narcotic 
Drugs in 2011 and re-acceded it a year later with a 
reservation allowing coca cultivation and sales for 
cultural, medicinal and traditional uses.636 
In 2010, the government implemented a partici-
patory Community Control Support Programme, 
based on sovereignty, shared responsibility and 
respect for human rights.637 The 2017 General 
Coca Law further differentiated coca from co-
caine, decriminalising coca cultivation with the 
hope of reducing the stigma surrounding coca 
cultivation. The Bolivian model for community 
coca control has promoted:
• A reduction in illegal crop cultivation via a de-
velopment strategy seeking to address affect-
ed communities’ basic needs and by limiting 
repression638
• Citizenship and access to information, em-
powering and involving communities in the 
formulation and implementation of develop-
ment policies, providing subsistence income 
through legal plots, while working to voluntar-
ily reduce excess coca production and diversi-
fying their economy639 
• Development and poverty alleviation in coca 
growing regions by strengthening public ser-
vices and institutional frameworks for margin-
alised communities640
• Respect for the fundamental human rights 
and wellbeing of families and vulnerable 
communities, preventing illegal cultivation of 
coca, while taking into account traditional licit 
uses641 
• Cooperation between farmers, the state, and 
international stakeholders such as the EU and 
the UNODC to develop crop monitoring sys-
tems and impact assessment tools focusing on 
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A 2015 report by Open Society Foundations con-
cluded that there was ‘little evidence’ to suggest 
that alternative development programmes would 
alleviate the environmental impacts of drug crop 
eradication. For instance, in reference to Colombia 
and Bolivia, researchers found that ‘under alterna-
tive development initiatives, coca farmers cleared 
more primary forest to plant “land hungry substitute 
crops” that could not be cultivated as intensively as 
coca’. The report also concluded that ‘The loss of for-
ests and the degradation of natural habitats in drug 
production and drug trafficking zones contributes 
to the crisis of biodiversity decline worldwide’.652 It 
should be recalled here that forest conservation is 
essential to tackling climate change, since 11% of 
global emissions originate from deforestation.653 
Nevertheless, environment protection is barely 
discussed at the CND, while discussions at the High 
Level Political Forums on the SDGs, at the UN Frame-
work Convention on Climate Change or within the 
UN Environment Programme have so far largely 
ignored the links between drug control and envi-
ronment degradation. 
In recognition of this worrying trend, the UNODC 
reported that since 2010 an increasing number of 
member states have included environmental con-
servation in their alternative development strat-
egies. This includes reforestation, soil restoration, 
the use of bio-fertilisers, the diversification of crops, 
organic production, and more rarely ecotourism.654 
2.3.5 Protecting the environment in drug 
control strategies
In various areas, illegal crop cultivation has contrib-
uted to the deforestation and degradation of the 
environment because of the chemicals used to grow 
and process crops, such as agrochemicals, sulfuric 
acid, kerosene and others, being discharged into 
soil and streams.643 This, however, is not limited to 
the cultivation of crops destined for the illegal drug 
market, with similar environmental harms associat-
ed with many other forms of agriculture. Rather than 
minimising harms to the environment, forced crop 
eradication campaigns have exacerbated environ-
mental damage, by displacing subsistence farmers 
into new, more remote environments, including na-
tional parks and indigenous territories.644 In Colom-
bia, for instance, the UNODC estimated in 2016 that 
32% of coca was being cultivated in national parks, 
indigenous reserves and Afro-Colombian Com-
munity Lands, and that the areas cultivated within 
these territories had been in ‘constant increase in 
the last years’.645 
The use of harmful pesticides to destroy crops des-
tined for the illegal drug market has also damaged 
fish and other aquatic life due to contaminated water, 
as well as fauna, insects and soil composition.646 The 
destruction of natural habitats and tropical ecosys-
tems is likely to result in harms to native species.647 
In recognition of concerns over both human and en-
vironmental harms, Peru, Bolivia, Ecuador and Thai-
land have all banned the use of chemical agents in 
eradication efforts.648 Colombia’s discontinuation of 
aerial spraying is likely to be reversed under the new 
government, while substances like glyphosate649 con-
tinue to be used for manual fumigation.650 
2009 Political Declaration and Plan of Action
Action 22(e): ‘Promote supply reduction 
measures that take due account of traditional 
licit uses, where there is historical evidence of 
such use, as well as environmental protection, in 
conformity with the United Nations Convention 
against Illicit Traffic in Narcotic Drugs and 
Psychotropic Substances of 1988’
Action 49(e): ‘Ensure that development 
partners, affected States and other relevant key 
development actors examine innovative ways to 
promote alternative development programmes, 
including preventive alternative development 
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to receiving any development assistance, resulting 
in a variety of human rights violations. In Afghani-
stan, for instance, militarised interventions funded 
first by the USA and then by the Russian Federation 
have resulted in a more precarious security situ-
ation with increased levels of crime, an ongoing 
Taliban insurgency and official and unofficial mi-
litias remaining active in the region – with severe 
consequences for subsistence farmers.659 A 2017 
Brookings Institution report found that this had 
resulted in increased support from the population 
to the Taliban which provides armed security, jobs 
and subsistence, especially in remote rural areas 
of the country.660 The recent shift towards broader 
development strategies in illegal crop production 
areas by donors like GIZ and the European Union is 
therefore welcome, but remains the exception. 
References to human rights and alternative devel-
opment are often put in the context of ensuring that 
human rights are taken into account in implement-
ing drug control programmes. These, however, are 
not policy choices per se, but rather obligations that 
need to be respected. Eradication prior to the estab-
lishment of alternative livelihoods pushes people 
deeper into poverty, and fosters human rights viola-
tions, social unrest, instability and violence, among 
other negative impacts. It exacerbates stigmatisa-
tion and marginalisation of small-scale producers, 
and can result in imprisonment, displacement, and 
the criminalisation of indigenous and traditional 
cultural practices. According to the Transnational 
Institute: ‘People have the right to be free from 
hunger, to an adequate standard of living, to live a 
life in dignity, and to social security. When states fail 
in meeting their obligations to secure these rights, 
a strong argument can be made that they cannot 
interfere when people as a consequence are forced 
to find their own ways to do so, even if that means 
their involvement in illicit cultivation in absence of 
viable licit alternatives’.661
The need to ensure ‘environmental sustainability’ 
is also recognised within paragraph 7.g of the UN-
GASS Outcome Document.655 
As an example, Thailand has incorporated a strong 
environment protection component in its alterna-
tive development strategy, including in land distri-
bution, which areas should be cultivated and which 
should be reforested, how to use natural resources 
sustainably, etc. The programme also includes envi-
ronmental education ‘so that new generations can 
continue to be stewards of environmental sustain-
ability’.656 Similarly, in Colombia the UNODC – with 
support from GPDPD and the climate protection 
project REDD+657 – has conducted a comprehen-
sive analysis of the environmental impact of coca 
cultivation in the country, offering a set of criteria 
and recommendations to address this critical issue, 
including the use of traditional production models, 
as well as the creation of partnerships with affected 
communities.658 
2.3.6 Ensuring that development assistance 
protects human rights 
Until recently, the links between drugs and devel-
opment have been largely misunderstood and have 
generally been ignored by international donors. In 
other cases, foreign aid has been conditioned to the 
adoption of a drug control approach by recipient 
countries, including eradicating all cultivation prior 
2009 Political Declaration and Plan of Action
Action 47(c): ‘Ensure that development 
assistance provided to communities in areas 
affected by illicit cultivation of crops used for the 
production of narcotic drugs and psychotropic 
substances takes into account the overall aims of 
human rights protection and poverty eradication’
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Part 3: 
What next? 
Designing new benchmarks for global drug policy
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‘The cross-cutting UNGASS 2016 approach consti-
tutes a new and better linkage of the objective of 
drug-control – protection of the health and welfare 
of humanity – with the key priorities of the UN system, 
including the SDGs. I encourage the continuation of 
this structure for future UN drug policy debates’, UN 
High Commissioner for Human Rights, 2018662
When it was adopted in April 2016, the UNGASS 
Outcome Document was criticised by civil socie-
ty663 and a number of government officials664 for 
failing to question the punitive approach to global 
drug control, and for failing to mention decrimi-
nalisation and the abolition of the death penalty 
for drug offences, among other issues. The call, 
in the preamble of the Outcome Document, for 
the achievement of a ‘society free of drug abuse’, 
remains particularly problematic considering the 
lack of progress and severe consequences associ-
ated with efforts to achieve this goal over the past 
10 years. Perhaps unsurprisingly, the issue of reg-
ulated markets for certain substances likewise did 
not make it into the final document (see Box 21). 
Initial analysis by IDPC – to be published later in 
2018 – confirms that all recommendations and 
thematic areas covered in the 2009 Political Dec-
laration and Plan of Action were also incorporated 
in the Outcome Document, apart from one issue 
(witness protection, mentioned in Paragraphs 61 
and 62 of the Plan of Action). Both the spirit and 
themes of the 2009 Political Declaration are there-
fore largely reflected within in the 2016 Outcome 
Document. 
Nonetheless, in many regards the Outcome Doc-
ument represents a significant improvement over 
past high-level drug policy documents – including 
the 2009 Political Declaration and its plan of ac-
tion. Indeed, a number of critical drug policy issues 
which were either not included or only partially 
covered in 2009 were incorporated in the 2016 doc-
ument. This includes issues affecting women and 
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1 The UNGASS Outcome Document as a 
policy framework beyond 2019
Figure 13. Comparing the structure and number of actions/recommendations of the 2009 Plan of 
Action with that of the 2016 UNGASS Outcome Document665 
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Box 21  The UN drug control conventions and the legal 
regulation of cannabis for non-medical use
One of the greatest disconnects between con-
temporary reality and the UN’s 2019 drug policy 
targets has to do with cannabis. The UN drug 
control treaties expressly limit cannabis use to 
medical and scientific purposes, and cannabis 
is placed under the strictest of the conventions’ 
control schedules, meaning that its liability ‘to 
abuse and to produce ill effects… is not offset 
by substantial therapeutic advantages’. How-
ever, cannabis is by far the world’s most widely 
used illegal drug.666 Instead of persisting with 
efforts to ban cannabis markets, an increasing 
number of jurisdictions are choosing to provide 
for legal, regulated access to cannabis for adults 
for non-medical purposes. These jurisdictions 
have concluded – in somxe cases by public bal-
lot – that regulation would be better suited to 
promote the health, security, and human rights 
of their citizens. 
Movement toward regulation of non-medi-
cal cannabis is most obvious in the Americas, 
namely in Uruguay,667 Canada,668 and the USA,669 
and these policy shifts are prompting renewed 
debate on cannabis regulation elsewhere in the 
world, such as in the Netherlands,670 Switzer-
land671 and New Zealand.672 In the Caribbean, 
where Jamaica already allows for cannabis use 
in religious ceremonies673 and St Vincent and 
the Grenadines is about to adopt a similar bill, 
a recent report of the Caribbean Community 
(CARICOM) Regional Commission on Marijuana 
recommends that ‘the end-goals for CARICOM 
should be the removal of a prohibitionist re-
gime that has proven to be ineffective, unjust 
and caused more harm than it sought to pre-
vent’ and that ‘CARICOM Member States should 
negotiate the tensions arising between redun-
dant treaties and other requirements, not uni-
laterally, but as a unified entity’.674
There is little doubt that legal regulation of 
non-medical cannabis is beyond the bounds 
of what the drug control treaties permit. But 
regulation is moving ahead all the same, and 
the resulting treaty tensions are now a matter 
of intense debate at UN drug policy forums.675 
The so-called ‘Vienna consensus’ is fractured, 
and the starkly different approaches to canna-
bis are among the key reasons why. Reaching 
a new global consensus to revise or amend the 
UN drug control conventions in order to accom-
modate legally regulated markets for cannabis 
does not appear to be a viable scenario for the 
foreseeable future. Meanwhile, the limits of flex-
ible treaty interpretations have been reached, 
and overstretching them any further would 
result in undermining the basic principles of 
international law. States that intend to move 
towards legal regulation, or that have already 
done so, are therefore obliged to explore other 
options to reconcile such policy changes with 
their obligations under international law. Only 
a few options are available that do not require 
the consent of all the treaty parties.
The WHO can recommend, after a critical review 
by its ECDD, to change the schedule of a con-
trolled substance or remove it from the sched-
ules altogether, and the CND is then asked to 
adopt the recommendation by a simple or 
two-thirds majority vote (for the 1961 and 1971 
conventions, respectively). The ECDD’s first-ev-
er critical review of cannabis is indeed under-
way.676 This review is likely to result in WHO 
recommendations by the end of the year to 
re-schedule cannabis (plant, resin and extracts) 
within the 1961 treaty and its active THC com-
pounds within the 1971 treaty, although reach-
ing the required CND majority to adopt them 
may prove difficult. The other options that do 
not require UN consensus are either a unilateral 
procedure by late reservations to the treaties 
or denunciation and re-accession with new 
reservations (as Bolivia did with regard to coca), 
or collective inter se modifications negotiated 
between like-minded countries – a procedure 
provided for under Article 41 of the Vienna Con-
vention on the Law of Treaties.677
The inter se procedure was specifically de-
signed to find a balance between the stability 
of treaty regimes and the necessity of change 
in the absence of consensus. This option would 
require the like-minded agreement to include 
a clear commitment to the original treaty aim 
to promote the health and welfare of human-
kind and to maintaining the original treaty 
obligations vis-à-vis countries not party to the 
inter se agreement. The situation in which the 
Continued overleaf
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of the 2009 Declaration (i.e. demand reduction, 
supply reduction and international cooperation). 
In addition to better reflecting the complexities of 
the illegal drug market, this new structure enables 
member states to address a broader range of drug 
policy issues that do not fit under the headings of 
‘demand reduction’, ‘supply reduction’ and ‘Coun-
tering money-laundering and promoting judicial 
cooperation to enhance international cooperation’. 
The inclusion of separate chapters on access to 
controlled medicines, human rights and develop-
ment are particularly important for drug control to 
better contribute to the broader UN objectives of 
protecting human rights, peace and security, and 
development. 
Furthermore, the level of visibility allocated to each 
of the seven themes within the Outcome Docu-
ment is much more balanced than in 2009. Then, 
the Plan of Action included 122 actions to reduce 
supply compared to only 50 on demand reduction. 
In comparison, the Outcome Document provides 
a much more balanced alternative (see Figure 13).
UN drug control treaty regime finds itself to-
day – systemic challenges and inconsistencies, 
increasing tensions with state practices, huge 
political and procedural obstacles to amend-
ments, and unilateral escape attempts – merit 
a careful exploration of the legitimacy and via-
bility of inter se agreements. As more countries 
opt for legal regulation of cannabis, the coor-
dinated collective response entailed by inter 
se agreements has clear benefits compared to 
a chaotic scenario of a growing number of dif-
ferent unilateral reservations and questionable  
re-interpretations.678
children, key harm reduction interventions (such 
as overdose prevention and NSPs, although the 
term ‘harm reduction’ failed once again to feature 
in the final text), proportionality of sentencing, key 
human rights issues (including the right to a fair 
trial and due process, to be free from torture and 
cruel punishment, among others), as well as devel-
opmental considerations with a strong link to the 
need to alleviate poverty and to achieve the SDGs 
in both rural and urban settings. Finally, it is worth 
noting that the UNGASS Outcome Document does 
not include the unrealistic drug-free world targets 
that were incorporated in both the 1998 and 2009 
Political Declarations. This omission leaves the 
door open to consider new metrics and indicators 
through which progress can be evaluated. 
The seven-pillar structure of the Outcome Docu-
ment (i.e. demand reduction, supply reduction, in-
ternational cooperation, access to controlled med-
icines, human rights, evolving realities, trends and 
challenges, and development) is also a welcome 
departure from the siloed three-pillar approach 
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The 2019 Ministerial Segment is a critical moment to 
take stock of what has – and has not – been achieved 
over the past decade, as well as to build on the im-
portant progress reflected in the UNGASS Outcome 
Document. It is also a key opportunity to re-orientate 
international drug policy away from harmful punitive 
approaches towards more effective and humane pol-
icies. Ahead of the Segment, the IDPC network679 de-
veloped four recommendations to inform the 2019 
event and global drug policy going forward.
2.1  Moving away from ‘drug-free 
world’ targets
The data presented in this Shadow Report show 
that the targets aiming to ‘eliminate or reduce 
significantly and measurably’ the illegal drug 
market have failed to materialise. Over the past 
decade, these targets have distorted policy prior-
ities, diverting funding away from proven public 
health and development approaches, and have 
been used to justify a number of human rights 
abuses. Beyond 2019, the international commu-
nity should consider adopting more meaningful 
goals and targets in line with the 2030 Agenda for 
Sustainable Development, the UNGASS Outcome 
Document and international human rights com-
mitments. Examples of possible new targets are 
available below. 
2.2  Meaningfully reflect the impacts 
of drug policies on the UN goals of 
promoting health, human rights, 
development, peace and security
Most drug policies worldwide have undermined or 
run counter to the overarching priorities of the UN to 
protect human rights, consolidate peace and security 
and advance development. Undeniable progress has 
been made within the UNGASS Outcome Document 
to better reflect these key priorities, in particular with 
references to the SDGs. Going forward, the overall 
objective of global drug policies should actively seek 
to contribute to advancing the 2030 Agenda for Sus-
tainable Development, including protecting basic 
2  The 2019 Ministerial Segment:
Establishing a timeline for the  
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human rights, strengthening good governance and 
promoting the well-being of society, especially those 
most marginalised and vulnerable. 
2.3 Reflecting the realities of drug 
policies on the ground, both positive 
and negative
The Shadow Report highlights significant changes 
in the global drug policy landscape since 2009, 
with unprecedented reforms taking place at local 
Box 22  Options for drug policy reform
Ahead of the 2016 UNGASS, IDPC released the 
third edition of its Drug Policy Guide.680 Bringing 
together global evidence and best practices, the 
Guide provides expert analysis across the spec-
trum of drug policy, including on aspects related 
to public health, criminal justice and develop-
ment. Each theme explores the latest available 
evidence of effectiveness, illustrated by country 
case studies, and offers advice and recommen-
dations for effective, balanced and humane drug 
policies. These include:
• The scale up, expansion and funding of evi-
dence-based drug prevention, harm reduc-
tion and drug dependence treatment servic-
es in the community and in prison settings
• The removal of legislative, regulatory and 
technical barriers that hampers access to 
controlled medicines, especially in the Glob-
al South
• The decriminalisation of people who use 
drugs and subsistence farmers engaged in 
illegal crop cultivation
• The consideration of legally regulated mar-
kets to address the harms associated with 
punitive drug control, in particular mass 
incarceration, human rights abuses, stigma 
and discrimination
• The use of effective and humane alternatives 
to incarceration for non-violent drug offend-
ers, and the review of current drug laws to 
ensure more proportionate sentencing for 
all drug offences
• The abolition of the death penalty for drug 
offences
• The incorporation of a development per-
spective in drug policies to address poverty, 
marginalisation and vulnerability, with the 
goal of leaving no one behind
• The recognition and protection of the rights 
of indigenous peoples, including the right 
to grow and use internationally controlled 
substances
• The consideration of new metrics and indi-
cators to measure the effectiveness of drug 
policy, using the Human Rights Index and 
the SDGs
• The inclusion of civil society, in particular 
affected communities, in all aspects of the 
design, implementation, monitoring and 
evaluation of drug policy.681 
and national levels in the fields of harm reduc-
tion, treatment, decriminalisation, alternatives to 
incarceration, medicinal cannabis, and the crea-
tion of legally regulated markets for non-medical 
use, among others. 2019 will be a critical juncture 
at which these reforms should be discussed, in 
particular with regards to the possible resulting 
tensions with the international drug control re-
gime (see Box 21). On the other side of the policy 
spectrum, it is equally important to acknowledge 
the human rights abuses committed in the name 
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approach to drug policy, in order to redress some 
of the social harms associated with punitive drug 
control. Putting people first also requires that the 
UN address the ongoing tensions between UN 
drug control obligations and the rights of indig-
enous peoples. In this context, a rights-centred 
approach should aim to protect the traditional 
and medicinal practices of indigenous commu-
nities, including their right to cultivate and use 
controlled substances. 
This shift in focus requires civil society and com-
munity involvement in all aspects of the design, 
implementation, evaluation and monitoring of 
drug policies at local, national, regional and inter-
national levels. This imperative had already been 
recognised within the 2009 Political Declaration 
and Plan of Action (Actions 10 and 12(b)) and was 
reiterated in the 2016 UNGASS Outcome Docu-
ment (Preamble and paragraphs 1.q, 4.g, 7.l and 
9). Beyond 2019, global drug policy should include 
the continued and meaningful participation of 
most affected groups, in particular people who use 
drugs, people involved in subsistence farming of 
crops destined for the illegal drug market, formerly 
incarcerated drug offenders, indigenous peoples, 
and other communities such as affected women, 
children and youth. 
of drug control, including the continued use of 
the death penalty for drug offences, extrajudi-
cial killings, compulsory detention centres, mass 
incarceration and dire prison conditions, stigma 
and discrimination against people who use drugs, 
and others. These serious human rights concerns 
should feature prominently in the 2019 debates to 
ensure a paradigm shift in drug policy that is en-
shrined in international human rights law, health 
and social inclusion. 
2.4   Ending punitive approaches  
and putting people and 
communities first
This Shadow Report has showcased how drug 
policies have so far placed a disproportionate 
emphasis on the substances they seek to con-
trol, rather than on the well-being of people and 
communities they seek to serve. Beyond 2019, 
the global drug strategy should focus on putting 
people and communities at the centre, and seek 
to improve their living conditions, address their 
vulnerabilities and protect their human rights 
– in line with the SDG vision of ‘leaving no one 
behind’. This entails embracing a social justice 
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of complexity, requiring the UN and its member 
states to recalibrate their policies – including those 
relating to drug control – to achieve the 2030 
Agenda for Sustainable Development. By continu-
ing to promote drug-free targets while side-lining 
other critical aspects of drug policy, governments 
may run the risk of failing to achieve many of the 
SDGs agreed upon in 2015. 
The difficulty now lies in defining which new 
metrics and indicators member states and the 
UN should use to measure progress. The SDGs are 
highlighted within the UNGASS Outcome Docu-
ment’s preamble and paragraph 7.g. The Goals, 
along with their detailed targets and indicators, 
provide an invaluable resource for every aspect of 
policy making at the UN level. The interrelation-
ship between the SDGs and drug policy has been 
extensively discussed elsewhere683 and this anal-
ysis will therefore not be repeated here. Instead, 
this section proposes possible new metrics and 
indicators based on the SDGs and closely aligned 
with the UNGASS Outcome Document’s operation-
al recommendations. While not every SDG may be 
relevant to drug policy, the targets and indicators 
they provide can be used and adapted to meas-
The success of drug control strategies should be 
measured through an assessment of the impact of 
drug control efforts in the enjoyment of human rights 
and other critical aspects such as security, health and 
social-economic development’, OHCHR, 2018682
Reconsidering the overall goals of global drug pol-
icy beyond the mere objective of achieving a drug-
free society entails a rethink of the metrics and in-
dicators being used to evaluate progress achieved 
by drug policies and strategies worldwide. If drug 
control no longer has a singular focus on reducing 
cultivation, trafficking and use – objectives that 
have not been achieved over the past 20 years 
– but rather on minimising drug-related health 
harms, improving access to healthcare, upholding 
basic human rights, reducing poverty in cultiva-
tion and trafficking areas, improving citizen safety 
and reducing corruption, the use of indicators fo-
cusing on measuring the scale of the illegal drug 
market will no longer be enough. Furthermore, the 
additional thematic areas covered in the UNGASS 
Outcome Document require the development of 
additional indicators to measure progress, and 
their inclusion in a revised ARQ. Finally, the adop-






3  Identifying new indicators
for measuring the success of
drug policy: How to leverage the
Sustainable Development Goals
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the work currently being undergone by NGOs, UN 
agencies and government bodies on the issue, and 
aim to offer a starting point for further discussion 
on the matter.684 
ure the success of drug policies, strategies and 
programmes. This is also an opportunity to iden-
tify ‘outcome’ or ‘impact’ metrics and indicators, 
instead of solely using ‘process’ or ‘activity’ indi-
cators. These proposed indicators are based upon 
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3.1 Chapter 1: Demand reduction and related measures
The current UNODC data reporting mechanism already covers levels of drug use and dependence, as well as 
some drug use-related health issues. However, various SDG targets and indicators may be helpful to consider, 
in particular to track progress in removing the political, legislative and practical barriers (including discrimina-
tion, cases of abuse, lack of adequate services, etc.) hampering access to healthcare settings:
Original SDG target/indicator Possible drug policy target/indicator & relevant par-agraph in the UNGASS Outcome Document
Indicator 1.1.1: Proportion of population below the 
international poverty line, by sex, age, employment 
status and geographical location (urban/rural)
Proportion of people who use drugs below the interna-
tional poverty line, by sex, age, employment status and 
geographical location (urban/rural) (para 1.h)
Target 3.3: By 2030 end the epidemics of AIDS, tuber-
culosis, malaria, and neglected tropical diseases and 
combat hepatitis, water-borne diseases, and other 
communicable diseases
By 2030 end the epidemics of AIDS, tuberculosis and com-
bat hepatitis and other communicable diseases among 
people who inject drugs (para 1.o)
Indicator 3.3.1: Number of new HIV infections per 
1,000 uninfected population, by sex, age and key pop-
ulations
Number of new HIV infections per 1,000 uninfected peo-
ple who inject drugs, by sex, age (para 1.o)
Number of people who inject drugs living with HIV under 
ART, by sex, age (para 1.o)
Indicator 3.3.2: Tuberculosis incidence per 1,000 pop-
ulation
Tuberculosis per 1,000 people who inject drugs, by sex, 
age (para 1.o)
Proportion/Number of people who inject drugs infected 
by tuberculosis who have been treated and cured, by sex, 
age (para 1.o)
Indicator 3.3.4: Hepatitis B incidence per 100,000 
population
Hepatitis B and C685 incidence per 100,000 people who 
inject drugs, by sex, age (para 1.o)
Number of people who inject drugs infected by hepatitis B 
and C under treatment, by sex, age (para 1.o)
Target 3.5: Strengthen prevention and treatment of 
substance abuse, including narcotic drug abuse and 
harmful use of alcohol
Adoption of minimum quality standards for drug pre-
vention and treatment, modelled on those developed by 
UNODC (para 1.h)
Indicator 3.5.1: Coverage of treatment interventions 
(pharmaceutical, psychosocial and rehabilitation and 
aftercare services) for substance use disorders
Coverage of treatment interventions (pharmaceutical, 
psychosocial and rehabilitation and aftercare services) for 
drug dependency both in the community and in prison, 
by sex, age (para 1.j, 4.m)
Proportion/number of people dependent on drugs access-
ing voluntary and evidence-based drug dependence treat-
ment, number of those having completed their treatment, 
and retention rate, by sex, age (para 1.j)
Indicator 10.3.1: Proportion of the population re-
porting having personally felt discriminated against or 
harassed within the previous 12 months on the basis of 
a ground of discrimination prohibited under interna-
tional human rights law
Proportion/number of people who use drugs reporting 
having personally felt discriminated against or harassed 
within the previous 12 months on the basis of a ground 
of discrimination prohibited under international human 
rights law, by sex, age (para 1.j)
Indicator 11.7.2: Proportion of persons victim of phys-
ical or sexual harassment, by sex, age, disability status 
and place of occurrence, in the previous 12 months
Proportion/number of people who use drugs victim of 
physical or sexual harassment, by sex, age, disability status 
and place of occurrence, in the previous 12 months (para 
4.c)
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3.2 Chapter 2: Ensuring access to controlled medicines
The issue of improving access to controlled medicines was only covered in one action in the 2009 Political 
Declaration and Plan of Action, but was allocated an entire chapter in the UNGASS Outcome Document. This 
is a key opportunity for member states to report on progress made in this regard. Within the SDGs, two targets 
are particularly relevant for this topic:
Original SDG target/indicator Possible drug policy target/indicator & relevant paragraph in the UNGASS Outcome Document
Target 3.5: Strengthen prevention and treatment of 
substance abuse, including narcotic drug abuse and 
harmful use of alcohol
Ensure access to controlled medicines included in the 
WHO Model List of Essential Medicines for the treatment 
of drug dependence, including methadone, buprenor-
phine and morphine (para 2.a, 1.k, 1.o))
% of people dependent on opioids receiving substitution 
therapy with methadone, buprenorphine or morphine, in 
the community and in prison, by sex, age (para 1.k, 1.o, 2.a, 
4.b, 4.m)
Availability of naloxone (among peers, in hospitals, in 
healthcare facilities, etc.) (para 1.m)
Target 3.8 Achieve universal health coverage (UHC), 
including financial risk protection, access to quality 
essential health care services, and access to safe, effec-
tive, quality, and affordable essential medicines and 
vaccines for all
Achieve universal health coverage, including access to 
essential healthcare services, and access to safe, effective, 
quality and affordable essential medicines for all (para 2)
Legislation or regulations to improve access to controlled 
substances for medical and scientific purposes (e.g. sub-
stances available, requirements to prescribe; requirements 
for patients to obtain prior permission or register to be 
eligible, for physicians to receive special licences, for phar-
macies to obtain prior licences to dispense medicines, etc.) 
(para 2, 2.a)
% of people suffering from moderate to severe or chronic 
pain receiving controlled medicines, by sex, age (para 2)
Number of pharmaceutical establishments that can 
dispense opioids for pain management per 100,000 inhab-
itants (para 2.a, 2.d)
% of medical and nursing schools providing palliative care 
and pain management training in their curriculum (para 
2.e)
Coverage of training for healthcare professionals on 
palliative care and the treatment of moderate to severe or 
chronic pain with controlled medicines (para 2.e)
100  Taking stock: A decade of drug policy
3.3 Chapter 3: Supply reduction and related measures
Progress in supply reduction has so far mostly been measured according to process indicators tracking num-
bers of seizures of drugs, crops eradicated and arrests of cultivators, traffickers and dealers. The UNGASS Out-
come Document provides an opportunity to develop new indicators assessing the socio-economic conditions 
of vulnerable communities (para 3.b) and measuring evolutions in levels of violence and corruption, using the 
following SDG targets and indicators:
Original SDG target/indicator Possible drug policy target/indicator & relevant par-agraph in the UNGASS Outcome Document
Indicator 1.1.1: Proportion of population below the 
international poverty line, by sex, age, employment 
status and geographical location (urban/rural)
Proportion of population below the international poverty 
line in areas affected by illegal drug cultivation, produc-
tion, trafficking and sale, by sex, age (urban/rural) (para 
3.b)
Target 16.1: Significantly reduce all forms of violence 
and related death rates everywhere
Significantly reduce all forms of violence and related death 
rates in areas affected by illegal drug cultivation, produc-
tion, trafficking and sale (para 3.a)
Indicator 16.1.1: Number of victims of intentional 
homicide per 100,000 population, by sex and age
Numbers of victims of intentional homicide per 100,000 
population in areas affected by illegal drug cultivation, 
production, trafficking and sale, by sex and age (para 3.a)
Target 16.5: Substantially reduce corruption and brib-
ery in all their forms
Significantly reduce corruption and bribery in areas affect-
ed by illegal drug cultivation, production, trafficking and 
sale (para 3.a)
Increased number of financial investigations and confisca-
tions in relation to the proceeds of drug-related organised 
crime (para 3.q, 3.r)
Perception of public sector corruption (para 3.a)
Number of investigations and prosecutions for drug-relat-
ed corruption and/or money-laundering cases involving 
governments (para 3.f )
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3.4 Chapter 4: Human rights, youth, children, women and communities
The Outcome Document is the first example in the history of international drug control of a high-level docu-
ment dedicating a whole chapter to human rights. Despite the sensitivities associated with the issue through-
out the negotiations of the Outcome Document, this chapter includes key operational recommendations on 
proportionality of sentencing, due process, the prevention of torture and ill-treatment, as well as the rights of 
women and children. This provides an opportunity to develop indicators through which member states – but 
also UN agencies and civil society – may report back on progress, or lack thereof, towards the achievement of 
the following SDG targets and indicators:
Original SDG target/indicator Possible drug policy target/indicator & relevant paragraph in the UNGASS Outcome Document
Target 1.1: By 2030, eradicate extreme poverty for 
all people everywhere, currently measured as people 
living on less than $1.25 a day
Number of people incarcerated for drug offences living 
below the poverty line and who are the sole care provider 
of children and other dependent relatives (para 4.d)
Target 3.3: By 2030, end the epidemics of AIDS, 
tuberculosis, malaria and neglected tropical diseases 
and combat hepatitis, water-borne diseases and other 
communicable diseases
Availability and coverage of gender-sensitive harm reduc-
tion interventions in the community and in prison settings 
(para 1.k, 1, o, 4.b)
Indicator 3.5.1: Coverage of treatment interventions 
(pharmacological, psychosocial and rehabilitation and 
aftercare services) for substance use disorders
Availability and coverage of gender-sensitive treatment 
interventions (pharmacological, psychosocial and reha-
bilitation and aftercare services) in the community and in 
prison settings (para 1.i, 4.m, 4.o)
Target 5.1: End all forms of discrimination against all 
women and girls everywhere
Reported cases of stigma and discrimination in accessing 
healthcare services by women who use drugs (para 4.b
Indicator 5.1.1: Indicator 5.1.1: Whether or not legal 
frameworks are in place to promote, enforce and moni-
tor equality and non-discrimination on the basis of sex
Legal framework adopted/in place to monitor and redress 
cases of discrimination against women and girls who use 
drugs (para 4.b)
Target 5.2: Eliminate all forms of violence against all 
women and girls in the public and private spheres, 
including trafficking and sexual and other types of 
exploitation
See Indicator 5.2.2
Indicator 5.2.2: Proportion of women and girls aged 
15 years and older subjected to sexual violence by 
persons other than an intimate partner in the previous 
12 months, by age and place of occurrence
Reported cases of sexual violence against women and girls 
who use drugs and female drug offenders (para 4.d)
Target 5.C: Adopt and strengthen sound policies and 
enforceable legislation for the promotion of gender 
equality and the empowerment of all women and girls 
at all levels
Legislation, regulation or measure passed/reviewed to en-
sure a gender-sensitive approach to drug policies and pro-
grammes, including in the implementation of the Bangkok 
Rules (para 4.n)
Target 10.3: Ensure equal opportunity and reduce 
inequalities of outcome, including by eliminating dis-
criminatory laws, policies and practices and promoting 
appropriate legislation, policies and action in this 
regard
Legal and/or policy framework adopted/in place to moni-
tor and redress cases of discrimination against people who 
use drugs and drug offenders (paras 4.b, 4.d, 4.g)
Target 10.3.1: Proportion of the population reporting 
having personally felt discriminated against or harassed 
within the previous 12 months on the basis of a ground 
of discrimination prohibited under international human 
rights law
Reported cases of stigma and discrimination in accessing 
healthcare services, by sex, age (paras 1.k, 4.b, 4.d)
Indicator 11.7.2: Proportion of persons victim of phys-
ical or sexual harassment, by sex, age, disability status 
and place of occurrence, in the previous 12 months
Reported cases of sexual violence against people who use 
drugs, by sex, age (para 4.d)
Continued overleaf
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Target 16.1: Significantly reduce all forms of violence 
and related death rates everywhere
Reported cases of violence against, and extrajudicial kill-
ings of, suspected drug offenders, by sex, age (para 4.o)
Indicator 16.1.3: Proportion of population subjected 
to physical, psychological or sexual violence in the 
previous 12 months
Legislation, regulation or measure passed to eliminate acts 
of ill-treatment or punishment against drug offenders, by 
sex, age (para 4.c, 4.o)
Incidence and prevalence of physical and psychological 
abuse, including by law enforcement officials, against 
(suspected) drug offenders, by sex, age (para 4.o)
Target 16.2: End abuse, exploitation, trafficking and all 
forms of violence against and torture of children
Reported cases of abuse, exploitation, trafficking and 
violence by drug traffickers and organised crime organi-
sations against children and youth involved in illegal drug 
activities, by sex (para 4.d, 4.f )
Reported cases of abuse and violence by police and law 
enforcement officers against children and youth involved 
in illegal activities, by sex (para 4.d, 4.f )
Target 16.3: Promote the rule of law at the national 
and international levels and ensure equal access to 
justice for all
Legislation, regulation or measure passed/reviewed to en-
sure more proportionate penalties and alternatives to in-
carceration for drug offences (para 4.l, 4.j)
Legislation, regulation or measure passed to eliminate im-
punity (para 4.o)
Reported cases of arbitrary detention, by sex, age (para 
4.o)
Proportion of victims of ill-treatment or punishment ac-
cused of drug offences who have received compensation 
and rehabilitation, by sex, age (para 4.c, 4.o)
% of people accused of drug offences who received legal 
aid during trial (para 4.o)
Indicator 16.3.2: Unsentenced detainees as a propor-
tion of overall prison population
Proportion of drug offenders held in pre-trial detention, by 
sex, age (para 4.j)
Target 16.7: Ensure responsive, inclusive, participatory 
and representative decision-making at all levels
Legislation, regulation or measure passed/reviewed to en-
sure the involvement of affected communities in the de-
velopment, implementation, monitoring and evaluation of 
drug policies and programmes (para 4.b)
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3.5 Chapter 5: Evolving reality, trends and existing circumstances
In an increasingly complex and fast-evolving global drug market, this chapter of the UNGASS Outcome Docu-
ment is critical, in particular with regards to responding to the possible health and social harms associated with 
NPS and ATS. Much of the recommendations within this chapter relate to supply reduction efforts, but several 
also focus on health. In this regard, the following SDG targets may be useful:
Original SDG target/indicator Possible drug policy target/indicator & relevant paragraph in the UNGASS Outcome Document
Target 3.3: By 2030, end the epidemics of AIDS, tuber-
culosis, malaria and neglected tropical diseases and 
combat hepatitis, water-borne diseases and other com-
municable diseases
By 2030, end the epidemics of AIDS, tuberculosis and com-
bat hepatitis and other communicable diseases among 
people using NPS or ATS (para 5.d)
Availability of innovative, accessible interventions to ad-
dress the adverse health consequences of NPS and ATS 
use (para 5.d)
Indicator 3.3.1: Number of new HIV infections per 
1,000 uninfected population, by sex, age and key pop-
ulations
Number of new HIV infections per 1,000 uninfected peo-
ple using NPS or ATS, by sex, age (para 5.d)
Indicator 3.3.2: Tuberculosis incidence per 1,000 pop-
ulation
Tuberculosis incidence per 1,000 people using NPS or ATS, 
by sex, age (para 5.d)
Indicator 3.3.4: Hepatitis B incidence per 100,000 pop-
ulation
Hepatitis B and C incidence per 100,000 people using NPS 
or ATS, by sex, age (para 5.d)
Target 3.5: Strengthen the prevention and treatment 
of substance abuse, including narcotic drug abuse and 
harmful use of alcohol
Proportion/number of people dependent on NPS or ATS 
receiving evidence-based drug dependence treatment, in-
cluding substitution treatment (para 5.d)
Availability of minimum quality standards for the preven-
tion and treatment of NPS or ATS dependence (para 5.d)
Indicator 3.5.1: Coverage of treatment interventions 
(pharmacological, psychosocial and rehabilitation and 
aftercare services) for substance use disorders
% of people dependent on NPS or ATS accessing evi-
dence-based treatment, by sex, age (para 5.d)
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3.6 Chapter 6: Strengthening international cooperation
This topic is extensively covered in the 2009 Political Declaration and within the current ARQ. However, two 
SDG Targets may be useful to consider:
Original SDG target/indicator Possible drug policy target/indicator & relevant paragraph in the UNGASS Outcome Document
Target 16.A: Strengthen relevant national institutions, 
including through international cooperation, 
for building capacity at all levels, in particular in 
developing countries, to prevent violence and combat 
terrorism and crime
Level of information sharing through effective 
coordination mechanisms at national, regional, sub-
regional and international levels on expertise and best 
practice in drug policy (para 6.c)
Target 17.6: Enhance North-South, South-South and 
triangular regional and international cooperation on 
and access to science, technology and innovation and 
enhance knowledge sharing on mutually agreed terms, 
including through improved coordination among 
existing mechanisms, in particular at the United Nations 
level, and through a global technology facilitation 
mechanism
Formal and informal mechanisms established to enhance 
North-South, South-South and triangular cooperation 
among member states on drug policy (para 6.b)
Indicator 17.14.1: Number of countries with 
mechanisms in place to enhance policy coherence of 
sustainable development
Legislation, policy and/or strategy adopted and 
implemented to enhance policy coherence between drug 
control and sustainable development (para 6.d)
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3.7 Chapter 7: Alternative development, development-oriented balanced drug control policy
Here again, the UNGASS Outcome Document made significant progress in expanding the concept of alter-
native development to include broader development considerations, including addressing socio-economic 
vulnerabilities, improving access to education, employment, land tenure and natural resources, addressing 
inequalities and protecting the environment – both in rural and urban settings. Unsurprisingly, there are many 
relevant SDG targets and indicators relevant to this issue:
Original SDG target/indicator Possible drug policy target/indicator & relevant paragraph in the UNGASS Outcome Document
Target 1.1: By 2030, eradicate extreme poverty for all 
people everywhere, currently measured as people liv-
ing on less than $1.25 a day
By 2030, eradicate extreme poverty for people living in ar-
eas affected by illegal drug cultivation, production, traf-
ficking and sale, currently measured as people living on 
less than $1.25 a day (para 3.b, 5.v, 7.b)
Indicator 1.1.1: Proportion of population below the in-
ternational poverty line, by sex, age, employment status 
and geographical location (urban/rural)
Proportion of people living below the poverty line in com-
munities affected by illegal drug cultivation, production, 
trafficking and sale (para 3.b, 5.v, 7.b)
Poverty level among families where illegal drug cultivation 
is the primary source of income (para 3.b, 5.v, 7.b)
Poverty levels among people prosecuted/arrested for drug 
supply/trafficking offences (para 3.b, 5.v, 7.b)
Comparison of poverty levels before and two years after 
sustainable development programmes have been imple-
mented, in areas affected by illegal crop cultivation (para 
7.b, 7.j)
Target 1.4: By 2030, ensure that all men and women, 
in particular the poor and the vulnerable, have equal 
rights to economic resources, as well as access to ba-
sic services, ownership and control over land and other 
forms of property, inheritance, natural resources, appro-
priate new technology and financial services, including 
microfinance
By 2030 ensure that all men and women, particularly the 
poor and the vulnerable in areas affected by illegal drug 
cultivation, production, trafficking and sale, have equal 
rights to economic resources, as well as access to basic ser-
vices, ownership, and control over land and other forms of 
property, inheritance, natural resources, appropriate new 
technology, and financial services including microfinance 
(para 7.j)
Increase/reduction in the number of people displaced 
from their land due to crop eradication activities and other 
drug law enforcement efforts (para 7.j)
Indicator 1.4.2: Proportion of total adult population 
with secure tenure rights to land, with legally recog-
nized documentation and who perceive their rights to 
land as secure, by sex and by type of tenure
Percentage of women, men, indigenous peoples, and local 
communities in areas affected by illegal drug cultivation, 
production, trafficking and sale with secure rights to land, 
property, and natural resources, measured by (i) percent-
age with documented or recognised evidence of tenure, 
and (ii) percentage who perceive their rights are recog-
nised and protected (para 7.j)
Target 4.1: By 2030, ensure that all girls and boys com-
plete free, equitable and quality primary and second-
ary education leading to relevant and effective learning 
outcomes
By 2030, ensure that all girls and boys complete free, equi-
table and quality primary and secondary education lead-
ing to relevant and effective learning outcomes in areas 
affected by illegal drug cultivation, production, trafficking 
and sale (para 7.h, 7.j)
Indicator 4.3.1: Participation rate of youth and adults 
in formal and non-formal education and training in the 
previous 12 months, by sex
Percentage of people having access to primary, secondary 
and higher education in areas affected by illegal drug cul-
tivation, production, trafficking and sale (para 7.h, 7.j)
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Target 5.A: Undertake reforms to give women equal 
rights to economic resources, as well as access to own-
ership and control over land and other forms of proper-
ty, financial services, inheritance and natural resources, 
in accordance with national laws
Undertake reforms to give women equal rights to eco-
nomic resources, as well as access to ownership and con-
trol over land and other forms of property, financial ser-
vices, inheritance and natural resources in areas affected 
by illegal drug cultivation, production, trafficking and sale 
(para 7.j)
Indicator 5.A.1: (a) Proportion of total agricultural 
population with ownership or secure rights over 
agricultural land, by sex; and (b) share of women 
among owners or rights-bearers of agricultural land, by 
type of tenure
Proportion of total agricultural population in areas 
affected by illegal crop cultivation with ownership or 
secure rights over agricultural land, by sex; and share of 
women among owners or rights-bearers of agricultural 
land, by type of tenure (para 7.j)
Indicator 5.A.2: Proportion of countries where the 
legal framework (including customary law) guarantees 
women’s equal rights to land ownership and/or control
Proportion of countries affected by illegal drug cultivation, 
production, trafficking and sale where the legal framework 
(including customary law) guarantees women’s equal 
rights to land ownership and/or control (para 7.j)
Target 6.6: By 2020, protect and restore water-related 
ecosystems, including mountains, forests, wetlands, 
rivers, aquifers and lakes
By 2020, protect and restore water-related ecosystems, 
including mountains, forests, wetlands, rivers, aquifers and 
lakes, in areas affected by illegal crop cultivation (para 7.b, 
7.i, 7.g)
Proportion of countries with alternative development 
programmes having incorporated environmental 
protection components aiming to protect and restore 
water-related ecosystems, including mountains, forests, 
wetlands, rivers, aquifers and lakes (para 7.b, 7.i, 7.g)
Indicator 8.6.1: Proportion of youth (aged 15-24 years) 
not in education, employment or training
Proportion of youth (aged 15-24 years) not in education, 
employment or training in areas affected by illegal drug 
cultivation, production, trafficking and sale (para 7.h, 7.j)
Target 9.3: Increase the access of small-scale industrial 
and other enterprises, in particular in developing 
countries, to financial services, including affordable 
credit, and their integration into value chains and 
markets
Proportion of the population in areas affected by illegal 
drug cultivation, production, trafficking and sale having 
increased access to small-scale industrial and other 
enterprises and financial services, including affordable 
credit, and their integration into value chains and markets 
(para 5.v, 7.b)
Increase in access to licit markets for products derived 
from local cultivation, production and manufacture in 
areas affected by illegal crop cultivation (para 7.b)
Target 11.1: By 2030, ensure access for all to adequate, 
safe and affordable housing and basic services and 
upgrade slums
By 2030, ensure access for all to adequate, safe and 
affordable housing and basic services and upgrade slums 
in areas affected by illegal drug cultivation, production, 
trafficking and sale (para 7.h, 7.j)
Percentage of people having access to stable housing 
in communities affected by illegal drug cultivation, 
production, trafficking and sale, by sex, age (7.h, 7.j)
Target 13.2: Integrate climate change measures into 
national policies, strategies and planning
Proportion of countries having integrated climate change 
measures into their drug policies, strategies and planning 
(para 7.b, 7.i, 7.g)
Indicator 15.3.1: Proportion of land that is degraded 
over total land area
Proportion of land that is degraded over total land area 
in areas affected by illegal drug cultivation, production, 
trafficking and sale (para 7.b, 7.i, 7.g)
Continued on next page
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Target 16.7: Ensure responsive, inclusive, participatory 
and representative decision-making at all levels
Ensure responsive, inclusive, participatory and 
representative decision-making on drug policies, 
strategies and programmes at all levels (para 7.b)
Proportion of countries having adopted mechanisms 
to ensure responsive, inclusive, participatory and 
representative decision-making at all levels in drug 
policies, strategies and programmes (para 7.b)
Indicator 16.7.2: Proportion of population who believe 
decision-making is inclusive and responsive, by sex, 
age, disability and population group
Proportion of population living in areas affected by illegal 
drug cultivation, production, trafficking and sale who 
believe decision-making is inclusive and responsive, by 
sex, age, disability and population group (para 7.b)
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Annex : Actions selected from the 2009 Political Declaration and Plan of Action for the Shadow Report
HUMAN RIGHTS
Actions from the 2009 Political Declaration and Plan of Action Issue of relevance
Action 2(g): ‘Develop and implement, in cooperation with international 
and regional agencies, a sound and long-term advocacy strategy, including 
harnessing the power of communication media, aimed at reducing 
discrimination that may be associated with substance abuse, promoting the 
concept of drug dependence as a multifactorial health and social problem 
and raising awareness, where appropriate, of interventions based on scientific 
evidence that are both effective and cost-effective’
Right to health: enhancing 
access to evidence-based drug 
prevention and right to be free from 
discrimination
Action 4(h): ‘Consider developing a comprehensive treatment system 
offering a wide range of integrated pharmacological (such as detoxification 
and opioid agonist and antagonist maintenance) and psychosocial (such as 
counselling, cognitive behavioural therapy and social support) interventions 
based on scientific evidence and focused on the process of rehabilitation, 
recovery and social reintegration’
Right to health: ensuring access to 
evidence-based drug dependence 
treatment
Action 4(i): ‘Strengthen their efforts aimed at reducing the adverse 
consequences of drug abuse for individuals and society as a whole, taking 
into consideration not only the prevention of related infectious diseases, 
such as HIV, hepatitis B and C and tuberculosis, but also all other health 
consequences, such as overdose, workplace and traffic accidents and somatic 
and psychiatric disorders, and social consequences, such as family problems, 
the effects of drug markets in communities and crime’
Right to health: ensuring access to 
harm reduction interventions
Action 6(a): ‘Ensure that demand reduction measures respect human rights 
and the inherent dignity of all individuals and facilitate access for all drug 
users to prevention services and health-care and social services, with a view 
to social reintegration’
Right to be free from torture, cruel, 
inhuman treatment or punishment, 
right to life, right to due process and 
a fair trial, and right to liberty and be 
free from arbitrary detention
Action 10(b): ‘Ensure, where appropriate, the sufficient availability of 
substances for medication-assisted therapy, including those within the scope 
of control under the international drug control conventions, as part of a 
comprehensive package of services for the treatment of drug dependence’
Right to health: ensuring access to 
harm reduction interventions and 
evidence-based drug dependence 
treatment
Action 10(c): ‘Continue to comply with the procedures established under 
the international drug control conventions and relevant resolutions of the 
Economic and Social Council relating to the submission to the International 
Narcotics Control Board of estimates of their requirements for narcotic 
drugs and assessments of requirements for psychotropic substances so 
as to facilitate the import of the required narcotic drugs and psychotropic 
substances and to enable the Board, in cooperation with Governments, 
to maintain a balance between the demand for and the supply of those 
drugs and substances in order to ensure the relief of pain and suffering and 
the availability of medication-assisted therapy as part of a comprehensive 
package of services for the treatment of drug dependence, while bearing in 
mind, in accordance with national legislation, the World Health Organization 
Model List of Essential Medicines’
Right to health: improving access to 
controlled substances for medical 
purposes
Action 14(a): ‘Ensure that a broad range of drug demand reduction services, 
including those in the areas of prevention, treatment, rehabilitation and related 
support services, provide approaches that serve the needs of vulnerable groups 
and are differentiated on the basis of scientific evidence so that they respond 
best to the needs of those groups, taking into account gender considerations 
and cultural background’
Right to health: ensuring access to 
drug services for women
Continued on next page
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Action 14(c): ‘Provide specialized training for those who work with vulner-
able groups, such as patients with psychiatric co-morbidities, minors and 
women, including pregnant women’
Right to health: ensuring access to 
drug services for women
Action 15(a): ‘Working within their legal frameworks and in compliance with 
applicable international law, consider allowing the full implementation of 
drug dependence treatment and care options for offenders, in particular, 
when appropriate, providing treatment as an alternative to incarceration’
Right to health: ensuring access 
to drug services in prisons and 
providing alternatives to prison or 
punishment for people who use 
drugs
Right to liberty and be free from ar-
bitrary detention
Action 15(c): ‘Implement comprehensive treatment programmes in 
detention facilities; commit themselves to offering a range of treatment, 
care and related support services to drug-dependent inmates, including 
those aimed at prevention of the transmission of related infectious diseases, 
pharmacological and psychosocial treatment and rehabilitation; and 
further commit themselves to providing programmes aimed at preparation 
for release and prisoner support programmes for the transition between 
incarceration and release, re-entry and social reintegration’
Right to health: ensuring access to 
drug services in prisons 
Action 16(d): ‘Provide appropriate training so that criminal justice and/or 
prison staff carry out drug demand reduction measures that are based on 
scientific evidence and are ethical and so that their attitudes are respectful, 
non-judgemental and non-stigmatizing’
Right to health: ensuring access to 
drug services in prisons
Action 22(c): ‘Ensure that supply reduction measures are carried out in 
full conformity with the purposes and the principles of the Charter of the 
United Nations and international law, the three international drug control 
conventions and, in particular, with full respect for the sovereignty and 
territorial integrity of States, the principle of non-intervention in the internal 
affairs of States and all human rights and fundamental freedoms’
Right to be free from torture, cruel, 
inhuman treatment or punishment, 
right to life, right to due process and 
a fair trial, and right to liberty and be 
free from arbitrary detention
Action 22(e): ‘Promote supply reduction measures that take due account of 
traditional licit uses, where there is historical evidence of such use, as well as 
environmental protection, in conformity with the United Nations Convention 
against Illicit Traffic in Narcotic Drugs and Psychotropic Substances of 1988’
Rights of indigenous people
Action 22(l): ‘Remain up to date on scientific studies, data and research on 
the medicinal and other legitimate uses of plants containing narcotic and 
psychotropic substances, taking into account the provisions of the three 
international drug control conventions’
Right to science
Action 28(c): ‘Develop prevention and treatment programmes tailored to the 
specific characteristics of the phenomenon of amphetamine-type stimulants 
as key elements in any relevant strategy to reduce demand and minimize 
health risks’
Right to health: ensuring access to 
harm reduction interventions and 
evidence-based drug dependence 
treatment
Action 41(c): ‘Ensure that measures to control precursors and amphetamine-
type stimulants are carried out in full conformity with the purposes and 
the principles of the Charter of the United Nations and international law, 
the international drug control conventions and, in particular, with full 
respect for the sovereignty and territorial integrity of States, the principle 
of non-intervention in the internal affairs of States and all human rights and 
fundamental freedoms’
Right to life, and right to due process 
and a fair trial
Action 14(b) ‘Ensure that prevention programmes target and involve youth 
and children with a view to increasing their reach and effectiveness’
Right to health: ensuring access to 
drug services for children
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PROMOTING PEACE AND SECURITY
Actions from the 2009 Political Declaration and Plan of Action Issue of relevance
Action 22(c): ‘Ensure that supply reduction measures are carried out in full 
conformity with the purposes and the principles of the Charter of the Unit-
ed Nations and international law, the three international drug control con-
ventions and, in particular, with full respect for the sovereignty and terri-
torial integrity of States, the principle of non-intervention in the internal 
affairs of States and all human rights and fundamental freedoms’
Balloon effect & escalating levels of 
violence, and right to life
Action 24(g): ‘Implement strategies to disrupt and dismantle major or-
ganizations involved in trafficking in narcotic drugs and psychotropic sub-
stances and to address emerging trends’
Balloon effect & escalating levels of 
violence
Action 36(a): ‘Address through concerted action the illegal sale of prepa-
rations containing amphetamine-type stimulants via the Internet and the 
misuse of postal and courier services for smuggling such preparations’
Responses to crypto-drug markets
Action 51(a): ‘Establishing new or strengthening existing domestic leg-
islative frameworks to criminalize the laundering of money derived from 
drug trafficking, precursor diversion and other serious crimes of a transna-
tional nature in order to provide for the prevention, detection, investiga-
tion and prosecution of money laundering’
Tackling money-laundering
Action 51(d): ‘Promoting effective cooperation in strategies for counter-
ing money-laundering and in money-laundering cases’
Tackling money-laundering
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ADVANCING DEVELOPMENT
Actions from the 2009 Political Declaration and Plan of Action Issue of relevance
Action 22(e): ‘Promote supply reduction measures that take due account of tra-
ditional licit uses, where there is historical evidence of such use, as well as envi-
ronmental protection, in conformity with the United Nations Convention against 
Illicit Traffic in Narcotic Drugs and Psychotropic Substances of 1988’
Protecting the environment in 
drug control strategies
Action 43(b): ‘Conduct research to assess the factors leading to the illicit culti-
vation of drug crops used for the production of narcotic drugs and psychotropic 
substances’
Analysing factors leading to ille-
gal crop cultivation
Action 43(d): ‘Ensure that States with the necessary expertise, the United Na-
tions Office on Drugs and Crime and other relevant United Nations organizations 
assist affected States in designing and improving systems to monitor and assess 
the qualitative and quantitative impact of alternative development and drug 
crop eradication programmes with respect to the sustainability of illicit crop re-
duction and socio-economic development; such assessment should include the 
use of human development indicators that reflect the Millennium Development 
Goals’
Support and cooperation for al-
ternative development
Action 45(c): ‘Establish, where possible, sustainable alternative development 
programmes, in particular in drug-producing regions, including those with high 
levels of poverty, as they are more vulnerable to exploitation by traffickers and 
more likely to be affected by the illicit cultivation of drug crops and the illicit pro-
duction of and trafficking in narcotic drugs and psychotropic substances’
Promoting sustainable develop-
ment in cultivation and traffick-
ing areas
Action 45(d): ‘Consider, where appropriate, including in their national devel-
opment strategies, integrated and sustainable alternative development pro-
grammes, recognizing that poverty and vulnerability are some of the factors 
behind illicit drug crop cultivation and that poverty eradication is a principal 
objective of the Millennium Development Goals; and request development or-
ganizations and international financial institutions to ensure that alternative de-
velopment strategies, including, when appropriate, preventive alternative devel-
opment programmes, are incorporated into poverty reduction strategy papers 
and country assistance strategies for States affected by the illicit cultivation of 
crops used for the production of narcotic drugs and psychotropic substances’
Promoting sustainable develop-
ment in cultivation and traffick-
ing areas
Action 45(f): ‘Ensure that the design and implementation of alternative develop-
ment programmes, including, when appropriate, a preventive approach, involve 
all stakeholders, take into account the specific characteristics of the target area 
and incorporate grass-roots communities in project formulation, implementation 
and monitoring’
Ensuring collaboration with local 
communities in illegal crop culti-
vation areas
Action 47(b): ‘Develop alternative development programmes and eradication 
measures while fully respecting relevant international instruments, including hu-
man rights instruments, and, when designing alternative development interven-
tions, taking into consideration the cultural and social traditions of participating 
communities’
Ensuring collaboration with local 
communities in illegal crop culti-
vation areas
Action 47(c): ‘Ensure that development assistance provided to communities in 
areas affected by illicit cultivation of crops used for the production of narcotic 
drugs and psychotropic substances takes into account the overall aims of human 
rights protection and poverty eradication’
Ensuring that development as-
sistance protects human rights
Action 47(d): ‘Ensure that the implementation of alternative development and 
preventive alternative development, as appropriate, enhances synergy and trust 
among the national Government, local administrations and communities in 
building local ownership’
Ensuring collaboration with local 
communities in illegal crop culti-
vation areas
Continued on next page
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Action 47(f): ‘Ensure the proper and coordinated sequencing of development 
interventions when designing alternative development programmes; and, 
in this connection, the issues of the establishment of agreements and viable 
partnerships with small producers, favourable climatic conditions, strong political 
support and adequate market access should be taken into account’
Promoting sustainable 
development in cultivation and 
trafficking areas
Action 49(e): ‘Ensure that development partners, affected States and other 
relevant key development actors examine innovative ways to promote 
alternative development programmes, including preventive alternative 
development programmes, where appropriate, that are environmentally friendly’
Protecting the environment in 
drug control strategies
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Action on International Cooperation towards an Integrated and Balanced 
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